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10 General introduction
General introduction
Th is thesis describes genetic and environmental factors which are important in pre- and postnatal 
growth disorders and specifi cally focuses on children born small for gestational age (SGA) with 
or without postnatal catch-up growth. It also presents a subclassifi cation of short SGA subjects 
according to length, weight and head circumference at birth. In addition, it reports investigations 
in three genes which have been found to play a central role in growth regulation: the insulin-
like growth factor 1 (IGF1), the insulin-like growth factor 1 receptor (IGF1R) and the insulin 
(INS) gene and their associations with short SGA and SGA catch-up subjects. In addition, the 
thesis describes the results of a study into relatively large deletions and duplications (also called 
“copy number changes”) in 18 growth-related genes, performed in short SGA subjects. Th e last 
chapter describes phenotypic data of a large group of subjects participating in the Network 
of European Studies in Genes in growth (NESTEGG). Th is group consisted of subjects born 
SGA, either with persistent short or normal stature, idiopathic short stature (ISS) and controls. 
Finally, the aims of the study and outline of this thesis are described. 
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1. Small for gestational age (SGA)
Defi nitions
According to the consensus reached by the International SGA advisory board [1,2], children 
being born small for gestational age (SGA) had a birth length and or birth weight below -2.0 
standard deviation score (SDS). 
 SGA refers to the size of the infant at birth, and not to intrauterine growth. Th e term 
intrauterine growth retardation (IUGR) is used to describe reduced growth velocity in the fetus. 
Th is can be observed by ultrasound measurements as a deviation of the fetal growth chart, as 
registered by at least two intrauterine growth measurements. Although SGA is oft en related to 
IUGR, not all SGA infants have suff ered from IUGR, and infants who are born aft er a short 
period of IUGR are not necessarily SGA. Figure 1 shows the fetal growth pattern of SGA and 
IUGR newborns. 
 SGA born children can be grouped by their birth length (L), birth weight (W), or both 
being ≤ -2.00 SDS, termed as SGAL, SGAW or SGAL+W [3]. In this population-based postnatal 
growth study, 8.1% were classifi ed SGA. Children born short and light for gestational age were 
shorter as adults than those born either short or light [3]. In addition, others showed that 
some children born both short and light for gestational age also had a smaller postnatal head 
circumference [4]. 
+2 SD
-2 SD
0 SD
LGA
AGA
SGA
SGA and IUGR
IUGR but not SGA
SGA but not IUGR
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ng
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/w
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t
gestation birth
Figure 1. Fetal growth chart showing the diff erence between SGA and IUGR newborns.
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Prevalence and etiology 
When SGA is defi ned as a birth length and/or weight below -2 SDS for gestational age, 2.3% 
of all live-born infants are born SGA. In 2006, 10.46 live births per 1000 inhabitants of the 
European Union were reported (www.euro.who.int/HFADB) with a mid year population of 490 
million. According to the defi nition, 118,000 European children were born SGA in 2006. 
 SGA can be caused by several factors, including fetal, maternal, placental and demographic 
factors [5-7]. Identifi cation of the cause of SGA is important, as underlying mechanisms may 
aff ect prognosis and treatment. Table 1 shows several factors that were associated with SGA 
birth.
 Fetal factors include chromosomal abnormalities, genetic defects, metabolic problems 
and congenital anomalies. 
 Maternal factors can be divided into medical conditions and environmental factors. 
Medical conditions include: chronic vascular diseases (secondary to hypertension, diabetes 
mellitus type 2, renal disease, collagen vascular disease), conditions associated maternal 
hypoxemia, infections (particularly toxoplasmosis, rubella, cytomegalovirus and herpes virus) 
and malnutrition. Environmental factors include cigarette smoking, alcohol abuse, use of illicit 
drugs (heroin, cocaine), and therapeutic drugs (e.g. anticonvulsants, anticoagulants). 
 Placental factors are associated with problems in placental perfusion resulting in 
reduced fetal oxygenation. Th ese include structural abnormalities of the placenta, maternal or 
fetal thrombophilia, infarctions and suboptimal implantation site. 
 Demographic factors involve maternal age, parental race and height, obstetric history, 
and multiple gestation, particularly in case of shared fetal circulation. 
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Table 1. Factors associated with an increased incidence of infants who are born SGA. Adapted from 
Bernstein and Divon [5], Pollack and Divon [6], Wollmann [7] and Keller et al. [8].
Fetal factors
Karyotypic abnormalities Trisomy 21 (Down syndrome)
Trisomy 18 (Edward syndrome)
Monosomy X (Turner Syndrome)
Trisomy 13 (gonadal dysgenesis)
Other chromosomal abnormalities Autosomal deletions
Ring chromosomes
Genetic diseases Achondroplasia
Bloom syndrome
Congenital anomalies Potter syndrome
Cardiac abnormalities
Maternal factors
Medical conditions Hypertension
Renal disease
Diabetes mellitus (advanced stages)
Collagen vascular diseases (e.g. systemic lupus erythematosus)
Maternal hypoxemia (cyanotic heart disease, chronic anemia, chronic 
pulmonary disease)
Infection Toxoplasmosis
Rubella
Cytomegalovirus
Herpes virus
Malaria
Trypanosomiasis
Human immunodefi ciency virus
Nutritional status Low pre-pregnancy weight
Low pregnancy weight with poor weight gain during pregnany
Substance use/abuse Cigarette smoking
Alcohol
Illicit drugs
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Maternal factors (continued)
Th erapeutic drugs (e.g. warfarin, anticonvulsants, antineoplastic agents, 
folic acid antagonists)
Uterine/placental factors
Gross structural placental factors Single umbilical artery
Velamentous umbilical cord insertion
Bilobate placenta
Placental hemangiomas
Infarcts, focal lesions
Maternal and/or fetal thrombophilia
Insuffi  cient uteroplacental perfusion Suboptimal implantation site
Placenta praevia
Low-lying placenta
Placental abruption
Demographic factors
Maternal age Very young age 
Older age
Maternal height
Maternal weight
Maternal and paternal race
Parity Nulliparity
Grand multiparity
Maternal history Previous delivery of SGA infants
Multiple gestation Particularly severe in syndromes associated with shared fetal circulation
Genetic factors 
Although several factors have been identifi ed in the etiology of SGA born children, the cause 
remains unidentifi ed in up to 40% of the cases. SGA birth, as well as short stature, might be 
genetically determined. For that reason we investigated several genes, using a candidate-gene 
approach. In this approach specifi c genes are selected of which the protein is known to be 
involved in pre- and postnatal growth. Th ree genes were investigated which might be important 
in the development of the SGA neonate: the insulin-like growth factor 1 (IGF1), the insulin-
like growth factor 1 receptor (IGF1R) and the insulin (INS) gene. All three genes are part of the 
growth hormone (GH)- IGF- IGF binding protein (IGFBP) axis (Figure 5). 
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IGF1 gene
Th e IGF1-gene (OMIM*147440, gene map locus: 12q22-q24.1, Figure 2) is thought to be an 
important candidate gene for children born SGA, being a major pre- and postnatal growth 
factor [9,10]. Prenatally, IGF1 absence results in a 40% reduction in birth weight. During 
postnatal life, surviving IGF1 knock-out mice become 30% of normal adult weight [9]. Several 
case-reports have described point-mutations and deletions in the IGF1 [11-13]. Only a limited 
number of studies have investigated the relation of common genetic polymorphisms in the 
IGF1 gene with SGA children [14,15]. 
Figure 2. Th e IGF1 gene structure. 
IGF1R gene
Th e IGF1R-gene (OMIM*147370, gene map locus: 15q25-q26, Figure 3) is an important 
candidate gene for children born SGA, playing a major role in prenatal and postnatal growth, 
as IGF1R knockout mice did not survive postnatally [9,10]. Several case-reports have described 
point-mutations and deletions in the IGF1R gene in SGA children [16-29]. No studies on genetic 
polymorphisms in the IGF1R-gene in groups of SGA children have been published. 
Figure 3. Th e IGF1R gene structure.
INS gene region
Th e insulin (INS) gene region (OMIM+176730, gene map locus 11p15.5, Figure 4) is considered 
to be a major candidate gene for the SGA phenotype as insulin is involved in fetal and early 
postnatal growth [30-33]. 
 Th e most widely studied polymorphism in the INS gene is a variable number of tandem 
repeats (VNTR, OMIM *147510) which is located 600bp upstream of the INS transcription 
start site and comprises 14-25bp tandemly repeated sequence units. Th e insulin minisatellite 
has been associated with variations in birth size [31,34,35], obesity [32,36-39], diabetes mellitus 
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type 1 and type 2 [30], and polycystic ovary syndrome [33]. However, other studies could not 
demonstrate that the INS VNTR was associated with accelerated weight gain, reduced beta cell 
function or adiposity [40-43]. 
Figure 4. Th e INS gene region.
2. Th e GH-IGF-IGFBP axis, fetal and postnatal growth 
Growth hormone (GH), insulin-like growth factors (IGFs) and IGF-binding proteins 
(IGFBPs)
Th e physiology of the GH-IGF-IGFBP axis is shown in Figure 5. GH is secreted by the pituitary 
gland under control of the hypothalamic hormones, GH-releasing hormone (GHRH) and 
somatostatin, as well as ghrelin, a hormone mainly produced in the stomach [44]. GHRH 
and ghrelin bind to their respective receptors in the pituitary and stimulate GH secretion. 
Somatostatin inhibits GH release. Most of the anabolic actions of GH are mediated by IGF-I, 
but GH has also many cellular eff ects that are independent of IGF-I [45].
 Th e IGF system consists of 3 primary ligands: IGF-I, IGF-II, insulin, and three closely 
related membrane-bound receptors. IGF-I is an important member of the IGF system and shows 
structural and functional similarities with insulin and has important anabolic and metabolic 
eff ects. IGF-I is present in 2 forms: the circulating IGF-I which is primarily liver-derived and 
the extra-hepatic autocrine/paracrine form of IGF-I, which is produced by local tissues [46]. 
 Most of the circulating IGF-I is bound to IGFBPs, of which six classes have been 
identifi ed. IGFBP3 is the major carrier protein of IGF-I and binds 70-95% of IGF-I as a binary 
complex or a ternary complex together with acid-labile subunit (ALS) [47]. IGFBP3 and ALS are 
both regulated by GH. IGFBP-1 binds only a small fraction of IGF-I, but has direct inhibitory 
eff ects on IGF-I mediated processes in vivo [47]. Th e hepatic production of IGFBP-I is inversely 
regulated by the portal supply of insulin [48]. Less than 1% of IGF-I is unbound and circulates 
in its free form. Free IGF-I is believed to be the biological active form and several studies have 
indicated the importance of free versus total IGF-I in not only short-term dynamic metabolic 
changes, but also in long-term steady-state changes, like linear growth [49,50]. 
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Figure 5. Physiology of the GH-IGF-IGFBP axis. Adapted from Holt [44].
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Fetal growth
Th e exact role of GH in fetal growth remains unclear. Although high levels of GH in the fetal 
circulation have been reported [51,52], it appears that GH is not a major regulator of fetal 
growth, since the number of GH receptors in prenatal life is low [53]. On the other hand, in 
neonates with congenital GH defi ciency, birth length was on average 1 SDS lower compared 
with healthy neonates, suggesting that GH does have a small eff ect on fetal growth [54]. In SGA 
fetuses, GH levels were found to be similar to appropriate-for-gestational age (AGA) fetuses 
during the second half of gestation [55]. In SGA neonates, however, most studies reported 
elevated GH concentrations in cord blood as compared with AGA neonates [55-58]. Th e latter 
suggests that SGA neonates have a state of GH resistance, which is characterized by increased 
GH levels [54].
 Fetal IGF-I, IGF-II and insulin are the most important endocrine determinants of fetal 
growth and their concentrations are mainly regulated by genetic factors and fetal nutrition. 
IGF-I and IGF-II are already detectable in cord blood from the fi rst trimester and show a 2-3 fold 
increase during the last trimester [59,60]. In newborn SGA infants, IGF-I and IGF-II levels were 
signifi cantly reduced compared with AGA infants, suggesting an important role for low IGF-I 
levels in fetal growth retardation [55,59,60]. Gene deletion studies in mice demonstrated that 
IGF-I and IGF-II knock-out mice had a birth weight which was 60% of normal [10]. Th e growth-
promoting eff ect of IGF-II is also exerted via the IGF-I receptor. Hence inactivation of the IGF-I 
receptor even resulted in a more severe reduction in birth weight to 45% of normal, due to loss 
of both IGF-I and IGF-II action. Interestingly, inactivation of hepatic IGF-I production, as in 
the liver IGF-I defi cient (LID)-mice, had only a minimal eff ect on fetal growth, despite strongly 
reduced levels of circulating IGF-I [61]. Serum levels of free IGF-I were similar for LID-mice 
and wild-type controls, suggesting that normal growth in utero may result from circulating, free 
IGF-I levels. It might also be that the extra-hepatic autocrine/paracrine production of IGF-I was 
suffi  cient to maintain normal growth. In SGA fetuses, IGFBP-3 levels were lower than in AGA 
fetuses, wheras IGFBP-1 levels were elevated [59,62]. IGFBP-1 has been inversely related to 
insulin levels and it might be that low insulin levels in the growth-retarded fetus are responsible 
for the elevation of IGFBP-1 [44]. 
 Initially, insulin was thought to be the major growth-promoting hormone in fetal life. 
More recently, it has been shown that insulin acts directly via stimulation of cellular nutrient 
(glucose) uptake and indirectly by stimulation of IGF-I production [63]. Glucose availability 
and the subsequent increase in fetal insulin are the major regulators of fetal IGF-I production. 
Fetal pancreatectomy in sheep resulted in low fetal IGF-I levels and caused severe intrauterine 
growth retardation [64]. In addition, intrafetal infusions with either glucose or insulin increased 
fetal IGF-I. 
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Postnatal growth
Th e pathophysiology of persistent short stature in some children born SGA is not fully 
understood. Disturbances in the GH-IGF-IGFBP-axis may contribute to poor postnatal catch-
up growth as several studies have demonstrated that up to 60% of SGA children with persistent 
short stature show a reduced spontaneous GH secretion during a 24-hour GH-profi le and/or 
low GH peaks during GH provocation tests [65-69]. Serum IGF-I and IGFBP-3 levels were also 
reduced in short SGA children when compared with healthy controls with normal stature [67, 
70,71]. Some short SGA children have, however, normal or high GH-levels together with low 
levels of IGF-I and IGFBP-3, suggesting a reduced functioning of the GH-receptor [68]. High 
levels of GH and IGF-I have also been reported in some SGA individuals, which suggests that 
these children have a reduced function of the IGF-I receptor [72]. 
 Abnormalities in the GH-IGF-IGFBP axis, as well as a lower birth weight of subjects, 
has been associated with higher risks of diabetes mellitus type 2 and cardiovascular disease in 
adulthood [73-75]. Th erefore, in SGA subjects, disturbances in the GH-IGF-IGFBP axis may be 
related to the future development of these diseases. 
3. Clinical aspects and hypotheses 
Short stature
SGA is a common cause of short stature in childhood and adulthood, accounting for 20% of all 
cases [76]. Most children born SGA, show a spontaneous catch-up growth to a normal height 
above -2 SDS. However, approximately 10% of them do not attain a normal height and thus 
remain short throughout life. In a Swedish cohort of 111 infants born SGA, with a birth length 
below the -2 SDS, 13% still had a height below -2 SDS at the age of 2 years [3]. In another 
group of 724 infants born SGA, defi ned as a birth length below -1.88 SDS, Hokken-Koelega et 
al. found that 15% did not show catch-up growth to a normal height at the age of 2 years [77]. 
Catch-up growth is most pronounced during the fi rst 6 months and was usually completed at 
the age of 2 years [77]. However, in premature SGA infants catch-up growth might take longer 
]77,78[. 
 Chaussain et al. reported that SGA children with a birth length below the -2 SDS who 
remained short during childhood reached a mean adult height of 161.9 (8.0) cm (~-2.1 SDS) 
for boys and 147.6 (7.0) cm (~-2.8 SDS) for girls [79,80]. Th ese values were signifi cantly lower 
than the target heights of these children (p < 0.001) [79]. If a normal height above -2.0 SDS has 
not been achieved by 2 years of age, there is a 7-fold increased risk for short stature for those 
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born with a low birth length and a 5-fold increased risk for those born with a low birth weight 
[76].Th erefore, a child born SGA who is still short at 3 years of age, should be referred to a 
paediatrician with expertise in endocrinology [2]. 
Cardiovascular disease associated with SGA
In epidemiological studies, an inverse relation was found between birth weight and the risk of 
hypertension, cardiovascular disease and diabetes mellitus type 2 in adulthood [81-83]. Insulin 
resistance plays an important role in the pathogenesis of these diseases ]84,85[. Th e exact 
mechanisms underlying these associations are, however, still unknown. Several hypotheses 
have been proposed: 
Fetal origins hypothesis
Based on a number of epidemiological observations linking reduced birth weight and adult 
diseases, such as hypertension, hyperlipidemia, diabetes mellitus type 2, coronary artery disease 
and metabolic syndrome, Barker et al. suggested that fetal malnutrition results in permanent 
metabolic alterations and changes in organic structures in the fetus [81,82,84,85]. Th is re-
programming would be in favor of short-term survival, but detrimental on the long-term as it 
would result in adult diseases (Figure 6).
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Figure 6. Representation of the fetal origins of the metabolic syndrome. Adapted from Barker et al. 
[82,86].
Fetal insulin hypothesis
Th e fetal insulin hypothesis was formulated by Hattersley et al. It postulated that the association 
between low birth weight and adult insulin resistance is principally genetically determined [87]. 
Genes involved in insulin resistance would result in low-insulin-mediated fetal growth as well 
as insulin resistance in childhood and adulthood (Figure 7). 
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Figure 7. Simplifi ed representation of fetal insulin hypothesis. Adapted from Hattersley et al. [87].
Growth acceleration hypothesis
Singhal and Lucas suggested that rapid postnatal growth rather than birth weight per se, could 
have adverse long-term eff ects and might result in adult diseases (Figure 8) [88].
Rapid postnatal 
growth in weight
Low birth weight Adult diseases 
Figure 8. Simplifi ed representation of growth acceleration hypothesis. Adapted from Singhal and Lucas 
[88].
Fat accumulation hypothesis
Based on detailed measurements on body composition by dual energy x-ray absorptiometry 
(DXA), Leunissen et al. took the growth acceleration hypothesis by Singhal and Lucas a step 
further by specifying growth acceleration into fat accumulation (Figure 9) [89]. According to 
this hypothesis, small size at birth followed by growth in height and weight as such is not a 
problem as long as a subject continues to have a normal amount of fat for its age, gender and 
height. 
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Figure 9. Simplifi ed representation of fat accumulation hypothesis. Adapted from Leunissen et al. [89].
4. Genetic studies in Dutch SGA children
Since 1991, we have performed prospective cohort studies to evaluate the eff ects of growth 
hormone (GH) treatment in short SGA children [4,71,90]. Th e children who participated in 
these studies were enrolled in the genetic study when the parents and/or their child agreed 
to participate and when children fullfi lled the in- and exclusion criteria (Appendix A). Our 
genetic study has given us the unique opportunity to study genetic variations in a large group of 
short SGA children with detailed phenotypic data, before and during GH treatment.
 Since 2003, the Programming Factors for growth and Metabolism (PROGRAM) study 
was started in which both short SGA, SGA catch-up, idiopathic short stature (ISS) and control 
young adults were enrolled [89,91]. Th e in- and exclusion criteria were similar to the NESTEGG 
study (Appendix B). 
5. Th e Network of European Studies in Genes in growth (NESTEGG)
In 2001, the Network of European Studies in Genes in Growth (NESTEGG) was initiated by 
pediatric endocrinologists and molecular geneticists to study the etiology of pre- and postnatal 
growth failure in children and their parents (Appendix B) [92]. Th e primary aim of NESTEGG 
was to identify genetic infl uences on fetal and postnatal growth by studying subjects born 
small for gestational age (SGA) with and without postnatal catch-up growth and children 
with idiopathic short stature (ISS) (Figure 10). Th e secondary aim of NESTEGG was to study 
phenotypic characteristics of SGA and ISS subjects and their parents in order to identify parent-
of-origin eff ects of genetic polymorphisms and to study growth response in growth hormone 
(GH) treated patients in relation to phenotype and genotype. 
 Children were collected in Th e Netherlands, France, Germany and the United Kingdom. 
SGA children were included when birth weight and/or birth length was less than ≤ –1.88 
standard deviation score (SDS) according to the national growth charts (Th e Netherlands and 
Germany [93]; France [94]; United Kingdom [95]). Height at or aft er 3 years of age determined 
whether a child had caught up (> –1.88 SDS: SGA catch-up) or remained short (< –1.88 SDS: 
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short SGA) (Th e Netherlands [96]; France [97]; United Kingdom [95]; Germany [98]). Subjects 
in the ISS group had a birth weight and/or birth length above –1.88 but less than +2.00 SDS 
(Th e Netherlands [96]; France [97]; United Kingdom [95]; Germany (98]) and a actual height 
< -1.88 SDS (Th e Netherlands [96]; France [97]; United Kingdom [95]; Germany [98]). 
Height (SDS)
Age (Years)
-1.88
Short SGA
Height (SDS)
Age (Years)
-1.88
ISS
Height (SDS)
Age (Years)
-1.88
SGA Catch-up
Figure 10. NESTEGG groups: Growth patterns of short SGA, SGA catch-up and ISS subjects. 
6. Genetic variations, strategy and techniques in the Dutch study
In this study, several genetic variations were investigated among SGA subjects. Th e genetic 
variations which were investigated were single nucleotide polymorphisms (SNPs), variable 
number of tandem repeats (VNTRs) and relatively large deletions and duplications.
Genetic variations
Genetic variations comprise a diversity of variations in the genome. Th ey can be subdivided in 
genetic polymorphisms and mutations. A genetic polymorphism is a variant, not necessarily 
related to disease, which occurs in more than 1% of the normal population. A mutation is a 
change in genetic information, by defi nition occurring in less than 1% of the normal population 
and oft en related to disease.
 Genetic polymorphisms can be subdivided in polymorphisms which comprise one base 
pair, also called single nucleotide polymorphisms or SNPs, or polymorphisms which consist of 
a tandemly repeating sequence in the genome at a particular locus, also called “variable number 
of tandem repeats” (VNTRs). 
 Th e most frequent mutations are single base-pair changes (so called point mutations). 
Point mutations can change the DNA sequence. Depending on the eff ect of the point mutation 
on the DNA code, the mutation is named: silent, missense or nonsense. Silent mutations code for 
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the same amino acid. Missense mutations code for another amino acid and nonsense mutations 
induce a stopcode which results in a truncated protein.. Also (relatively) large parts of the 
genome might be deleted or duplicated, these are also called copy number variants (CNVs).
Strategy
In the Dutch study genetic polymorphisms and copy number variations were studied.
Genetic polymorphisms
To investigate genetic polymorphisms in SGA children, we have used a candidate-gene approach. 
Th e IGF1, IGF1R and INS gene were studied by the following strategy:
Step 1:
Investigation of literature for the genetic polymorphisms in the gene and specifi cally for 
polymorphisms which are associated with SGA-related outcomes. Reports of genetic 
polymorphisms with functional studies showing the eff ect of the genetic polymorphism on 
RNA or protein level, were collected.
Step 2:
Investigation of genomic databases which contain single nucleotide polymorphisms throughout 
the genome. Th e presence of SNPs in coding regions, being either non-synonymous or 
synonymous, intronic regions or the promoter and 3’UTR region were noted.
Step 3:
Investigation of genetic databases which describe linkage disequilibrium (LD) in the gene and 
the tagging SNPs per LD-block per gene.
Step 4:
An integration of Step 1-3 was performed in which genetic polymorphisms reported in 
literature were selected when associated with SGA-related outcomes and especially when 
functional studies had been performed. Th ese genetic polymorphisms were integrated with the 
SNPs collected from Step 2, in which the LD was taken into account and also particular gene 
regions like the promoter which is known for the binding of transcription factors regulating 
gene expression. Transcription factor binding site databases were investigated to identify 
transcription factors which change their binding depending on the allelic status of the genetic 
polymorphisms. In addition, a power calculation was performed in which the delta (diff erence 
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in population means) and sigma (the within group standard deviation) were estimated from the 
current literature. Depending on the group size, allele frequency or previous studies, cases with 
homozygous carriers of the minor allele were grouped together with the heterozygous carriers. 
Step 5:
When the allelic status of the selected genetic polymorphisms was assessed in the population, 
the LD was determined. Subsequently haplotypes were constructed according to the observed 
LD patterns.
 
Step 6:
Association studies between the genetic polymorphisms, haplotypes and the SGA-related 
outcomes were performed.
Web resources which were used for this approach were:
Celera genome browser: http://www.celera.com/ −
HapMap genomic database: http://www.hapmap.org/ −
Haploview v3.2: http://www.broad.mit.edu/mpg/haploview/ −
NCBI SNP browser: http://www.ncbi.nlm.nih.gov/entrez/ −
PHASE: http://www.stat.washington.edu/stephens/soft ware.html −
Power and sample size calculation: http://biostat.mc.vanderbilt.edu/twiki/bin/view/ −
Main/PowerSampleSize
PubMed: http://www.ncbi.nlm.nih.gov/entrez −
TESS: Transcription Element Search System: http://www.cbil.upenn.edu/tess −
TFSEARCH: Searching Transcription Factor Binding Sites: http://www.cbrc.jp/research/ −
db/TFSEARCH.html
Copy number variants
To investigate copy number variants in growth-related genes of SGA children, we used a broader 
candidate-gene approach by investigating 18 growth associated genes. Th is strategy consisted 
of:
Step 1:
Investigating a short SGA population for copy number variants in 18 growth associated genes 
by using a multiplex ligation-dependent probe amplifi cation (MLPA) kit. 
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Step 2:
Examining all exonic area’s of the gene in which a deletion or duplication was observed at Step 
1, also by MLPA-kit. 
Step 3:
Specify the extent of the deletion or duplication by testing multiple SNPs in the aberrant region, 
using the SNP array technique.
Techniques
Th e main genetic techniques described in this thesis are the Taqman genotyping assay and 
the multiplex ligation dependent probe amplifi cation (MLPA, Appendix C). Th e Taqman 
genotyping assay was used to detect the allelic status of single nucleotide polymorphisms 
(SNPs). By the MLPA, relatively-large deletions and duplications were detected. Also, variable 
number of tandem repeats were determined by using the Genescan technique. To specify the 
exact copy number variant of the MLPA fi ndings, the Aff ymetrix 262K NspI array was used.
Aims of the study
Subclassifi cation of short SGA children
As short SGA children form a heterogeneous population including several subgroups, we 
subclassifi ed the short SGA population according to their length, weight and head circumference 
at birth. We wanted to investigate whether these subgroups would demonstrate diff erent 
postnatal growth patterns and would have a diff erential response to GH treatment. 
Genetic polymorphisms of the IGF1, IGF1R and INS gene
To assess genetic variations in the the IGF1, IGF1R and INS gene and their surrounding region in 
a large group of children born SGA, with either short or normal stature. Linkage disequilibrium 
was investigated and haplotypes were associated with birth size, as well as postnatal and GH-
induced growth. In addition, we performed association studies between INS genetic variations 
and blood pressure. 
Relatively large deletions and duplications in growth-related genes
To assess the presence of deletions or duplications in 18 growth-associated genes in a large group 
of short SGA children. In addition, a detailed genetic and phenotypic work-up was performed 
in two short SGA patients with a deletion in the IGF1R gene.
28 General introduction
Gestational factors in short SGA, SGA catch-up and ISS subjects 
To evaluate the frequency of hypertension, smoking and alcohol use during gestation in a large 
group of short SGA, SGA catch-up and idiopathic short stature (ISS) subjects (NESTEGG). 
In addition, we investigated associations between the gestational factors and spontaneous 
postnatal growth and growth during GH treatment.
Outline of the thesis
Chapter 1 gives an introduction in the topics described in this thesis.
Chapter 2 proposes a subclassifi cation of small for gestational age children with persistent 
short stature, based on birth weight, birth length and head circumference at birth. In addition, 
the spontaneous and GH-induced postnatal growth pattern was determined in the various 
subgroups. Chapter 3 reviews the current literature with regard to genetic polymorphisms in 
the IGF1 and IGF1R gene. 
Chapter 4 reports associations between birth size, spontaneous postnatal and GH-induced 
growth, in relation with IGF1 gene polymorphisms and haplotypes.
Chapter 5 shows associations which were found in a much larger population consisting of both 
short SGA and SGA catch-up children. 
Chapter 6 describes a genetic association study of IGF1R polymorphisms and haplotypes with 
spontaneous postnatal growth in short SGA and SGA catch-up children. 
Chapter 7 presents associations between insulin gene polymorphisms and haplotypes with 
spontaneous postnatal growth in short SGA and SGA catch-up children.
Chapter 8 shows the results of a detailed study in which relatively large deletions and duplications 
of 18 growth-associated genes in short SGA children were investigated. 
Chapter 9 describes the characteristics and spontaneous postnatal growth and growth during 
GH-treatment of short SGA, SGA catch-up and ISS subjects (NESTEGG) and the relations with 
gestational hypertension, smoking and alcohol use.
Chapter 10 discusses our data in relation to current literature and comments on the clinical 
implications and conclusions of our study results.
Chapter 11 summarizes our fi ndings in English.
Chapter 12 presents a Dutch summary.
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Appendix A. Genetic studies in Dutch SGA patients
Inclusion criteria 
Born small for gestational age (SGA), defi ned as a birth length ≤ –2.00 SDS [93]  −
Persistent short stature, defi ned as a height ≤ -2.00 SDS at the age ≥ 3 years [96]  −
Catch-up growth, defi ned as a height > -2.00 SDS at the age ≥ 3 years [96] −
Caucasian descent  −
Uncomplicated postnatal period  −
Exclusion criteria 
severe chronic illness  −
endocrine disorders  −
chromosomal or genetic abnormalities  −
positive endomysial or transglutaminase antibodies  −
skeletal disorders  −
psychosocial dwarfi sm  −
growth failure caused by other syndromes (except Silver Russell syndrome) −
Design
Th e Dutch genetic studies started in 2000. Th e initial study population in 2002 consisted of 
201 short SGA children. Th e total populaion consisted of 635 SGA children either short stature 
or normal stature. Th e genetic studies were performed at the ErasmusMC, Sophia Children’s 
Hospital, Rotterdam.
30 General introduction
Appendix B. Network of European Studies in Genes in Growth 
(NESTEGG) 
Aim
Th e primary aim of NESTEGG was to identify genetic infl uences on fetal and postnatal growth 
by studying subjects born small for gestational age (SGA) with and without postnatal catch-up 
growth and children with idiopathic short stature (ISS). 
 Th e second and third aims of NESTEGG included the study of phenotypic characteristics 
of SGA and ISS subjects and their parents, to identify parent-of-origin eff ects of genetic 
polymorphisms and to study growth hormone response in treated patients and relate this to 
phenotype and genotype. Growth hormone therapy was not a requirement for inclusion in this 
study.
Patients
Recruitment of all subjects was performed according to standard operating procedures in 
four paediatric endocrinology departments, namely, Sophia Children’s Hospital Erasmus 
University Medical Centre Rotterdam; University Children’s Hospital Toulouse; University 
Children’s Hospital Tübingen and Bart’s and the Royal London Hospitals London. Each centre 
gained ethical approval from their regional ethics review board. Subjects were free to refuse to 
participate in this study without altering their future medical management. Th e short subjects 
were recruited from the growth clinics, the SGA catch-up group was recruited from studies 
in young adult or from particular targeted recruitment, based on identifi cation through birth 
cohorts.
Inclusion criteria 
SGA was defi ned as a birth weight and/or birth length ≤ –1.88 standard deviation score  −
(SDS) according to the national growth charts (Th e Netherlands and Germany [93]; 
France [94]; United Kingdom [95]). 
Height at or aft er 3 years of age determined whether a child had caught up (> –1.88 SDS:  −
SGA catch-up) or remained short (< –1.88 SDS: short SGA) (Th e Netherlands [96]; 
France [97]; United Kingdom [95]; Germany [98]). 
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ISS children were selected by having a birth weight and/or birth length > –1.88 to +2.00  −
SDS and a prepubertal height aft er 3 years of age ≤ –1.88 SDS (Th e Netherlands [96]; 
France [97]; United Kingdom [95]; Germany [98]).
Gestation ≥ 30 weeks with uncomplicated postnatal period (ventilation < 72 hours not  −
including CPAP). 
Subjects were included only when they were of Caucasian origin and all grandparents  −
and parents must have been born and living in Western Europe. 
Exclusion criteria 
syndrome or dysmorphic features (except Russell Silver syndrome)  −
chromosomal or genetic abnormality  −
severe chronic illness or endocrine disease  −
positive gliadin, endomysial or reticulin antibodies  −
growth hormone defi ciency  −
severe disproportionate short stature  −
psychosocial dwarfi sm  −
any psychiatric, neurodegenerative, or chronic illness in parents, which may aff ect their  −
ability to give fully informed consent or donate blood 
adoption of the child −
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Appendix C. Genetic techniques
Th e main genetic techniques described in this thesis are the Taqman genotyping assay and the 
multiplex ligation dependent probe amplifi cation (MLPA). 
Taqman: Taqman ® SNP genotyping assays, Applied Biosystems
Taqman SNP genotyping assay is based on the design of two Taqman probes, specifi c for the 
wild type and the mutant allele. Each of the two probes is labelled with a diff erent fl uorescent 
reporter (usually VIC or FAM), and each is designed with the genetic variation aff ecting the 
middle part of the probe sequence. Each of the reporters is “quenched” (silenced) by TAMRA 
(6-carboxyl-tetramethyl-rhodamine) attached by the left  arm located at the 3’end of each probe. 
When the probe is intact, the proximity of the reporter dye to the quencher dye results in 
suppression of the reporter fl uorescence. During PCR, forward and reverse primers hybridize 
to a specifi c sequence of the target DNA. Th e Taqman probe hybridizes to a target sequence 
within the PCR product. Th e AmpliTaq Gold enzyme cleaves the Taqman probe with its 5’-
3’nucelease activity. Th e reporter dye and quencher dye are separated upon cleavage. Th e 
3’end of the Taqman probe is blocked to prevent extension of the probe during PCR. Th e 
separation of the reporter dyes from the quencher dye results in increased fl uorescence for 
each of the VIC and FAM reporters. Both primer and probe must hybridize to their targets 
for amplifi cation and cleavage to occur. Th e fl uorescence signals are generated only if the 
target sequences for the probes are amplifying during PCR. Th e increase in fl uorescence is 
measured, and is a direct consequence of target amplifi cation during PCR (Figure 11). 
Figure 11. Example of a Taqman assay result on a genotyped population. 
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Multiplex ligation dependent probe amplifi cation (MLPA) 
MLPA can be used to detect the copy number of approximately 45 sequences in one test. Each 
probe consists of a two oligonucleotides, recognizing adjacent target sites on the DNA. When 
the two probes are hybridized to their target sequence, they can be ligated to each other (Figure 
12). Only ligated probes will be amplifi ed by universal primer pairs. Th e amplifi cation product 
of each probe has a unique length, which makes it possible to separate and quantify the PCR 
products using electrophoresis (Figure 13). 
PCR Primer Y
Hybridization sequences
Stuffer
PCR P
rimer X
Target
PCR Primer Y Stuffe
r PC
R Prim
er X
Target
LigasePCR Primer Y Stuffe
r PC
R Prim
er X
Target
Amplification of probe
PCR Primer Y Stuffer PCR Primer X
Separation and
quantitation
Figure 12. Th e principle of the MLPA technique.
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Figure 13. Example of an MLPA results in which the peak height indicates a copy number change of the 
probe target sequence. Th e two lanes represent DNA of a case and a control study participant whose peak 
heights can be compared. 
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Abstract
Aim
We determined whether subclassifi cation of short SGA children according to birth anthropo-
metrics could delineate diff erent patterns in gestation, delivery, postnatal growth, response to 
growth hormone (GH) treatment and parental height.
Methods
201 short SGA children were divided over 3 groups, SGAL, SGAL+W and SGAL+W+HC, according 
to birth length (L), weight (W) and head circumference (HC) ≤ -2.00 standard deviation score 
(SDS). 
Results
SGAL+W+HC children were born aft er the shortest gestational age and more oft en by caesarean 
section than SGAL children (36.3 vs. 38.1 weeks, 68.4 vs. 24.4%). SGAL+W children had an 
intermediate pattern and experienced most gestational hypertension (P = 0.01). At birth, 
SGAL+W+HC children were shorter than SGAL or SGAL+W (-4.12 vs. -2.67 and -3.72 SDS, 
P ≤ 0.001). During the fi rst 3 years of life, SGAL+W+HC children exhibited an increased 
growth in height (0.98 SDS) and HC (1.28 SDS) than SGAL (height, -0.06 SDS; HC, -0.30 
SDS) and SGAL+W (height, 0.62 SDS; HC, -0.31 SDS). However, HC SDS remained smaller 
for SGAL+W+HC than the other groups at age 3. Th e groups did not diff er in growth response 
during GH treatment. SGAL children tended to have shorter parents and target height than 
SGAL+W+HC children.
Conclusions
Our study shows that subclassifi cation of short SGA children might be a useful method for 
investigating SGA children as the subgroups revealed a diff erent gestation, delivery and 
postnatal growth pattern. Response to GH treatment was not diff erent between the groups.
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2Introduction
Small for gestational age (SGA) is the term used to describe a group of children born with a 
birth weight and/or birth length below the normal range of a reference population, corrected 
for gestational age at birth. Since reduced size at birth may result from any number of fetal, 
maternal, placental or demographic infl uences, children born SGA comprise a heterogeneous 
group with a broad spectrum of clinical characteristics. While many children born SGA achieve 
suffi  cient growth to normalize their stature by 2 years of age, approximately 10–15% maintain 
a height below -2 standard deviation scores (SDS) and continue to be short throughout 
adolescence and adulthood [1]. Furthermore, in a population-based postnatal growth study of 
3650 infants, of whom 8.1% were classifi ed SGA according to their birth weight and birth length 
SDS, children born both short and light for gestational age were found to be shorter as adults 
than those born either short or light [2]. 
 Short SGA children appear to benefi t from growth hormone (GH) treatment in terms 
of height increment. However, even aft er accounting for diff erences in parental height, age and 
duration of treatment, there appears to be a wide variation in the response to GH treatment that 
has been diffi  cult to explain. Th e recent European approval of GH therapy to improve growth in 
short SGA children highlights the clinical relevance of ascertaining which short SGA children 
are most likely to benefi t from treatment because potentially 23000 European children meet the 
criteria for GH therapy annually [1-3].
 We have previously demonstrated that mean head circumference (HC) is signifi cantly 
smaller (P < 0.001) in short SGA children with a reduced birth weight and birth length 
(≤ -2.00 SDS) than in short SGA children born with merely a short birth length (≤ –2.00 
SDS) [4]. Th e objective of this study was to determine whether subclassifi cation of short SGA 
children according to their birth anthropometrics could delineate diff erences in gestation, type 
of delivery, postnatal growth, response to GH treatment and parental height. 
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Methods
Patients
Data was evaluated of 201 SGA children with persistent short stature who were participating 
in prospective cohort trials evaluating the eff ect of growth hormone (GH) treatment [4-9]. 
SGA was defi ned as a birth length ≤ –2.00 SDS [10]. Persistent short stature was defi ned as a 
height ≤ -2.00 SDS at the age ≥ 3 years [11]. Children were divided into three groups based on 
anthropometrics at birth: group 1, comprised children with a reduced birth length (≤ –2.00 
SDS) and normal birth weight and HC (SDS > -2.00) (SGAL), group 2 comprised children 
with reduced birth length and weight (≤ –2.00 SDS) and normal HC (SDS > -2.00) (SGAL+W), 
and group 3 included children with a reduced birth length, weight and HC (SDS ≤ –2.00) 
SGAL+W+HC [10]. All children fulfi lled the inclusion criteria of being Caucasian and having an 
uncomplicated postnatal period. Children with severe chronic illness or endocrine disorders, 
chromosomal or genetic abnormalities, positive endomysial or transglutaminase antibodies, 
skeletal disorders, psychosocial dwarfi sm, and growth failure caused by other syndromes 
(except Silver Russell syndrome), were excluded from the study. 
 Th e effi  cacy of 12 months GH treatment was evaluated in a subpopulation of 143 
prepubertal children who were prepubertal at start and aft er one year of GH treatment. Pre-
puberty was defi ned as a bilateral testicular volume of 3 ml or less for boys and Tanner stage M1 
for girls. Children receiving medication for induction or postponement of puberty were excluded 
from the analysis. Th e study protocol was approved by local Medical Ethics Committees and 
written informed consent was obtained from the parents/guardians of each child. 
Clinical parameters
Data regarding gestational age and birth measurements were retrieved from medical records of 
201 children. Maternal medical records of 120 children were traced for the type of delivery. Data 
regarding gestational hypertension, smoking (by mother, father or both) and use of alcohol were 
retrieved by questionnaires. Postnatal growth patterns from birth to 3 years of age were assessed 
using growth measurements from primary health care records, hospital records and baseline 
data from GH treatment studies of all 201 children. All measurements were plotted on a growth 
chart per child and checked for outliers to reduce within and between observer errors. 
 Ponderal index was calculated by ((birth weight in grams/ birth length in cm3)*100) 
and expressed as SDS [12]. Body mass index was calculated by (weight in kg/ height in meters2) 
and SDS calculated according to Dutch reference values [11]. A measure for birth head size 
compared to length was obtained by subtracting birth head circumference SDS from birth 
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2length SDS. Height, weight, HC and sitting height were measured at start and aft er one year of GH treatment according to standardized methods [4,5]. Sitting height/ standing height ratio’s 
for age were expressed as SDS using Dutch reference values [12]. 
 Parental heights of 160 mothers and 157 fathers were assessed using a Harpenden 
stadiometer and expressed as SDS using Dutch reference values [13]. Target height (TH) SDS 
was calculated using Dutch reference values according to the formula: 1/2 * (Height father+ 
Height mother+ 13) + 4.5 for boys and 1/2 * (Height father+ Height mother– 13) + 4.5 for 
girls, where the addition of 4.5 cm represents the secular trend [11]. During GH treatment, 
biosynthetic GH was injected subcutaneously once daily at a dose of 1 to 2 mg/m2 body surface 
area/day. 
Statistical analysis
Anthropometric data were analyzed from birth until 3 years of age and before and aft er 12 
months GH treatment. Analyses from birth to 3 years of age were performed on the total cohort 
of 201 children by univariate analysis of variance (ANOVA). Absolute birth size was adjusted 
for sex and gestational age to adjust for prematurity. Anthropometric SDS up to 3 years of age 
were also corrected for gestational age. Th e standard deviation (SD) of the adjusted means was 
approximated by SD = SE * (√n). Th e Chi-square test was used to analyze data on delivery and 
gestational factors. 
 A subgroup analysis on the eff ect of GH treatment on growth was performed in a group 
of 143 prepubertal children. Analysis of the growth response was performed by using ANOVA. 
Baseline measurements were corrected for age at start of GH treatment, as covariate in ANOVA. 
Th e growth response during 12 months of GH treatment was adjusted for GH dose and age at 
start of GH treatment, also as covariate in ANOVA. Standard deviations (SD) of the adjusted 
means were approximated by SD = SE * (√n). Parental and target heights were compared by 
using ANOVA. Parental heights were compared to 0 SDS by one-sample t-test. 
 If an overall test comparing the three groups was signifi cant (P-value ≤ 0.05), post-hoc 
tests with Bonferroni correction were performed. Statistical tests were performed using SPSS 
11.0 package (SPSS Inc., Chicago, IL, USA). 
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Results
Birth anthropometrics and delivery
As shown in Table 1, there were statistically signifi cant diff erences in anthropometric birth 
data between the SGAL, SGAL+W and SGAL+W+HC children, with the latter being the most 
severely aff ected ones with regard to all anthropometric data (Table 1). Whereas SGAL+W+HC 
children were most proportional as expected, SGAL+W children were most disproportional with 
a low birth length SDS in combination with a spared head in the normal range. SGAL children 
displayed an intermediate pattern. Th e type of delivery was diff erent between groups. Th e 
majority (76%) of the SGAL group was born aft er vaginal delivery in contrast to the SGAL+W 
and SGAL+W+HC children (46 and 32%, Table 1). Whereas the frequency of acute caesarean 
sections was not diff erent between the groups, the frequency of elective caesarean sections was 
diff erent. Within the SGAL+W+HC group, 53% of children were born aft er an elective caesarean 
section in contrast to 41% of the SGAL+W and 13% of the SGAL group. 
 Gestational hypertension occurred most frequently in the SGAL+W children, in contrast 
with SGAL and SGAL+W+HC children (37.9 vs. 13.6 and 28.3 %). Smoking during pregnancy 
was highly prevalent (49.7%) but did diff er between the groups. Alcohol use during gestation 
was reported in 7.4% of the total population and tended to be the most frequent in the SGAL+W 
children, although not statistically diff erent between the groups.
Change in height, weight and HC during the fi rst three years of life
During the fi rst 3 years of postnatal life, the extent of spontaneous growth diff ered between 
SGAL children and children in the SGAL+W and SGAL+W+HC groups (Figure 1; Table 2). 
Growth in height was greatest for SGAL+W+HC children. At birth, children in the SGAL+W+HC 
group were shorter than those in the other groups (Table 1), but by 6 months of age they had 
attained a height SDS that was similar to SGAL+W children (-3.21 SDS) although they remained 
signifi cantly shorter than SGAL children (-2.62 SDS; P = 0.001, Table 2). In contrast, the height 
SDS of SGAL children remained virtually unchanged during this period (Figure 1). 
 Whereas the SGAL children had a substantial reduction in weight SDS from birth until 
the age of 3 years (Figure 2; Table 2), SGAL+W and SGAL+W+HC children maintained their weight 
SDS. 
 At birth, HC was by defi nition signifi cantly (P < 0.001) smaller in SGAL+W+HC children 
than in the SGAL and SGAL+W children (Table 1). During the fi rst 6 months of postnatal life there was a 
substantial increase in HC SDS in SGAL+W+HC children from -2.9 SDS at birth to -1.9 SDS at 6 months 
followed by a further, albeit slower increase to -1.6 SDS at 3 years of age (Figure 3; Table 2). Despite this 
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2marked increase, HC was at 3 years of age signifi cantly smaller (P < 0.001) in the SGAL+W+HC children as compared to children in the other two groups. For children born SGAL or SGAL+W, 
HC decreased slightly during the fi rst 6 months of life and remained below their HC SDS at 
birth until the age of 3 years (Table 2).
Table 1. Baseline characteristics of the total study population and the short SGA groups.
Total SGAL SGAL+W SGAL+W+HC P-value*
Sex boys/girls 109/92 36/31 35/35 38/26 0.55
GA weeks 36.8 (3.5) 38.1 (3.1) 36.0 (3.7) 36.3 (3.7) 0.00041
Birth length cm 41.6 (4.9) 42.8 (2.1) 41.3 (2.0) 40.7 (2.0) <0.0000011
SDS -3.50 (1.30) -2.67 (0.54) -3.72 (1.30) -4.12 (1.42) <0.000011
Birth weight grams 1921 (716) 2347 (238) 1762 (234) 1649 (233) <0.0000013
SDS -2.46 (1.11) -1.25 (0.62) -2.88 (0.64) -3.27 (0.79) <0.0000013
Birth HC cm 31.5 (3.0) 32.4 (1.2) 32.4 (1.2) 29.7 (1.2) <0.0000012
SDS -1.34 (1.45) -0.64 (0.88) -0.59 (1.11) -2.89 (0.98) <0.0000012
Birth HC-Birth Length SDS 2.16 (1.71) 2.03 (1.09) 3.13 (1.89) 1.23 (1.48) <0.0000013
Height mother cm 162.3 (7.3) 160.6 (9.0) 163.3 (5.7) 163.0 (6.3) 0.09
SDS -0.97 (1.17) -1.24 (1.45) -0.80 (0.93) -0.85 (1.01) 0.09
Height father cm 176.5 (6.9) 176.2 (7.7) 175.4 (6.9) 178.4 (5.7) 0.07
SDS -0.82 (1.04) -0.87 (1.15) -0.99 (1.03) -0.53 (0.85) 0.07
TH SDS -0.51 (0.86) -0.66 (0.86) -0.52 (0.87) -0.29 (0.83) 0.12
Birth length-TH SDS -2.89 (1.59) -1.95 (1.12) -3.07 (1.38) -3.81 (1.74) <0.0000013
Height-TH SDS -2.61 (0.85) -2.53 (0.85) -2.63 (0.85) -2.72 (0.83) 0.70
Type of delivery:
Vaginal % (n) 52.5 (63) 75.6 (34) 45.9 (17) 31.6 (12) 0.00023
GA 
(weeks)
38.9 (2.1) 39.1 (2.2) 38.6 (2.5) 38.6 (1.4) 0.66
Acute CS % (n) 13.3 (16) 11.1 (5) 13.5 (5) 15.8 (6) 0.82
GA 
(weeks)
37.1 (3.3) 35.8 (4.3) 37.4 (3.9) 37.8 (1.7) 0.61
Elective CS % (n) 34.2 (41) 13.3 (6) 40.5 (15) 52.6 (20) 0.0013
GA 
(weeks)
35.0 (2.8) 37.5 (2.1) 33.8 (2.3) 35.1 (2.9) 0.02 4
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(continued) Total SGAL SGAL+W SGAL+W+HC P-value*
Gestational factors:
Hypertension % (n) 26.4 (43) 13.6 (8) 37.9 (22) 28.3 (13) 0.014
Smoking % (n) 49.7 (42) 50.0 (25) 46.0 (23) 53.3 (24) 0.77
Alcohol % (n) 7.4 (12) 3.4 (2) 12.3 (7) 6.5 (3) 0.18
Values are means (standard deviation) unless indicated otherwise. *= Th e overall P-value is presented by ANOVA for continuous and 
by chi-square test for categorical variables. Post-hoc testing showed; 1= SGAL diff ered in comparison to the SGAL+W and SGAL+W+HC 
groups; 2= SGAL+W+HC diff ered in comparison to the SGAL+W and SGAL groups; 3= All groups diff ered signifi cantly from each other, 
4= SGAL diff ered in comparison to the SGAL+W group. GA= gestational age, HC= head circumference, TH= target height, CS= 
caesarean section, SDS= standard deviation score. 
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Figure 1. Height (SDS) during the fi rst three years of life and during one year of GH treatment for the short 
SGA groups. Data shown are means with standard errors. 
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Figure 2. Weight (SDS) during the fi rst three years of life and during one year of GH treatment for the short 
SGA groups. Data shown are means with standard errors. 
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Figure 3. Head circumference (SDS) during the fi rst three years of life and during one year of GH treatment 
for the short SGA groups. Data shown are means with standard errors. 
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Table 2. Spontaneous growth during the fi rst 3 years of life in the total population and the three groups of 
short SGA children.
Total SGAL SGAL+W SGAL+W+HC P-value*
Height
0.0 year SDS -3.50 (1.30) -2.67 (0.54) -3.72 (1.30) -4.12 (1.42) <0.000011
0.5 year SDS -3.01 (1.08) -2.62 (1.03) -3.21 (1.01) -3.21 (1.00) 0.0011
1.0 year SDS -2.83 (0.84) -2.55 (0.83) -2.96 (0.81) -2.98 (0.81) 0.0041
2.0 years SDS -2.97 (0.73) -2.82 (0.74) -2.98 (0.73) -3.12 (0.73) 0.07
3.0 years SDS -3.00 (0.70) -2.88 (0.72) -3.01 (0.71) -3.11 (0.70) 0.20
Change 0-3 SDS 0.50 (1.37) -0.06 (1.23) 0.62 (1.15) 0.98 (1.19) <0.000011
Weight
0.0 year SDS -2.46 (1.11) -1.25 (0.62) -2.88 (0.64) -3.27 (0.79) <0.0000013
0.5 year SDS -2.74 (1.28) -2.08 (1.16) -2.95 (1.14) -3.21 (1.13) <0.000011
1.0 year SDS -2.75 (1.14) -2.14 (1.07) -2.94 (1.05) -3.19 (1.05) <0.000011
2.0 years SDS -2.78 (1.02) -2.21 (0.96) -2.94 (0.94) -3.21 (0.94) <0.000011
3.0 years SDS -2.82 (0.96) -2.34 (0.92) -2.96 (0.91) -3.19 (0.90) 0.000011
Change 0-3 SDS -0.36 (1.10) -1.04 (0.98) -0.10 (0.99) 0.07 (0.95) <0.000011
HC
0.0 year SDS -1.34 (1.45) -0.64 (0.88) -0.59 (1.11) -2.89 (0.98) <0.0000012
0.5 year SDS -1.40 (0.94) -0.98 (0.84) -1.31 (0.83) -1.91 (0.83) <0.0000013
1.0 year SDS -1.26 (0.89) -0.92 (0.81) -1.10 (0.80) -1.76 (0.80) <0.000012
2.0 years SDS -1.15 (0.87) -0.86 (0.82) -1.04 (0.81) -1.60 (0.81) <0.000012
3.0 years SDS -1.14 (0.89) -0.86 (0.84) -1.05 (0.83) -1.59 (0.83) 0.000022
Change 0-3 SDS 0.17 (1.35) -0.30 (1.17) -0.31 (1.10) 1.28 (1.16) <0.000012
Total SGAL SGAL+W SGAL+W+HC P-value*
PI and BMI
0 year PI (SDS) 1.57 (3.31) 3.86 (2.86) 0.66 (2.84) 0.17 (2.88) <0.00001
1
1 BMI (SDS) -1.24 (1.23) -0.59 (1.17) -1.40 (1.17) -1.73 (1.10) <0.00001
1
3 BMI (SDS) -1.08 (1.03) -0.55 (0.94) -1.24 (0.94) -1.44 (0.94) <0.00001
1
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continued Total SGAL SGAL+W SGAL+W+HC P-value*
Change BMI 
1-3
BMI 
(SDS) 0.17 (0.81) 0.05 (0.86) 0.16 (0.86) 0.29 (0.79) 0.26
Values are means (standard deviation) which, at age 0.5 until 3 years were adjusted for gestational age. *= Th e overall P-value is 
presented of the SGA groups. Post-hoc testing showed; 1= SGAL diff ered in comparison to the SGAL+W and SGAL+W+HC groups; 2= 
SGAL+W+HC diff ered in comparison to the SGAL+W and SGAL groups; 3= All groups diff ered signifi cantly from each other; 4= the 
SGAL group diff ered from the SGAL+W+HC group. HC= head circumference, PI= ponderal index, BMI= body mass index, SDS= 
standard deviation score.
Ponderal- and body mass index (BMI) were investigated as measures for weight for height ratio 
at birth until the age of 3. SGAL children had the highest ponderal index SDS at birth (3.86 SDS) 
in comparison with SGAL+W+HC children (0.17 SDS). SGAL+W children showed an intermediate 
pattern (0.66 SDS). Although SGAL children had the highest ponderal index SDS at birth, they 
had a decrease in weight SDS especially during the fi rst 6 months, resulting in a normal BMI 
SDS at age 3. From age 1 until age 3, SGAL+W and SGAL+W+HC children showed an increase in 
BMI (0.16 vs. 0.29 SDS), whereas SGAL children remained at the same SDS. 
Eff ect of GH treatment on height, weight and HC
Mean age (6.8 ± 2.3 years) at start of GH treatment was comparable between the SGA groups 
(P = 0.40, Table 3). From 3 years of age until start of GH treatment height SDS was maintained 
at a similar level within each group, and did not diff er markedly between groups (Table 3). 
GH treatment for 12 months resulted in a similar increase in height SDS (mean increase = 
0.86 SDS) in all groups (Figure 1). In all groups, height SDS aft er 12 months GH treatment 
was signifi cantly (P < 0.001) higher than height SDS at start of treatment and was not diff erent 
between groups (P = 0.35, Table 3). 
 Between 3 years of age and start of GH treatment, weight SDS remained at approximately 
the same level in all groups (Figure 2, Tables 2 and 3), with SGAL children remaining at a weight 
SDS of approximately -2.5 SDS which was signifi cantly higher than those in the other two groups 
during this period (Tables 2 and 3). GH treatment resulted in a signifi cantly greater increment 
in weight SDS for the SGAL+W+HC children than the SGAL children (P = 0.02; Table 3).
At start of GH treatment, HC SDS was signifi cantly greater in SGAL children than in SGAL+W or 
SGAL+W+HC children (P = 0.002; Table 3, Figure 3). GH treatment resulted in a similar increase 
in HC in all groups (Table 3). Despite this increase, HC remained the smallest for SGAL+W+HC 
and SGAL+W children aft er 1 year of GH treatment at -1.12 SDS and -0.88 SDS in comparison 
with the children in the SGAL group, being –0.46 SDS (P = 0.001). 
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At start of GH treatment, the sitting height to height ratio was not statistically signifi cant 
between the groups, SGAL children having a mean (SD) of 1.42 (1.63) SDS, SGAL+W children 
1.33 (1.22) SDS and SGAL+W+HC children 1.51 (1.60) SDS (P = 0.86). 
Table 3. Th e eff ect of growth hormone (GH) treatment on growth parameters in the total population and 
in the short SGA groups. 
Total SGAL SGAL+W SGAL+W+HC P-value
Sex boys/girls 75/68 24/29 23/22 28/17 0.24
Age at start years 6.81 (2.29) 7.12 (2.42) 6.49 (2.28) 6.79 (2.14) 0.40
GH dose mg/m2/day 1.11 (0.29) 1.10 (0.28) 1.13 (0.31) 1.09 (0.29) 0.76
Height
Start* SDS -3.04 (0.62) -3.05 (0.62) -3.10 (0.62) -2.96 (0.62) 0.54
Aft er 1 year** SDS -2.18 (0.65) -2.25 (0.64) -2.21 (0.64) -2.07 (0.63) 0.35
Changes during 1 year** SDS 0.86 (0.36) 0.81 (0.24) 0.89 (0.24) 0.89 (0.24) 0.13
Weight
Start* SDS -3.00 (0.92) -2.59 (0.85) -3.32 (0.85) -3.18 (0.85) 0.000071
Aft er 1 year** SDS -2.22 (0.87) -1.92 (0.84) -2.50 (0.84) -2.29 (0.84) 0.0031
Changes during 1 year** SDS 0.78 (0.43) 0.67 (0.37) 0.82 (0.37) 0.88 (0.37) 0.024
HC
Start* SDS -1.11 (0.88) -0.77 (0.85) -1.19 (0.85) -1.43 (0.85) 0.0021
Aft er 1 year** SDS -0.80 (0.92) -0.46 (0.87) -0.88 (0.87) -1.12 (0.87) 0.0011
Changes during 1 year** SDS 0.31 (0.39) 0.30 (0.36) 0.33 (0.37) 0.31 (0.36) 0.91
Values are means (standard deviation). *= Means are adjusted for age at start of GH treatment; **= Means are adjusted for age at 
start of GH treatment and GH dose. Th e overall P-value is presented of the SGA groups. Post-hoc testing showed; 1= SGAL diff ered 
in comparison to the SGAL+W and SGAL+W+HC groups; 4= the SGAL group diff ered from the SGAL+W+HC group. HC = head 
circumference, SDS= standard deviation score.
Parental height 
Parental heights (mother and father) were not signifi cantly diff erent between the SGA groups 
(Table 1). Parental height was lower than average (mother, -0.97 SDS; father, -0.82 SDS, in 
comparison to 0 SDS, both P < 0.001). Although mean height SDS for mothers of SGAL children 
(-1.24 SDS) was lower than those of the other SGA groups, there was no statistical diff erence 
between the three groups (P = 0.09, Table 1). Target height (TH) SDS tended to be the lowest 
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signifi cantly diff erent at birth but not at start of GH treatment (Birth length-TH, Height-TH 
SDS, Table 1). All groups had a height SDS far below their TH SDS (Table 1).
Discussion
Th e aim of this study was to determine in short SGA children whether diff erences in birth 
anthropometrics, with respect to length, weight, and head circumference (HC), were associated 
with diff erences in gestation, type of delivery, postnatal growth, parental height, and response to 
GH treatment. Our results show that SGAL+W+HC children experienced the most severe growth 
restriction during pregnancy. Th is is partly explained by their defi nition to have a length, weight 
and HC ≤ -2.00 SDS, but was oft en 1 until 2 SDS below -2.00 SDS. SGAL+W children showed 
an intermediate pattern with regard to birth length and weight in comparison with SGAL and 
SGAL+W+HC children. Notably, SGAL+W+HC had the greatest increase in height and HC during 
early postnatal life, although at the age of 3, HC SDS and weight SDS still were signifi cantly 
lower then those born SGAL. SGA subclassifi cation could not predict a diff erential response to 
GH treatment as an increased growth was seen for all three groups. Aft er 1 year of treatment 
however, HC and weight of SGAL+W+HC and SGAL+W children remained signifi cantly below 
those of SGAL children. 
 SGAL children had no postnatal increase in growth, showed a marked decrease in 
weight and also a decline in HC SDS. In contrast, short SGAL+W and SGAL+W+HC children 
had a signifi cant increase in growth during early postnatal life. Th ese diff erences in postnatal 
growth patterns might result from diff erent genetic and environmental parameters infl uencing 
SGAL children as compared with the SGAL+W and SGAL+W+HC children. SGAL+W+HC children 
suff ered from severely impaired prenatal growth, but experienced a marked increase in growth 
aft er birth. In contrast, SGAL children were mostly born aft er a vaginal delivery, were less 
small at birth and showed a decrease in growth in height and weight aft er birth. Also, parents 
of SGAL children and especially their mothers, tended to be shorter than those of the other 
groups. Th ese fi ndings suggest that SGAL children resemble a growth pattern as observed in 
children with idiopathic short stature (ISS) who are also mainly born aft er a vaginal delivery, 
have a decreased growth aft er birth and in many cases short parents. It might well be that 
subtle skeletal abnormalities play a role in some short SGAL children instead of generalized 
fetal growth restriction, explaining the more frequent vaginal deliveries. For this group of SGA 
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children it might be interesting to perform genetic research into genes involved in pre- and 
postnatal bone development. 
 SGAL+W children were characterized by their intermediate birth size, type of delivery, 
and postnatal growth pattern in comparison to the SGAL and SGAL+W+HC children. Th ese 
children also had the highest frequency of gestational hypertension which might explain 
their short gestational age during elective cesarean section and their spared birth HC. Th is 
observation might suggest that SGAL+W children, in contrast to SGAL and SGAL+W+HC children, 
might be a consequence of gestational hypertension. A previous report also showed that the 
combination of low birth weight and height is most frequent aft er gestational hypertension [14], 
which confi rms our observation. We however could not observe that SGAL+W children were 
more prone to have cardiovascular risk factors as a higher postnatal weight or BMI increase in 
comparison to the other groups. Further long-term follow-up of SGAL+W children is needed, to 
identify a potential higher risk to cardiovascular risk factors. 
 SGAL+W+HC children were the smallest at birth, with regard to length, weight and HC. 
We expected to fi nd a comparable or somewhat smaller birth length SDS than in the other 
children, as birth length SDS ≤ -2.00 was the major inclusion criterion for all children in the 
study cohort. However, we found that SGAL+W+HC children had a considerably shorter birth 
length than SGAL and SGAL+W children, despite of having the highest target height of the 
groups. Interestingly, SGAL+W+HC children had the greatest increase in growth parameters of 
all groups, indicating that SGAL+W+HC children might have had the most severe fetal growth 
restraint which disappeared aft er birth. Postnatal growth of the children with the most severe 
growth retardation might be explained by regression to the mean. However, if this growth would 
be due to regression to the mean then we would have expected growth of all growth parameters 
in the SGAL+W+HC children. As there was no growth in weight, we suspect that regression had 
only a limited eff ect. 
 Of note was the fi nding that 68% of SGAL+W+HC children were delivered by caesarean 
section in contrast to SGAL children of whom 76% were born aft er vaginal delivery. It is likely 
that the SGAL+W+HC children experienced growth retardation from early in pregnancy, also 
aff ecting head growth. It might well be that the percentage of deliveries by elective caesarean 
section was high due to this severe growth retardation which is oft en seen in combination with 
reduced placental blood fl ow. 
 Phenotypic variation is by defi nition determined by the interaction between genetic 
and environmental factors. Currently most genetic research in short SGA children is focused 
on the role of the insulin-like growth factor-I (IGF-I), IGF-I receptor (IGF-IR) and growth 
hormone receptor (GHR) genes in determining size at birth [15-21]. Of particular interest is 
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showed, however, a combination of severe prenatal growth restraint and remarkable postnatal 
growth in height and HC, which is not a characteristic of subjects with a deletion or mutation 
in the IGF-I or IGF-IR gene. For that reason, it is unlikely that SGAL+W+HC children have major 
deletions in these genes but minor variants might play a role. Further research into gene-gene 
and gene-environment interactions are needed to elucidate the etiology of SGAL+W+HC.
 Evidence from several studies suggests that pre- and postnatal head circumference 
growth may infl uence cognitive function in SGA children [22-24]. For example, SGA children 
with reduced head circumference (≤ P10) at birth and at 9 months of age experienced widespread 
impairments in their verbal and nonverbal IQ ratings, phonological awareness skills, visual-
motor integration skills, problem-solving abilities and literacy skills at age 7-9 [23]. Other 
studies have shown that SGA children with a reduced height and/ or insuffi  cient growth in HC 
and/ or height had the highest risk for subnormal intellectual and psychological performance 
[22,24,25]. Hence identifi cation of short SGA children with small HC SDS may be clinically 
relevant as it may help to identify children at particular risk for learning diffi  culties. 
 In this study, we have specifi cally evaluated SGA children with persistent short stature, 
in contrast to SGA catch-up children, having a height above -2.00 SDS at 3 years of age. As a fi rst 
step in subphenotyping the heterogeneous SGA group, we have focused on short SGA children 
as they receive endocrine care for their growth retardation, oft en including growth hormone 
treatment. 
 In conclusion, our study suggests that SGA children with persistent short stature may 
be subclassifi ed according to their birth length, weight and HC. Subclassifi cation using these 
criteria may provide a useful framework to explore the mechanisms underlying diff erences in 
the extent of spontaneous postnatal growth that are observed in a population of short SGA 
children. Such a subclassifi cation of short SGA children might also be useful for elucidating 
underlying genetic or environmental causes of SGA and future risk profi les with regard to adult 
diseases. Where SGAL children appeared to experience the least fetal growth retardation and 
postnatal height increment as within ISS children, SGAL+W children were most aff ected by 
gestational hypertension which might suggest eff ects on cardiovascular risk profi les in later life. 
SGAL+W+HC children were born with the lowest HC but experienced a major increase in HC 
growth postnatally. In this group of children, further studies might be directed at specialized 
interventions such as remedial teaching on cognition during early infancy as well as evaluating 
the eff ect of GH treatment at an earlier age. 
56 Subclassifi cation of short SGA children
Acknowledgements
We thank the children and their families who agreed to take part in this study and we thank 
J. van Nieuwkasteele, E. Lems, M. Huibregtse, J. Bruinings, J. van Houten, research nurses for 
their technical assistance and help with data collection. We also thank K. van Dinteren and 
D. Assink, research assistants, for their help with data collection. Th e participating physicians 
of the original GH trials were: H. Reeser, Juliana Children’s Hospital, Th e Hague; J. Waelkens, 
Catharina Hospital, Eindhoven; M. Jansen, Wilhelmina Children’s Hospital, Utrecht; E. Houdijk, 
P. Voorhoeve, Free University Hospital Amsterdam; R. Odink, W. Bakker-van Waarde, Beatrix 
Children’s Hospital, Groningen; J. Mulder, Rijnstate Hospital, Arnhem; C. Rongen-Westerlaken, 
Canisius-Wilhelmina Hospital, Nijmegen; B. Bakker, University Medical Center Leiden; B. 
Otten, C. Noordam, University Medical Center Sint Radboud, Nijmegen; E. Sulkers, Hospital 
Walcheren, Vlissingen; J. van der Hulst, Zaans Medical Center, Zaandam; A. Hokken-Koelega, 
ErasmusMC – Sophia Children’s Hospital, Rotterdam Th e Netherlands. 
57
Chapter
2ReferencesHokken-Koelega AC, De Ridder MA, Lemmen RJ, Den Hartog H, De Muinck Keizer-Schrama SM, Drop SL:1.  
Children born small for gestational age: do they catch up? Pediatr Res 1995;38:267-271.
Albertsson-Wikland K, Karlberg J: 2. Natural growth in children born small for gestational age with and without 
catch-up growth. Acta Paediatr Suppl 1994;399:64-70; discussion 71.
European health for all database (HFA-DB). Available at: 3. www.euro.who.int/hfadb.
Arends NJ, Boonstra VH, Hokken-Koelega AC4. : Head circumference and body proportions before and during 
growth hormone treatment in short children who were born small for gestational age. Pediatrics 2004;114:683-
690.
Sas TC, Gerver WJ, De Bruin R,5.  et al.: Body proportions during 6 years of GH treatment in children with 
short stature born small for gestational age participating in a randomised, double-blind, dose-response trial. Clin 
Endocrinol (Oxf) 2000;53:675-681.
Sas T, Mulder P, Hokken-Koelega A: 6. Body composition, blood pressure, and lipid metabolism before and during 
long-term growth hormone (GH) treatment in children with short stature born small for gestational age either 
with or without GH defi ciency. J Clin Endocrinol Metab 2000;85:3786-3792.
Sas T, Mulder P, Aanstoot HJ,7.  et al.: Carbohydrate metabolism during long-term growth hormone treatment in 
children with short stature born small for gestational age. Clin Endocrinol (Oxf) 2001;54:243-251.
Van Pareren Y, Mulder P, Houdijk M, Jansen M, Reeser M, Hokken-Koelega A:8.  Adult height aft er long-
term, continuous growth hormone (GH) treatment in short children born small for gestational age: results of a 
randomized, double-blind, dose-response GH trial. J Clin Endocrinol Metab 2003;88:3584-3590.
van Pareren YK, Duivenvoorden HJ, Slijper FS, Koot HM, Hokken-Koelega AC: 9. Intelligence and psychosocial 
functioning during long-term growth hormone therapy in children born small for gestational age. J Clin 
Endocrinol Metab 2004;89:5295-5302.
Usher R, McLean F: 10. Intrauterine growth of live-born Caucasian infants at sea level: standards obtained from 
measurements in 7 dimensions of infants born between 25 and 44 weeks of gestation. J Pediatr 1969;74:901-910.
Fredriks AM, van Buuren S, Burgmeijer RJ, 11. et al.: Continuing positive secular growth change in Th e Netherlands 
1955-1997. Pediatr Res 2000;47:316-323.
Gerver WJ, Bruin, R. de: 12. Paediatric Morphometrics, a reference manual; In: Paediatric Morphometrics, a reference 
manual. Maastricht, University Press, 2001.
Roede MJ, van Wieringen, J.C.:13.  Growth diagrams 1980. Netherlands third nationwide survey. Tijdschrift  voor 
Sociale Gezondheidszorg 1985;1-34.
Mamelle N, Boniol M, Riviere O, 14. et al.: Identifi cation of newborns with Fetal Growth Restriction (FGR) in 
weight and/or length based on constitutional growth potential. Eur J Pediatr 2006;165:717-725.
Woods KA, Camacho-Hubner C, Savage MO, Clark AJ:15.  Intrauterine growth retardation and postnatal growth 
failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med 1996;335:1363-1367.
Johnston LB, Dahlgren J, Leger J, 16. et al.: Association between insulin-like growth factor I (IGF-I) polymorphisms, 
circulating IGF-I, and pre- and postnatal growth in two European small for gestational age populations. J Clin 
Endocrinol Metab 2003;88:4805-4810.
Walenkamp MJ, Karperien M, Pereira AM17. , et al.: Homozygous and heterozygous expression of a novel insulin-
like growth factor-I mutation. J Clin Endocrinol Metab 2005;90:2855-2864.
Abuzzahab MJ, Schneider A, Goddard A,18.  et al.: IGF-I receptor mutations resulting in intrauterine and postnatal 
growth retardation. N Engl J Med 2003;349:2211-2222.
Kawashima Y, Kanzaki S, Yang F,19.  et al.: Mutation at cleavage site of insulin-like growth factor receptor in a short-
stature child born with intrauterine growth retardation. J Clin Endocrinol Metab 2005;90:4679-4687.
Dos Santos C, Essioux L, Teinturier C, Tauber M, Goffi  n V, Bougneres P:20.  A common polymorphism of the 
growth hormone receptor is associated with increased responsiveness to growth hormone. Nat Genet 2004;36:720-
724.
Arends N, Johnston L, Hokken-Koelega A, 21. et al.: Polymorphism in the IGF-I gene: clinical relevance for short 
children born small for gestational age (SGA). J Clin Endocrinol Metab 2002;87:2720.
58 Subclassifi cation of short SGA children
Lundgren EM, Cnattingius S, Jonsson B, Tuvemo T:22.  Intellectual and psychological performance in males born 
small for gestational age with and without catch-up growth. Pediatr Res 2001;50:91-96.
Frisk V, Amsel R, Whyte HE:23.  Th e importance of head growth patterns in predicting the cognitive abilities and 
literacy skills of small-for-gestational-age children. Dev Neuropsychol 2002;22:565-593.
Brandt I, Sticker EJ, Lentze MJ:24.  Catch-up growth of head circumference of very low birth weight, small for 
gestational age preterm infants and mental development to adulthood. J Pediatr 2003;142:463-468.
Gale CR, O’Callaghan FJ, Godfrey KM, Law CM, Martyn CN25. : Critical periods of brain growth and cognitive 
function in children. Brain 2004;127:321-329.
Chapter 3
Polymorphisms in the IGF1 
and IGF1R gene and children 
born small for gestational age: 
Results of large population 
studies 
Ester, W.A.* MD, Hokken-Koelega, A.C.S., MD, PhD 
Department of Paediatrics, Division of Endocrinology, ErasmusMC-Sophia Children’s Hospital, 
Rotterdam, The Netherlands
Best Pract Res Clin Endocrinol Metab. 2008 Jun;22(3):415-31
60  Polymorphisms in the IGF1 and IGF1R gene
Abstract 
Small for gestational age (SGA) is the term used to describe a group of children born with a 
birth weight and/or birth length below the normal range of a reference population, corrected 
for their gestational age. Although animal models have shown that the insulin-like growth 
factor 1 (IGF1) and insulin-like growth factor 1 receptor (IGF1R) are important candidate 
genes for reduced pre- and postnatal growth, only limited case-reports have been published, 
describing mutations. Th is might suggest that IGF-I and IGF-IR are such crucial growth factors 
that only common genetic polymorphisms are allowed to survive. Common IGF1 and IGF1R 
gene polymorphisms, like single nucleotide polymorphisms (SNPs) and variable number of 
tandem repeats (VNTRs), have been investigated with confl icting results with respect to SGA 
related outcomes. Th e exact contribution of these polymorphisms to clinical practice remains 
to be elucidated. 
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Introduction
IGF1 gene, IGF1R gene and SGA
IGF1 (OMIM*147440, NM_000618, gene map locus: 12q22-q24.1) and the IGF1R 
(OMIM*147370, NM_000875, gene map locus: 15q25-q26) are thought to be important 
candidate genes for children born SGA, being major pre- and postnatal growth factors [1,2]. 
Prenatally, IGF1 and IGF1R absence results in mice with a respectively 40% and 55% reduction 
in birth weight. During postnatal life, surviving IGF1 knock-out mice become 30% of normal 
adult weight. In humans, growth hormone induced growth by IGF-I starts from 3 months of 
age. However as SGA might be the result of numerous maternal, foetal, and placental causes [3], 
it is unclear whether prenatal reduced IGF1 and/or IGF1R expression result from etiological 
factors as maternal smoking or maternal alcohol by inducing malnutrition, or that prenatal 
reduced IGF1 and IGF1R expression result from a genetic defect or variation in their respective 
genes [4]. Clinically, SGA children are defi ned as children born with a low birth weight and/
or birth length for gestational age. Since reduced size at birth may result from foetal, maternal, 
placental or demographic infl uences, children born SGA comprise a heterogeneous phenotype 
with a broad spectrum of clinical characteristics. Around 2% of all life-born neonates are born 
SGA and 10% of them remain short. SGA children with a persistent short stature have been 
studied due to their participation in prospective GH-treatment studies [5-8]. Studies at start 
of GH treatment showed that SGA children had a reduced lean body mass, fat mass, skin fold 
measurement and body mass index [5,6,8] .Th ey have a decreased caloric, fat and carbohydrate 
intake [7]. SGA children with catch-up growth until a height in the normal range are known 
for an increased risk for cardiovascular disease [9]. It seems likely that combinations of adverse 
genetic variations together with an adverse environmental factor result into intra-uterine 
growth retardation and SGA birth. 
Heritability and genetic polymorphisms
Several twin studies have shown that serum IGF-I levels are highly heritable, especially at a 
young age. Heritability of serum IGF-I levels ranges from 77-93% for girls and boys in cord 
blood until 54-66% in free serum IGF-I levels of 6-18 year old school girls [10,11]. Twin studies 
at middle-aged subjects and in the elderly showed a heritability ranging between 38-63% [12, 
13]. In this review we will focus on two common classes of genetic polymorphisms; single 
nucleotide polymorphisms (SNPs) and variable number of tandem repeats (VNTRs). SNPs are 
defi ned as a single nucleotide substitution by another nucleotide. Since coding DNA accounts 
for only about 1.5% of the human genome, most SNPs are found in non-coding DNA as introns 
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or intergenic sequences. Th ere is no uniform spread of SNPs across the genome; there are large 
chromosomal regions with very few SNPs who are oft en adjacent to large regions containing 
many SNPs. Variable number of tandem repeats (VNTR) consist of tandemly repeated runs of 
simple sequences. An example of a VNTR is a microsatellite, consisting of a simple sequence 
which is one or several nucleotides long and the array length ranges from less than 10 to over 
100 nucleotides. 
Linkage disequilibrium
An important concept of research into genetic polymorphisms is linkage disequilibrium (LD) 
and haplotypes [14]. Linkage disequilibrium can be defi ned as the co-occurrence of closely linked 
alleles more frequently than expected by chance. A haplotype is a set of alleles of linked genes that 
tend to be inherited together. Th e total human genome consists of about 3 billion basepairs in 
which variation is determined by recombination. Recombination however doesn’t occur evenly 
spaced throughout the genome but at certain hotspots. Th is means that areas without these 
hotspots are rather well conserved and tend to be inherited as one block together. Such a block 
is named a linkage disequilibrium block. Within these blocks, genetic polymorphisms have less 
variation than would be expected by chance. A combination of these limited combinations of 
genetic polymorphisms is called a haplotype. Haplotypes are interesting to investigate while 
due to the linkage disequilibrium-block it might not be necessary to investigate all the SNPs 
in the region but only the determining, or tagging, SNPs of the haplotype. An international 
project investigating linkage disequilibrium-blocks throughout the genome is the HapMap 
project (Web resources). Haplotypes and their tagging SNPs are of additional value above 
single genetic association studies due to their ability to identify combinations of SNPs with 
most associations.
Focus
Th is review will focus on genetic association studies in the IGF1 and IGF1R gene with SGA-
related outcomes and serum IGF-I levels. Studies were selected by searching Pubmed on the 
IGF1 and IGF1R gene together with “SNP”, “single nucleotide polymorphism”, height and SGA. 
Excluded studies were veterinary studies, case-reports and reviews. Due to the limited number 
of publications, we could not apply stringent criteria with respect to the study-design. Th e 
questions we wanted to answer were: what is the contribution of the currently known genetic 
association studies in the IGF1 and IGF1R gene into SGA-related outcomes, for clinical research 
and practice? What is the contribution of linkage disequilibrium and haplotype studies in the 
IGF1 and IGF1R gene into SGA-related outcomes? We also wanted to identify the contribution 
of gene-gene interaction studies with the IGF1 and IGF1R gene into these outcomes. 
63
Chapter
3
Polymorphisms in the insulin-like growth factor-1 gene 
IGF-I is the product of a single-copy gene located on the long arm of chromosome 12 (12q22-
q24.1, Figure 1). Th is gene is about 83kb in size and consists of 6 exons, of which exon 1, 2, 
5 and 6 are alternatively spliced. Exon 1 and 2 code for the signal peptide, exon 3 and 4 code 
for the active protein and exon 5 and 6 code for the E domain (Figure 2). Alternative splicing 
depends on tissue type and hormonal environment [15]. Alternative splicing results in three 
isoforms, IGF-IEa, IGF-IEb, and IGF-IEc or mechano growth factor [16]. Whereas hormonal 
factors result in the IGF-IEa (systemic) and IGF-IEb isoforms, mechanical signals on muscles 
as stretch or damage result in mechano growth factor (MGF). Th e alternative splices result in 
diff erent precursor peptides although they don’t alter the structure of the mature peptide. It 
is unclear how these IGF-I isoforms would result in a tissue-specifi c IGF-I protein expression 
although it is hypothesized that mechano growth factor has a 52bp insert in the E-domain 
which alters the reading frame to the 3’end. Th is may result into binding to a diff erent binding-
protein of the splice variant, thus localizing its action [17]. 
Figure 1. IGF1 gene structure.
Since single nucleotide polymorphisms are estimated to occur every 100-1000 nucleotides (Web 
resources: NCBI, HapMap, UCSC), 85-850 SNPs are theoretically expected to be present in the 
84648bp sized IGF1 gene. SNP research is usually performed by investigating SNP databases 
and literature. Main SNP providing databases, as NCBI, HapMap and UCSC (Web resources), 
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provide respectively 449 SNPs, 140 SNPs, and 126 SNPs in the IGF1 gene. Current literature 
provides numerous IGF1 gene association studies based on systematic sequencing of patient-
populations but also by studies focussing on a single SNP or VNTR.
Figure 2. IGF-I protein structure with amino acid 1-38 (back: blue) and amino acid 39-66 (front: red), 
according to PDBID 1GZY (Web resources: Rasmol, RCSB PDB) [46,47]. 
Th ere has been extensive research into IGF1 genetic polymorphisms with respect to diverse 
outcomes such as physical growth, cardiovascular disease, and malignancies, but also to the 
location of the polymorphisms in the gene, linkage disequilibrium and haplotypes. Several 
studies have investigated the association with serum IGF-I level as an indication for the 
functional properties of the genetic polymorphism. 
 Although there has been quite some research with regard to IGF1 genetic association 
studies, the studies reporting on the functionality of these polymorphisms are very limited. As 
most polymorphisms are, by defi nition, localized in non-coding areas of the gene, this is rather 
complex to perform in the IGF1 gene. Additionally, there are hardly any non-synonymous SNPs 
reported in SNP databases and none reported in literature, to our knowledge. Circulating serum 
IGF-I levels are shown as a proxy for the eff ect of the SNP on protein level. In this chapter, we 
will focus on IGF1 population studies who performed linkage disequilibrium and haplotype 
studies, investigating serum IGF-I levels with SGA-related outcomes.
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Associations of the IGF1 gene and SGA related outcomes
Promoter
Five polymorphisms have been investigated in the IGF1 gene promoter region of which the 
192bp CA-repeat located 841bp before start of exon 1 (Figure 1), is by far the most extensively 
studied IGF1 polymorphism (Table 1). Upstream of the 192bp CA-repeat, four polymorphisms 
are located in a 22kb spanning area [18-20]. Linkage disequilibrium analyses by Zhao[18] and 
Johnston[20] showed that high linkage disequilibrium was present from the promoter area 
until intron 3. Whereas Zhao [18] did not fi nd associations between haplotypes spanning the 
promoter until intron 3 area and age at menarche, Johnston [20] showed that the region ranging 
from 1.2kb in the promoter until intron 2 was important in determining catch-up growth of the 
SGA born child. Both studies showed that the linkage disequilibrium block was at least 19kb 
wide and that the highest linkage disequilibrium was downstream of the 192bp CA-repeat as 
the combination of the 192bp CA-repeat and intron 2 IGF1.PCR1 associated stronger with 
the short SGA phenotype than the combination of the T-1148C and 192bp CA-repeat. Lettre 
et al[19] also investigated a SNP in this promoter linkage disequilibrium block (rs35767), but 
did not fi nd an association with adult height in 1132 tall (90th-95th percentile) and 1057 short 
(5th-10th percentile) subjects and replicated this fi nding in additional Polish and Framingham 
Heart Study cohorts. 
 Twelve studies have investigated associations between the 192bp CA-repeat and 
prenatal growth, birth size and postnatal anthropometrics. Whereas eight studies reported 
associations with growth related outcomes as catch-up growth, head size, chest circumference, 
height and weight, four studies could not confi rm these associations (Table 1). Th e most 
discussed association concerned a higher birth weight in carriers of the 192bp-allele, which 
was shown by Vaessen [21] and te Velde [22] but not by Frayling [23], Day [24], Geelhoed 
[25] and Kinoshita [26]. Th is discrepancy was also seen for other outcomes like height. Th ese 
confl icting results might be due to diff erences in the selected populations, data acquisition and 
data analysis. Despite these diff erences, however, it would have been plausible that a universal 
biological phenomenon like this association would be replicated in several populations. As this 
association could not be replicated in these studies, the universality of this association remains 
to be questioned. Th e same result is seen with outcomes such as head circumference. Kinoshita 
[26] observed a larger head circumference in 192/192 carriers. Arends [27], Frayling [23] and 
Geelhoed [25] did not observe this association. Many studies have investigated haplotypes, 
whereas Rietveld [28] and Vaessen [29] observed that carriers of the 192bp allele were taller 
than the remainder genotypes in an elderly population, Johnston et al. [20] showed that the 
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haplotype containing the 192bp CA-repeat associated with short SGA subjects. Voorhoeve [30] 
showed in 2 cohorts contradicting associations with height in males and Arends [27], Frayling 
[23], Day [24], Geelhoed [24] and te Velde [22] could not observe an association with height. 
Voorhoeve [30] also found that female carriers of the 192 and 194bp allele had a lower weight, 
BMI, fat mass and waist circumference in one of the cohorts. Arends et al. [27] investigated fi rst 
transmission disequilibrium of all alleles of the 192bp CA-repeat and found that the rare 198bp-
allele was less transmitted from the parents to the short SGA child. As only one child was carrier 
of the 198bp-allele, the association with serum IGF-I level could not be further investigated. 
 
IGF1 gene
Four genetic polymorphisms have been investigated in intron 2 investigating associations 
with pre-eclampsia, age at menarche, head circumference and catch-up growth. Whereas no 
associations have been reported with pre-eclampsia and age at menarche, Arends [27] and 
Johnston [20] reported associations in SGA children. Th e 191bp-allele of IGF1.PCR1 associated 
with a smaller head circumference at 1.3 years of age which was at the same level as birth. 
Although non-carriers of the 191bp allele had the same head circumference at birth, head 
circumference was growing better in a selection of short SGA children with both a length and 
weight < -2.00 standard deviation score (SDS) at birth. Johnston[20] showed that IGF.PCR1 
was part of the linkage disequilibrium -block ranging from at least, the promoter until intron 2. 
Th e IGF.PCR1 189bp-allele was associated with birth size, which was investigated by comparing 
SGA cases vs. controls, and also with persistent short stature in SGA children. Th e combination 
of the 189bp common allele of the IGF1.PCR1 and T-1148C SNP polymorphism associated 
with a short SGA phenotype. No associations were found between the A-23C polymorphism 
and the SGA phenotype.
 Eleven polymorphisms have been studied in a 51kb area located in intron 3. Zhao 
[18] identifi ed two linkage disequilibrium-blocks in the intron 3 region: one ranging from the 
promoter until intron 3, and a second ranging from intron 3 until intron 5. However, none 
of these polymorphisms and haplotypes showed associations with age at menarche. Lettre 
[19] investigated four polymorphisms in this area in relation to adult height. Th ree of these 
polymorphisms were identical with Zhao [18] and both did not observe associations except 
for rs10735380. Lettre [19] observed for rs10735380 and the combination of rs10735380 and 
rs7136446, an association with height in two of the three investigated cohorts. 
 Five polymorphisms have been investigated in intron 4 and 5 but Zhao [18] and Lettre 
[19] did not observe associations with age at menarche and adult height, respectively.
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3’UTR
Nine polymorphisms have been investigated in the 3’UTR area spanning 41kb. Two studies 
identifi ed linkage disequilibrium. Zhao [18] reported a linkage disequilibrium block ranging 
between rs6214 and rs6219, being 3.3kb in size. Both rs6214 alone and the combination of its 
A-allele and the rs6219 G-allele associated with a 0.27 year later start of menarche. Johnston 
[20] investigated haplotypes of the D12S318 polymorphism and the upstream T+1771C 
3’UTR polymorphism which did not show associations with birth size or postnatal growth 
in SGA subjects. However, when the D12S318 polymorphism was investigated separately, 
the most common allele associated with birth size and short stature in SGA subjects. Arends 
[27] also investigated the D12S318 polymorphism in a short SGA cohort by trio-design, but 
could not confi rm these associations. Lettre [19] reported the previously described rs10735380 
polymorphism in combination with rs7136446 and found an association with height in two of 
the three investigated cohorts. Th e other four polymorphisms from Lettre [19] and Zhao [18] 
were not associated with adult height and age at menarche, respectively.
Associations of the IGF1 gene and serum IGF-I levels
Promoter
Two polymorphisms have been associated with serum IGF-I levels: the T-1148C SNP and the 
192bp CA-repeat. Johnston [20] investigated the T-1148C SNP and serum IGF-I levels in a short 
SGA population during childhood, and in a control population in late puberty. No associations 
were observed between the T-1148C SNP and serum IGF-I levels, adjusted for age, sex and 
pubertal status.
 Seven studies investigated the 192bp CA-repeat and serum IGF-I levels. Arends could 
not demonstrate an association between the 192bp CA-repeat and serum IGF-I levels in a 
population of 124 short SGA trios [27]. Johnston [20] investigated the 192bp CA-repeat and 
serum IGF-I levels in the same population as the T-1148C SNP, and found no associations. 
Frayling [23] investigated the 192bp CA-repeat with serum IGF-I levels in a young adult 
population (n = 640) and found that carriers of the 192/192 had a trend towards a lower serum 
IGF-I level whereas height was not diff erent between the genotypic groups. Serum IGF-I levels 
were adjusted for sex and age. Kinoshita [26] investigated the 192bp CA-repeat and the serum 
IGF-I levels in 160 neonates, fi ve days aft er birth. Carriers of the 192/192 genotype had a higher 
serum IGF-I level than the two other most frequent genotypes (192/196 and 196/196). Carriers 
of the 192bp allele had the longest duration of gestation, were the tallest and heaviest compared 
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with the 196bp allele carriers, although this was not statistically signifi cant. Serum IGF-I levels 
were not adjusted for age and sex, but all blood samples were taken fi ve days aft er birth with 
a similar sex distribution in the population. Rietveld [31] investigated the 192bp CA-repeat 
and serum IGF-I levels in 346 subjects of an elderly population. Th e population consisted of a 
randomly selected population-based sample of 196 subjects and 150 subjects who were selected 
on their IGF1 genotype, namely 192/192bp, 192/non192bp and non192/non192bp carriers, 
each group consisting of 50 subjects. Carriers of the 192/192bp genotype showed a decline of 
their serum IGF-I level with increasing age, which was not seen in 192/non192bp and non192/
non192bp carriers. Serum IGF-I levels were adjusted for age, sex and BMI. Rietveld [28] also 
investigated the previously described population with in addition 50 subjects who were selected 
on their genotype: homozygous carriers of less than 19 CA-repeats (< 192bp alleles), or carriers 
of more than 21 CA-repeats (> 194bp alleles). Homozygous carriers of the 192bp and 194bp 
allele had higher serum IGF-I levels than homozygous carriers of shorter or longer alleles. Serum 
IGF-I levels were adjusted for age, sex and BMI. Vaessen[29] investigated the same genotypic 
groups in the population Rietveld also described[31], in combination with their serum IGF-I 
levels (n = 150).
 
IGF1 gene
Both Arends [27] and Johnston [20] investigated the IGF1.PCR1 intron 2 polymorphism 
in combination with serum IGF-I levels. Arends [27] investigated fi rst the transmission 
disequilibrium of all alleles of the IGF1.PCR1 polymorphism. Th e second most common allele, 
the 191bp allele, was transmitted more frequent from the parents to the short SGA child than 
the other alleles. Secondly, short SGA children with and without the 191bp allele were compared 
for their serum IGF-I level. Short SGA children with the 191bp allele had a lower serum IGF-I 
level than non191bp carriers (-1.1 vs. -0.5 SDS, respectively) but had no diff erent height SDS. 
Serum IGF-I levels were adjusted for age and sex. 
 Johnston [20] also investigated the IGF1.PCR1 polymorphism in combination with 
serum IGF-I levels in an association study of two SGA populations and a control population. 
Carriers of the, most frequent, 189/189bp genotype, were associated with a lower IGF-I SDS 
than non-carriers. Th eir control population did not show this association between the 189bp 
allele and serum IGF-I level. 
 
3’UTR
In the 3’UTR, two polymorphisms were investigated in combination with serum IGF-I levels. 
Johnston [20] investigated the T+1771C SNP and the D12S318 polymorphism in a short, SGA 
catch-up and control population without observing an association with serum IGF-I levels.
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Polymorphisms in the insulin-like growth factor-i receptor gene 
Th e IGF1R gene contains 21 exons, spans about 310kb and is mapped on chromosome 15q25-
q26 (Figure 3) [32,33]. Th e gene for the IGF1R is homologous to the insulin receptor gene 
with respect to their exon and intron organisation and is for more than 50% identical. Both 
encode precursor proteins that undergo post-translational modifi cation to result in receptors 
which are composed of two alpha and two beta subunits, connected by disulfi de bonds to form 
an α2β2 heterotetrameric complex of generally similar design (Figure 4) [34]. Th e α-subunits 
are extracellular (exon 1-10), containing ligand-binding domains and the β-subunits are 
intracellular containing tyrosine kinase domains (exon 11-21). Th e region of the highest amino 
acid similarity in the IGF- and insulin-receptors (80-95%) consists of fi ve exons (exon 16-
20), encoding parts of the tyrosine kinase domain in the beta subunit. Th e 5’-fl anking and 
untranslated region is GC-rich and contains numerous potential SP1 and AP2 binding sites 
[35]. Th e IGF1R consists of a 1367- amino acid receptor precursor, including a 30-residue signal 
peptide, which is removed during translocation of the nascent polypeptide chain. Cleavage of 
the precursor generates the alpha and beta subunits as in the case of the insulin receptor. 
Figure 3. IGF1R gene structure.
Whereas the IGF1 gene has been extensively investigated for genetic polymorphisms, these 
studies are rare for the IGF1R gene. We only identifi ed one association study with SGA-related 
outcomes. Another four studies [36-39] described IGF1R polymorphisms with outcomes in 
polycystic ovary syndrome (PCOS), breast cancer, longevity and schizophrenia but not with 
SGA-related outcomes (Table 2). Th e absence of extensive genetic association studies, however, 
does not mean that the IGF1R gene is not polymorphic. Th e NCBI database provides at least 
1274 SNPs in the IGF1R gene of which 24 synonymous, 5 non-synonymous and 1 frame-shift  
polymorphism (Web resources: NCBI). Many of these SNPs have a low allele frequency (oft en 
< 5%) and have been rarely investigated in gene association studies. 
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Table 2. Overview of investigated IGF1R genetic polymorphisms. 
Location Position SNP / VNTR LD Main results Populations Study 
Promoter 97295748 ACG VNTR ND NA 72 PCOS patients and 42 
controls
San Millan, 2004
Intron 8 97274076 rs951715 - G: ↑risk of 
death 
1455 women with BRC Deming, 2007
Exon 16 97295748 G/A ND A: ↓free IGF-I 496 subjects Bonafe, 2003
Exon 16 97295748 G/A ND NA 1) 395 DM2 patients and 
238 matched controls, 
2) 349 young, healthy 
subjects
Rasmussen, 
2000
Exon 16 97295748 rs2229765 - NA See rs951715 Deming, 2007
Exon 16 97295748 rs2229765 ND NA 648 schizophrenia cases, 
712 controls, 
297 schizophrenia trios
Gunnell, 2007
Intron 20 97317779 rs2593053 - NA See rs951715 Deming, 2007
3’near gene 97319104 rs702497 - NA See rs951715 Deming, 2007
SNP= single nucleotide polymorphism, VNTR= variable number of tandem repeats, LD= linkage disequilibrium, ND= not 
determined, NA= not associated, PCOS= polycystic ovarian syndrome, BRC= breast cancer, DM2= diabetes mellitus type 2.
Figure 4. IGF-IR protein structure with amino acid chain A (left : green) and amino acid chain B (right: 
blue), according to PDBID 1P4O (Web resources: Rasmol, RCSB PDB) [47,48].
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Associations of the IGF1R gene and SGA-related outcomes
IGF1R gene
Only one polymorphism has been investigated in the IGF1R gene in relation with SGA-
related outcomes. Rasmussen et al. [40] sequenced all twenty-one IGF1R exons to identify 
polymorphisms in 82 probands of Danish families with diabetes mellitus type 2. Ten 
polymorphisms were found of which six were silent exonic and four were intronic variants. 
Only the exon 16 polymorphism (E1013E) was present in > 5% of the population. Further 
investigation, also in a population of 349 young, healthy subjects did not reveal associations 
with birth size and oral glucose tolerance test results in both populations.
IGF1 and IGF1R gene interaction studies and SGA-related outcomes
IGF1 gene
Lettre et al. [19] investigated gene-gene interaction with height in eight genes: GHR, GHRH, 
GHRHR, IGF1, IGFALS, IGFBP3, JAK2, STAT5B. All pairwise combinations between all 150 
SNPs and 82 multimarker predictors were tested. Only one interaction remained aft er applying 
Bonferroni correction: an interaction between the GHR and IGFALS genes (rs12233949* 
rs11540961) in a European-American height panel. However, this fi nding could not be 
replicated in a Poland height panel. No other studies were found with gene-gene interactions 
involving SGA-related outcomes.
IGF1R gene
Rasmussen [40] did not describe gene-gene interaction studies. No other studies were found 
with gene-gene interaction studies involving SGA-related outcomes.
Concluding remarks 
Th e objective of this review was to determine the contribution of the currently known genetic 
association studies in the IGF1 and IGF1R gene with regard to SGA-related outcomes both for 
clinical research and practice. We also determined the contribution of linkage disequilibrium 
and haplotype studies in the IGF1 and IGF1R gene in relation to SGA-related outcomes. 
Additionally, the contribution of gene-gene interaction studies with the IGF1 and IGF1R genes 
and SGA-related outcomes was studied. 
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Th is review showed that many IGF1 polymorphisms have been studied but that the 192bp CA-
repeat in the promoter was most likely to associate with SGA-related outcomes. Th e region 
ranging from the promoter until intron 2 is part of a linkage disequilibrium block which is 
important in SGA-related outcomes as all association studies in SGA populations report 
associations with polymorphisms in this area [20,27]. Confl icting results arise especially in 
general populations and with associations between birth size measures and polymorphisms in 
this gene region [23-25,29]. Th ere was only one study evaluating associations between IGF1R 
polymorphisms and SGA-related outcomes, which could not demonstrate any association [40]. 
Limited gene-gene interaction studies have been performed with SGA-related outcomes and no 
associations were found [19]. None of these genetic association studies are currently suitable as 
a diagnostic measure because no therapeutic outcome has been identifi ed yet. 
 Due to the diverse outcomes, it was not possible to perform a meta-analysis. We applied 
guidelines for a systematic review of these studies. However, the diverse outcomes demand 
criteria to determine if a genetic polymorphism is associated to an outcome or not. Th e 
confl icting results of the 192bp CA-repeat promoter polymorphism showed that replication 
of results in a comparable but not the same cohort was not possible, which makes it hard to 
conclude on the contribution of the polymorphism to SGA-related outcomes. A system in 
which genetic polymorphisms are scored based on their potential eff ect on the protein level 
might be needed. 
 Another recurring problem is the use of diff erent methods for correction of results for 
the number of performed tests. Lettre et al. [19] showed a large number of IGF1 SNPs and 
corrected all P-values by Bonferroni [41,42]. Most studies discussed in this review did, however, 
not follow this approach, which makes them hard to compare. 
 Another complicating factor in comparing study results of SGA populations, is the 
varying SGA defi nition. Although an SGA-consensus meeting [3] stated that SGA should be 
defi ned as a birth length and/or weight below the -2.00 standard deviation score, this is not 
widely applied. Also, many studies in adult populations do not correct for gestational age and 
only report unadjusted birth weights and/or lengths. By not adjusting for gestational age, it is 
almost impossible to draw conclusions about SGA children as many associations will be the 
result of premature birth. 
 A complicating factor of genetic association studies in the SGA population is the low 
prevalence of SGA. By defi nition, SGA children comprise only 2% of the population and only 
15% of them remains short. Th us it is almost impossible to ascertain a SGA population which 
is large enough to detect minor associations of their phenotype. A methodological concern 
in many association studies in SGA children is the occurrence of population stratifi cation 
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in case-control designs. Population stratifi cation is the situation in which cases and controls 
have diff erent allele frequencies which is attributable to diversity in background population, 
unrelated of outcome status [43]. A method to control for population stratifi cation is sample 
matching or estimation of the genetic diff erences by anonymous genetic markers. Anonymous 
genetic markers are at least 30 randomly selected SNPs throughout the genome which would 
refl ect the background diversity between the case and control population so that they can be 
addressed statistically. 
 Another factor which is important in genetic research in SGA children, is epistasis 
or genetic interaction. SGA is the result of a complex of factors, so it is likely that genetic 
interactions determine parts of the SGA phenotype. However, only one study has investigated 
gene-gene interaction with SGA-related outcomes. Th is study could not demonstrate signifi cant 
gene-gene interactions in relation to height [19]. Association studies into diverse adult diseases 
demonstrated potential gene-gene interactions between IGF1 192bp CA-repeat and the Insulin 
VNTR in a diabetic population [44] and an interaction between the IGF1 192bp CA-repeat, the 
oestrogen receptor α and oestrogen receptor β [45]. It remains to be investigated, whether these 
gene-gene interactions explain parts of the SGA phenotype. 
Practice points 
It is essential for both genetic and non-genetic research in SGA children that health care workers 
systematically measure and record height, weight and head circumference of infants at birth.
 Testing the biological function of polymorphisms is needed, especially of the IGF1 
192bp CA repeat, to show the eff ect of the polymorphism on protein level. 
 Many studies have reported associations between IGF1 gene polymorphisms and SGA-
related outcomes as birth size and postnatal growth. Results are, however, confl icting. It is 
unclear whether this is the result of small sample sizes, population stratifi cation or the diff erent 
defi nitions of SGA.
 Few studies have reported IGF1R genetic polymorphisms and SGA-related outcomes. 
Research agenda 
Association studies using etiological factors of the SGA phenotypes, should be per- −
formed.
Collaboration of international research consortia is required in order to increase the  −
SGA sample size.
Functional studies are needed on the  − IGF1 and IGF1R genetic polymorphisms.
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Studies into  − IGF1 gene isoforms and their tissue-specifi c actions into the SGA phenotype 
are needed.
Genome wide associations are to be performed into SGA populations to identify non- −
candidate, but important genes in the SGA phenotype. 
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Abstract
Background: Short SGA children experience pre- and postnatal growth restriction, which 
might be infl uenced by polymorphisms in the IGF1 gene. Th e well-known -841(CA)n/192bp 
polymorphism has been associated with birth size and cardiovascular disease.
Aims: To determine whether birth size, postnatal growth and growth during GH treatment, 
were associated with IGF1 gene polymorphisms and haplotypes.
Methods: 201 short SGA children were investigated for four IGF1 gene polymorphisms in the 
promoter (-G1245A, -841(CA)n), intron 2 (+3703(CT)n) and 3UTR (+A1830G). Spontaneous 
growth and growth during GH treatment were studied. 
Results: Th e -1245 A-allele was identifi ed as a marker-allele for the well-known -841(CA)n/ 
non192bp-allele, both part of Haplotype 2. Th e -1245 A-allele was not associated with head 
circumference at birth, but was associated with a postnatal 0.3 SDS smaller head circumference 
at age 1-3. Th e -1245 A-allele was also associated with a 1 week shorter gestational age which 
explained the association with a smaller absolute birth size. No associations were found with 
gestational age-adjusted birth size, height and weight SDS during postnatal life and with growth 
during GH treatment. 
Conclusions: Th e –G1245A SNP appeared to be a marker for the well-known -841(CA)n/ 
192bp polymorphism. Haplotype 2, of which the -1245 A-allele was the marker, was associated 
with a smaller head circumference SDS during spontaneous postnatal growth, but not during 
GH treatment. 
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Introduction
Small for gestational age (SGA) is the term used to describe a child born with a low birth 
weight and/or birth length for gestational age. Since reduced size at birth may result from fetal, 
maternal, placental or demographic infl uences, children born SGA comprise a heterogeneous 
phenotype with a broad spectrum of clinical characteristics. Around 2% of all life-born neonates 
is born SGA and 10% of them remain short [1,2]. 
 Phenotypic variation is determined by the interaction between genetic and environmental 
factors. Genes involved in pre- and postnatal growth are major candidate genes to explain 
pre- and postnatal growth restraint. Currently, most genetic research in short SGA children 
is focused on the role of the insulin-like growth factor 1 (IGF1, OMIM*147440, NM_000618, 
gene map locus: 12q22-q24.1), IGF-I receptor (IGF1R, OMIM*147370, NM_000875, gene map 
locus: 15q25-q26) and growth hormone receptor (GHR, OMIM*600946, NM_000163, gene 
map locus: 5p13-p12) genes [3-6]. Th e IGF1 gene is a major candidate as animal studies have 
shown that IGF1 knock-out mice had a 40% birth weight reduction and retarded postnatal 
growth in length and weight [7,8]. Additionally, case-reports have described patients with 
mutations in the IGF1 and IGF1R gene with a specifi c phenotype, consisting of short SGA, 
sensorineural deafness, a small head circumference and a low performal IQ [5,9-13]. Although 
only very few short SGA children have all the abnormalities described in the case-reports, they 
have as a group a smaller head circumference and lower IQ than average [14]. 
 Th e most common investigated genetic polymorphism in the IGF1 gene is a CA-repeat 
located in the promoter. From sequence analysis, it is known that 19 CA-repeats resemble 
the most frequently investigated “192bp allele”. Th e non-192bp allele is associated with a low 
birth weight, low adult height, low IGF-I serum level and a high risk for diabetes mellitus and 
myocardial infarction although confl icting results are reported [15-19]. At present, it is not 
known if the 192bp allele also associates with gestational age, birth head circumference and 
postnatal growth in short SGA children. Also it is unknown whether the 192bp allele associates 
with the response to GH treatment and whether nearby genetic variants might function as a 
genetic marker for the 192bp allele.
 In the present study we evaluated whether anthropometric measurements at birth, 
during postnatal growth and GH treatment, were associated with IGF1 gene polymorphisms 
and haplotypes in a population of 201 short SGA children. 
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Methods
Patients
Th e study population consisted of 201 SGA children with persistent short stature who participated 
in prospective cohort trials evaluating the eff ect of growth hormone (GH) treatment [14,20,21]. 
SGA was defi ned as a birth length ≤ –2.00 SDS [22]. Persistent short stature was defi ned as 
a height ≤ –2.00 SDS at ≥ 3 years of age [23]. For the present study, all children fulfi lled the 
inclusion criteria of Caucasian ethnicity and an uncomplicated postnatal period. Children with 
severe chronic illness or endocrine disorders, chromosomal or genetic abnormalities, positive 
endomysial or transglutaminase antibodies, skeletal abnormalities, psychosocial dwarfi sm, and 
growth failure caused by syndromes, were excluded from the study. Data regarding gestational 
age at birth and length, weight and head circumference measurements from birth until 3 years 
of age were retrieved from primary health care records.
 Th e effi  cacy of one year of GH treatment was evaluated in a subpopulation of 143 
prepubertal children who were prepubertal at start and aft er one year of GH treatment. 
Prepuberty was defi ned as a bilateral testicular volume of 3 ml or less for boys and Tanner stage 
M1 for girls. Children receiving medication for induction or postponement of puberty were 
excluded from the analysis. Th e study protocol was approved by the Medical Ethics Committee 
and written informed consent was obtained from the parents/guardians of each child. Parents 
could indicate on the informed consent form if they wanted to be informed about the genetic 
results of the population. 
Controls
A Dutch blood donor population of 207 individuals was used to determine allele frequencies 
in non-SGA subjects. 
Selection of IGF1 gene polymorphisms
Four IGF1 gene polymorphisms were studied: the -G1245A (rs35767) single nucleotide 
polymorphism (SNP), the -841(CA)n variable number of tandem repeat (VNTR), the 
+3703(CT)n VNTR, and the +A1830G SNP (rs6220, Figure 1A). Th e two SNPs, -G1245A 
[24,25] and the +A1830G were identifi ed by searching NCBI and Celera SNP databases (Web 
resources) and literature. Th e two VNTRs, -841(CA)n and +3703(CT)n were selected because of 
their previously reported associations with birth characteristics [3,4,16,19]. 
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Genotyping
Genomic DNA was extracted from samples of peripheral venous blood according to salting 
out procedure [26]. Genotypes were determined using the Taqman allelic discrimination 
assay. Th e Assay-by-Design service (www.appliedbio-systems.com) was used to set up a 
Taqman allelic discrimination assay for the -G1245A and +A1830G SNPs. Th e -G1245A 
forward primer consisted of GGATTTCAAGCAGAACTGTGTTTTCA, and reverse primer 
of GGTGGAAATAACCTGGACCTTGAAT. Th e -G1245A forward probe consisted of VIC-
TTTTTTCCGCATGACTCT and reverse probe of FAM-TTTTTTTTCCACATGACTCT. Th e 
+A1830G forward primer consisted of GAAAAGAAGGAATCATTGTGTTTTTCAAAATGAA 
and reverse primer of GCACTCACTGACTCTTCTATGCA. Th e +A1830G forward probe 
consisted of VIC-ATATCTAGTAAAACCTTGTTTAAT and reverse probe of FAM-
CTAGTAAAACCTCGTTTAAT. Th e PCR reaction mixture included 5ng of genomic DNA, 
0.125 μl TaqMan assay (40*, ABI), 2.5 μl Master mix (ABI) and 2.375 μl water. PCR was 
performed in 384 wells PCR plates in an ABI 9700 PCR system (Applied Biosystems Inc., Foster 
City, CA, USA) and consisted of initial denaturation for 10 minutes at 95° C, and 40 cycles 
with denaturation of 15 seconds at 92° C and annealing and extension for 60 seconds at 60° 
C. Results were analyzed by the ABI Taqman 7900HT using the sequence detection system 
2.22 soft ware (Applied Biosystems Inc., Foster City, CA, USA). Th e -841(CA)n and +3703(CT)
n VNTR were genotyped as previously described [3].
Linkage Disequilibrium and Transcription Factor Binding Sites 
Th e pairwise linkage disequilibrium (LD) coeffi  cients (D’) and correlation coeffi  cients (R2) 
were calculated with the use of Haploview soft ware (Web resources). Gene polymorphisms 
which were in high LD (> 0.90) were used for haplotype construction. We inferred haplotypes 
of the -G1245A and the -841(CA)n/192bp genotypes using PHASE 2.1 [27,28]. Identifi cation 
of previously known LD blocks in the IGF1 gene took place by searching the HapMap genomic 
database and PubMed (Web resources). Transcription factor binding sites (TFBS) around 
the -G1245A SNP were searched in the “Transcription Factor search” program [29] and the 
“Transcription Element Search System” (Web Resources). 
Statistical analysis
Th e power calculation was performed by the “Power and sample size calculation” tool of the 
Department of Biostatistics at Vanderbild University (Web resources). Cases consist of the 
homozygous carriers of the minor allele grouped together with the heterozygous carriers. Th e 
control group consists of the homozygous carriers of the major allele. As the genotype group 
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with the lowest allele frequency was above the minimal sample size of 52, we considered the 
power adequate.
Figure 1. IGF1 gene structure. A: IGF1 gene structure with the gene polymorphisms studied 
in this short SGA population and previous studies. Th e allele frequencies are presented of the 
studied gene polymorphisms. LD blocks were retrieved from the HapMap database and Cheng 
(Web resources) [25]. B: LD (D’ and R2) is shown for the -G1245A SNP, the -841(CA)n/192bp 
VNTR and the +3703(CT)n/189bp VNTR. C: Haplotypes were constructed of the -G1245A SNP 
and the -841(CA)n/192bp VNTR. Th eir frequency is presented for the short SGA population.
Hardy-Weinberg equilibrium (HWE) was calculated by computing the chi-square test for 
deviations in HWE. Association studies with birth size, postnatal growth and growth during 
GH treatment were performed by analyzing the -G1245A SNP, the -841(CA)n and +3703(CT)
n VNTRs and the +A1830G SNP separately. Th e gene polymorphisms were grouped according 
to a dominant model into homozygous carriers of the most frequent G-, 192bp-, 189bp- and 
A-allele, respectively, versus the remaining alleles. Secondly, haplotypes of the -G1245A SNP 
and the -841(CA)n VNTR were analyzed (Figure 1C). Haplotype 1 was grouped into 0 & 1 
vs. 2 allele copies due to the combination of the most frequent alleles. Haplotype 2 and 3 were 
grouped into 0 vs. 1 & 2 allele copies. Th e genotypic groups were compared for all anthropometric 
parameters by univariate analysis of variance (ANOVA). Anthropometric measurements at 1, 
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2 and 3 years of age were corrected for premature birth by adding gestational age as a covariate 
in ANOVA. A subgroup analysis on the eff ect of GH treatment on growth was performed in 
143 prepubertal children. Analysis of the growth response was performed by using ANOVA. 
Baseline measurements were corrected for age at start of GH treatment, as covariate in ANOVA. 
Th e growth response during one year of GH treatment was adjusted for GH dose and age at start 
of GH treatment, also as covariate in ANOVA. P< 0.05 was considered signifi cant. Statistical 
tests were performed using SPSS 11.0 (SPSS Inc., Chicago, IL, USA).
Results
Clinical characteristics
Th e study population consisted of 201 children (109 boys) and was characterized by their short 
birth length, low birth weight and below the mean head circumference, being respectively -3.50, 
-2.46 and -1.34 SDS. From birth until 3 years of age, height and head circumference increased 
by 0.5 and 0.2 SDS, respectively, whereas weight decreased by 0.4 SDS (Table 1).
 Th ere were 75 boys and 68 girls who were prepubertal at start and aft er 1 year of 
GH treatment. Th eir mean age was 6.8 years (SD = 2.3) and their GH dose was 1.11 (0.29) 
mg/m2/day.
 
Allelic frequencies of IGF1 polymorphisms
Figure 1A presents the allele frequencies of the -1245G, -841(CA)n/192bp, +3703(CT)n/189bp 
and +1830A alleles in the short SGA population, being respectively 85.3, 69.1, 67.5 and 76.3%. 
All gene polymorphisms were found to be in Hardy-Weinberg equilibrium (HWE: P = 0.45, 
P = 0.85, P = 0.71 and P = 0.68, respectively). Th e allele frequency of the -G1245A SNP was 
not signifi cantly diff erent between the total short SGA population and the control population 
(14.7% vs. 17.4%, respectively). 
Linkage disequilibrium in the IGF1 gene
Th ere was high LD between the -G1245A SNP and the well-known -841(CA)n/192bp 
VNTR (D’ = 0.93, R2 = 0.34, Figure 1B) both located in the promoter region. Haplotypes 
were constructed. Haplotype 1, 2 and 3 had a respective frequency of 68.6, 16.5 and 14.4 %, 
Haplotype 4 (H4) was not present in the population (Figure 1C). LD between the -G1245A SNP 
and +3703(CT)n VNTR and between the -841(CA)n VNTR and the +3703(CT)n VNTR was 
low (D’< 0.6), so no haplotypes were generated (Figure 1B).
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To investigate the consistency of high LD within the promoter region of the IGF1 gene, we 
searched the HapMap genomic database (Web resources) and literature. Cheng [25] and 
the HapMap database showed a consistent pattern of high LD in the IGF1 promoter region, 
confi rming what was observed in our study (Figure 1A). 
 Th e study of Cheng and the HapMap database showed that the -G1245A SNP (rs35767) 
appeared to be a tagging SNP for 2 haplotypes described in a Caucasian population [25]. Our 
study describes 3 instead of 2 haplotype blocks which might well be due to the -841(CA)n 
VNTR which was not present in the study of Cheng and the HapMap database because in these 
studies only SNPs and not VNTRs were genotyped. 
 
Th e -G1245A SNP 
Carriers of the -1245 A-allele had a shorter birth length, smaller birth head circumference and 
tended to have a lower birth weight (Table 2). When birth measurements were adjusted for 
the shorter gestational age ([GG] = 37.1 vs. [GA+AA] = 36.0 weeks, P = 0.04), no diff erences 
between SD scores were found. We therefore only describe birth data which are adjusted for 
gestational age (SDS). 
 Th e -G1245A SNP did not associate with a diff erent height SDS and weight SDS during 
the fi rst 3 years of life (Table 2), but carriers of the -1245 A-allele had a 0.3 SDS smaller head 
circumference from 1 until 3 years of age (P = 0.02, 0.01 and 0.06, Figure 2). Th e -G1245A SNP 
was not associated with the gain in height, weight and head circumference and IGF-I levels 
during GH treatment.
Th e -841(CA)n/192bp VNTR 
Th e non192bp-allele was associated with a one week shorter gestational age (36.3 vs. 37.3 weeks 
in 192bp-allele carriers, P = 0.05). No associations were found with gestational age adjusted 
birth measurements and measurements during postnatal life (data not shown). 
Promoter haplotypes 
Th ree haplotypes could be constructed of the -G1245A SNP and the -841(CA)n/192bp VNTR 
(Figure 1C). Haplotype 2, consisting of the -1245 A- and the -841(CA)n/non192bp-allele, was 
the only haplotype in our population which included the -1245 A-allele. Haplotype 2 showed 
comparable associations with gestational age and head circumference as those of the -1245 
A-allele separately. Haplotype 1 and 3 showed no associations (Table 3). 
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Table 2. Birth size and postnatal growth associations with the -G1245A SNP in the total short SGA 
population. 
Height Weight Head circumference
[GG] [GA+AA] [GG] [GA+AA] [GG] [GA+AA]
Birth Cm/ g /cm 42.1 (4.5) 40.4 (5.8) 2 1975 (630) 1781 (811) 1 31.8 (2.7) 30.7 (3.4) 2
Birth SDS -3.41 (1.21) -3.72 (1.50) 1 -2.42 (1.05) -2.57 (1.24) -1.28 (1.29) -1.49 (1.80)
Age 1* SDS -2.80 (0.07) -2.88 (0.11) -2.71 (0.10) -2.87 (0.15) -1.16 (0.81) -1.52 (0.86) 2
Age 2* SDS -2.95 (0.06) -3.03 (0.10) -2.77 (0.09) -2.84 (0.14) -1.04 (0.90) -1.42 (0.85) 3
Age 3* SDS -2.98 (0.06) -3.04 (0.10) -2.79 (0.08) -2.94 (0.13) -1.06 (0.90) -1.36 (0.84) 1
Values are given as means (SD) unless otherwise specifi ed. Birth size SDS were determined by using a gestational age specifi c growth 
chart [22]. *= Corrected for gestational age, being a covariate in ANOVA, to adjust for premature birth, presented with standard 
error. SDS= standard deviation score. P-values compare the [GG] vs. [GA+AA] genotype, 1= P-value ≤ 0.10, 2= P-value ≤ 0.05, 3= 
P-value ≤ 0.01.
Table 3. Gestational age and head circumference associations with the IGF1 promoter haplotypes in the 
total short SGA population. 
H1 = [-1245G] +
[-841/192bp]
H2 = [-1245A] +
[-841/n192bp]
H3 = [-1245G] +
[-841/n192bp]
H1 nH1 H2 nH2 H3 nH3
GA Weeks 36.8 (3.6) 36.5 (3.5) 35.8 (4.1) 37.2 (3.3) 1 36.7 (3.4) 36.9 (3.6)
Age 1* HC SDS -1.27 (0.07) -1.28 (0.21) -1.52 (0.12) -1.17 (0.08) 2 -1.21 (0.12) -1.29 (0.08)
Age 2* HC SDS -1.16 (0.07) -1.17 (0.22) -1.42 (0.12) -1.06 (0.08) 3 -1.08 (0.12) -1.20 (0.08)
Age 3* HC SDS -1.15 (0.07) -1.15 (0.22) -1.36 (0.13) -1.07 (0.08) 1 -1.08 (0.13) -1.18 (0.08)
Values are given as means (SD) unless otherwise specifi ed. *= Corrected for gestational age, being a covariate in ANOVA, to adjust 
for premature birth, presented with standard error. H1, H2 and H3 represent the homozygous haplotype carriers vs. the heterozygous 
carriers of the haplotype together with non-carriers of the haplotype (nH1, nH2, nH3). GA=gestational age, SDS= standard deviation 
score, HC= head circumference. P-values compare the [GG] vs. [GA+AA] genotype, 1= P-value ≤ 0.10, 2= P-value ≤ 0.05, 3= P-value 
≤ 0.01.
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Figure 2. Th e -G1245A SNP in short SGA children: Diff erence in postnatal head circumference SDS. 
Means are presented with P-values above, SDS= standard deviation score.
Marker alleles within haplotypes
Haplotype 2 consisted of the -1245A- and -841(CA)n/non192bp-alleles, who both were 
associated with a shorter gestational age. Th e -1245 A-allele only, showed an association with a 
smaller head size during the fi rst 3 years of life. Th erefore, the -1245 A-allele appeared to be the 
marker allele within Haplotype 2 (Figure 1C). 
Transcription factor binding sites in -G1245A 
Transcription factor binding site (TFBS) databases were searched for changes in transcription 
factor binding to the -1245 SNP sequence when either the G- or the A-allele was present. 
Blasting the -G1245A SNP and 20bp surrounding sequence on each site in TFBS-databases, 
showed that the A-allele induced a potential binding site for “upstream stimulatory factor” 
(USF: NCACGTGN, 88.6% homology). In case of a G instead of an A-allele, such a binding site 
was not found.
Th e +3703(CT)n/189bp VNTR 
Th e +3703(CT)n VNTR was not part of the promoter LD block, so association studies were 
performed with this VNTR separately. Carriers of the 189bp-allele had a shorter gestational age 
(P=0.04), but no associations were found with gestational age adjusted birth measurements and 
measurements during postnatal life. 
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Th e +A1830G SNP 
Due to the large intermarker distance and low LD, association studies were performed with this 
SNP separately. Th ere were no associations with gestational age adjusted birth measurements 
and measurements during postnatal life (data not shown).
Discussion
Th e aim of our study was to determine in short SGA children whether birth size, postnatal 
growth and growth during GH treatment were associated with IGF1 gene polymorphisms and 
haplotypes. Th e -1245 A-allele was identifi ed as a marker-allele for the well-known -841(CA)n/
non192bp-allele. Th e -1245 A-allele associated with a 0.3 SDS smaller head circumference during 
spontaneous postnatal growth, and a smaller absolute birth size but this was due to a one week 
shorter gestational age. Carriers of the intron 2 gene polymorphism had a shorter gestational 
age, whereas the 3UTR gene polymorphism did not show any association. No associations 
were found between the IGF1 gene polymorphisms and length, weight and head circumference 
standard deviation scores (SDS) at birth, and with height and weight SDS during postnatal life. 
IGF1 polymorphisms were not associated with growth during GH treatment. Th e frequency of 
the diff erent genetic polymorphisms was similar in SGA cases and controls.
 Th e -G1245A SNP in the IGF1 gene promoter was investigated for the fi rst time in 
relation to birth size, postnatal growth and growth during GH treatment. Th e -G1245A SNP 
is an informative SNP as it is in high linkage disequilibrium with the well-known -841(CA)n/ 
192bp VNTR. Th e latter being the most extensively investigated gene polymorphism in the IGF1 
gene region with numerous associations in childhood and adult life [3,4,15,25]. Th e -G1245A 
SNP and -841(CA)n/192bp VNTR were investigated together. Haplotype analysis showed that 
the -G1245A SNP was the tagging SNP for the -841(CA)n/192bp VNTR. Th is fi nding might 
enhance further research into this gene region as the -G1245A SNP is an easy to determine gene 
variant by Taqman assay compared to the -841(CA)n/192bp VNTR which is mainly determined 
by Genescan. 
 Th e association between the -841(CA)n non192bp-allele and a shorter gestational age 
might explain the discrepant fi ndings of Vaessen and Frayling [16,19]. Vaessen, reported an 
association between the non192bp-allele and a lower birth weight in grams, which could not 
be confi rmed by Frayling. Vaessen did however, neither select, nor adjust for gestational age in 
contrast to Frayling who only selected subjects between 36 and 44 weeks of gestation. It might 
well be that the associations found by Vaessen would have disappeared aft er correction for 
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gestational age. Th e association with a shorter gestational age was in line with previous studies 
showing an association between intrauterine growth retardation, a shorter gestational age and 
low IGF-I levels [30,31]. Th e shorter gestational age might well be an eff ect of prenatal low 
IGF-I levels resulting in a severely growth-retarded SGA fetus, which is a recognized indication 
to induce labor by caesarean section or chemical induction of contractions , especially when the 
head circumference is small. 
 By searching transcription factor binding site databases, we identifi ed a transcription 
factor known for growth inhibiting properties, upstream stimulatory factor (USF), which binds 
to the -1245 A-allele. In case of the common G-allele, USF is unable to bind the surrounding 
IGF1 promoter sequence. Th e fact that USF has growth inhibiting properties [32], suggests that 
the -1245 A-allele might result in reduced IGF-I protein expression in the short SGA child. 
Previous characterization of the region surrounding the -G1245A SNP showed that the region 
ranging from -1630 until -926 base pairs before the start of exon 1 is important for the activation 
of the IGF1 gene transcription [33]. Important regulatory elements might coincide with the 
promoter linkage disequilibrium block, containing the -G1245A SNP and the -841(CA)n/192bp 
VNTR, located at -1245 and at -841 base pairs before the start of exon 1.
 Th e IGF1 gene contains 2 promoter regions which regulate tissue-specifi c expression 
through alternative RNA processing [34,35]. Th ese 2 promoter regions are located in front of 
exon 1 (P1) and 2 (P2), respectively, and is the same region in which high linkage disequilibrium 
was found (this study, [4]). Polymorphisms in these regions might result in diff erent IGF1 
mRNA levels showing a cell-type specifi c expression pattern. Th e specifi c association of the 
-1245 A-allele with a smaller head circumference SDS, might be such a tissue-specifi c eff ect. 
Cheng showed that brains of IGF1 knock-out mice are highly dependent on locally produced 
IGF-I in promoting growth of the developing brain [36]. A reduced IGF1 gene expression has 
been associated with a reduced brain size in mice whereas IGF1 overexpression gives rise to 
increased brain growth, although the IGF-I level in brain tissue was among the lowest one 
measured in all body tissues [37,38]. Th ese fi ndings show that brain growth is extremely 
sensitive to local IGF-I levels. Although men and mice invariably diff er, it might well be that 
part of the IGF1 promoter induces brain-specifi c local IGF-I production. 
 IGF1 gene polymorphisms were not associated with growth and IGF-I levels during 
GH treatment. Th is might be due to a time- and tissue-specifi c eff ect of the -G1245A gene 
polymorphism which is important for head growth during early postnatal life. Animal studies 
have demonstrated that IGF1 induces growth mostly by tissue-specifi c actions, as liver IGF1-
defi cient mice with a 75% decrease in circulating IGF-I levels displayed a comparable postnatal 
growth pattern as control mice [39]. Th e -1245A-allele has also been associated with low IGF-I 
levels in a breast cancer population, indicating that this SNP has eff ects on protein level [40].
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For every genetic association study there is always a possibility that associations have arisen 
by chance, especially if they are novel. As the head circumference associations have also been 
demonstrated by Arends [3] in a selected, smaller population, we consider the observed head 
circumference associations as real. Th e association between gestational age and the -G1245A 
SNP is new, but many studies [16,19,41-44] have investigated the association between the 
-841/192bp VNTR and birth size. Th at gestational age might be an explanatory factor in these, 
sometimes, confl icting associations, is biologically plausible. However, replicative studies are 
needed to draw clinical conclusions from these associations. 
 Another explanation of novel associations is the occurrence of population stratifi cation 
i.e. the situation in which cases and controls have diff erent allele frequencies which is 
attributable to diversity in background population, unrelated of outcome status. Population 
stratifi cation seems less probable in our population, as family based studies using a transmission 
disequilibrium test (TDT), also showed an association between this IGF1 gene region and head 
size [3,45,46]. 
 In conclusion, the -1245 A-allele in the IGF1 promoter was the only polymorphism 
which associated with a smaller head circumference SDS during spontaneous postnatal growth 
and a shorter gestational age. No other associations were found with birth size and growth, 
neither spontaneously, nor during GH treatment. Th e -G1245A SNP appeared to be a marker 
for the well-known -841(CA)n/192bp polymorphism.
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Web resources
URLs for the presented data are: −
Celera genome browser: http://www.celera.com/ −
HapMap genomic database:  − http://www.hapmap.org/
Haploview v3.2:  − http://www.broad.mit.edu/mpg/haploview/
NCBI SNP browser: http://www.ncbi.nlm.nih.gov/entrez/ −
PHASE:  − http://www.stat.washington.edu/stephens/soft ware.html
Power and sample size calculation: http://biostat.mc.vanderbilt.edu/twiki/bin/view/ −
Main/PowerSampleSize
PubMed: http://www.ncbi.nlm.nih.gov/entrez −
TESS: Transcription Element Search System: http://www.cbil.upenn.edu/tess −
TFSEARCH: Searching Transcription Factor Binding Sites: http://www.cbrc.jp/research/ −
db/TFSEARCH.html
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Abstract
Context: SGA subjects experience pre- and postnatal growth restriction, which might 
be infl uenced by polymorphisms in the IGF1 gene. Th e well-known -841(CA)n/192bp 
polymorphism has been associated with birth size, cardiovascular disease and IGF-I levels, and 
is in linkage disequilibrium with the -G1245A SNP (rs35767).
Objective: To associate the –G1245A SNP with head circumference (HC) and brain sparing (a 
greater head compared to height standard deviation score (SDS)) in short SGA and SGA catch-
up subjects. 
Design: Gene association study.
Patients: 635 SGA subjects of which 439 remained short and 196 had a postnatal height > -2.00 
SDS. 
Measurements: Th e –G1245A SNP IGF1 gene polymorphism and head size. 
Results: All SGA subjects had a postnatal head size below the population mean (-1.01 SDS, 
P < 0.001). Whereas SGA catch-up subjects had a head size which was in proportion with their 
height, short SGA subjects displayed extensive brain sparing (HC – height: SGA CU: 0.01 vs. 
short SGA: 1.75 SDS, P < 0.001). Th e most severely SGA born subjects had a 0.4 SDS smaller 
postnatal head size and 0.6 SDS less brain sparing when carrying the -1245 A-allele in contrast to 
G-allele carriers (P = 0.03). Th e association between the –G1245A SNP and head size remained 
signifi cant aft er correction for birth weight and postnatal height SDS (P < 0.001). Birth weight, 
birth length and postnatal height SDS were not related with the –G1245A SNP. 
Conclusions: Th e -1245 A-allele of the IGF1 promoter SNP is associated with a small head 
size and less brain sparing in SGA born subjects and particularly those with the lowest birth 
weight. 
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Introduction
Around 2% of all life-born neonates are born small for gestational age (SGA) and ~10% of them 
remain short [1,2]. Since reduced size at birth may result from fetal, maternal, placental or 
demographic infl uences, SGA subjects comprise a heterogeneous group. SGA subjects without 
catch-up growth are known to have a smaller head circumference and a lower IQ [3] compared 
to SGA subjects catching up in height [4,5]. Head size preservation, or “brain sparing” is defi ned 
as centralisation of the fetal circulation in the brain 6 and is essential for the growth retarded 
fetus to prevent brain damage [7]. 
 Th e IGF1 gene (IGF1, OMIM*147440, NM_000618, gene map locus: 12q22-q24.1) is a 
major candidate gene for explaining parts of the SGA phenotype as animal studies have shown 
that IGF1 knock-out mice had a 40% birth weight reduction and retarded postnatal growth 
in length and weight [8,9]. Case-reports have described patients with IGF1 gene mutations 
who were born SGA, had a persistent short stature and sensorineural deafness, a small head 
circumference (HC) and a low performance IQ [10-12]. 
 Th e most common investigated polymorphism in the IGF1 gene is the 192bp CA-
repeat in the promoter. Th e non-192bp allele is associated with a low birth weight, low adult 
height, low IGF-I serum level and a higher risk for diabetes mellitus and myocardial infarction 
although confl icting results are reported [13-18]. Th e 192bp allele polymorphism and the 
–G1245A SNP (rs35767) are located in the same linkage disequilibrium (LD) block and studies 
have shown that the –G1245A SNP can be used as a marker for the 192-bp polymorphism 
(Hapmap, Web resources) [19,20]. A subgroup of the short SGA population which is described 
in the current study, has already previously shown that a haplotype, of which the -1245 
A-allele was the marker, was associated with a smaller head circumference during spontaneous 
postnatal growth, but not during GH treatment in short SGA children [20]. Th us, the IGF1 
gene is involved in determining head size, and SGA subjects have a smaller head circumference 
and lower IQ depending on the extent of postnatal catch-up growth. It is unknown whether 
the IGF1 192bp gene polymorphism is related to head size in short SGA versus SGA catch-up 
subjects. In addition, it is unknown whether SGA severity modifi es the relation between brain 
sparing and this genetic polymorphism.
 Th erefore, we investigated whether the –G1245A SNP was associated with head 
circumference and brain sparing in a large cohort of 439 short SGA and 196 SGA catch-up 
subjects. 
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Methods
Patients
All 635 subjects were born small for gestational age (SGA: birth length and/or weight ≤ -2 
standard deviation score or SDS for their gestational age [21]) and fulfi lled the inclusion criteria 
of Caucasian ethnicity and an uncomplicated postnatal period. Subjects with severe chronic 
illness or endocrine disorders, chromosomal or genetic abnormalities, positive endomysial or 
transglutaminase antibodies, skeletal abnormalities and psychosocial dwarfi sm were excluded 
from the study. Th e study protocol was approved of by the Medical Ethics Committee and written 
informed consent was obtained from the parents/guardians and subjects above 12 years. 
 SGA subjects were assigned to two subgroups according to their ability to attain a 
postnatal height in the normal range, consisting of 439 short [20] and 196 catch-up subjects. 
Th e SGA subjects who remained short (height ≤ -2.00 SDS: short SGA [22]) were investigated 
at start of GH treatment and were drawn from prospective cohort trials evaluating the eff ect 
of GH treatment [23,24]. SGA subjects who had catch-up growth to a normal height (height 
> -2.00 SDS: SGA catch-up [22]) were randomly selected from hospitals in the Netherlands, 
where they had been registered because of being small at birth. 
Clinical and biochemical measurements
Birth data of the SGA subjects were retrieved from records of hospitals, community health 
services and general practitioners. Birth weight SDS was used as a proxy for SGA severity as 
birth length and birth head circumference measurements are not always performed in case 
of a severely growth-retarded newborn. Anthropometrical measurements of the short SGA 
subjects were performed at the start of the GH trials [24]. Anthropometrical measurements of 
the SGA catch-up group were obtained at the out-patient clinic. Delta height was calculated by 
subtracting birth length (SDS) from height (SDS). Body mass index was calculated (weight in 
kg/ height in meters2) and adjusted for age and sex, expressed as SDS [25]. Brain sparing was 
calculated by subtracting height (SDS) from head circumference (SDS). Both height and head 
circumference measurements were present in a subset of 597 SGA subjects. Serum IGF-I levels 
were measured in the SGA subjects as previously described [26] and values were transformed 
in SDS by adjusting for sex and age [27]. 
Genotyping
Genomic DNA was extracted from samples of peripheral venous blood according to salting 
out procedure [28]. Genotypes were determined using the Taqman allelic discrimination assay. 
103
Chapter
5
Th e Assay-by-Design service (www.appliedbio-systems.com) was used to set up a Taqman 
allelic discrimination assay for the -G1245A SNP (rs35767). Primer sequences were: Forward: 
GGATTTCAAGCAGAACTGTGTTTTCA, reverse: GGTGGAAATAACCTGGACCTTGAAT. 
Probe sequences were for –G1245A, Forward: VIC-TTTTTTCCGCATGACTCT, reverse: 
FAM-TTTTTTTTCCACATGACTCT. Th e PCR reaction mixture included 5ng of genomic 
DNA, 0.125 μl TaqMan assay (40*, ABI), 2.5 μl Master mix (ABI) and 2.375 μl water. PCR was 
performed in 384 wells PCR plates in an ABI 9700 PCR system (Applied Biosystems Inc., Foster 
City, CA, USA) and consisted of initial denaturation for 10 minutes at 95° C, and 40 cycles 
with denaturation of 15 seconds at 92° C and annealing and extension for 60 seconds at 60° C. 
Results were analyzed by the ABI Taqman 7900HT using the sequence detection system 2.22 
soft ware (Applied Biosystems Inc., Foster City, CA, USA). 
Statistical analysis
Th e total SGA population was compared to the average population, defi ned at 0.00 SDS, 
using T-test. Continuous data were compared between the short SGA and the SGA catch-
up population by univariate analysis of variance (ANOVA). Th e Chi-square test was used 
to analyze categorical variables. Multiple regression analysis was performed by using head 
circumference SDS as dependent variable and gestational age, birth weight SDS, age and height 
SDS as independent variables. As height SDS and BMI SDS were highly interrelated, only height 
SDS was investigated in the regression analysis. Correlations were determined by Spearman 
correlation coeffi  cient.
 Th e –G1245A SNP was determined in the total SGA group of 635 subjects. Th e Hardy-
Weinberg equilibrium (HWE) was calculated by computing the chi-square test for deviations 
in HWE. Allele frequencies were calculated and tested by chi-square. Th e polymorphism 
was grouped according to a dominant model into the [GG] genotype versus the [GA]+[AA] 
genotype. Th e genotypic groups were compared for all anthropometric parameters by univariate 
analysis of variance (ANOVA). P-value ≤ 0.05 was considered signifi cant. Statistical tests were 
performed using SPSS 15.0 (SPSS Inc., Chicago, IL, USA).
Results
Clinical data
Th e total SGA group had a mean birth length of -3.00 SDS and a birth weight of -2.34 SDS 
(Table 1). Postnatally, they had a signifi cantly lower BMI and smaller head circumference than 
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the average population (P < 0.001), but compared to their height SDS, they had a large head 
(HC – height, 1.18 SDS). Th eir IGF-I level was signifi cantly lower than the average population 
(-0.93 SDS), but relatively high compared to their height of -2.24 SDS.
Table 1. Clinical data of the total, short SGA and SGA catch-up group.
Total SGA group SGA subgroups
Child: Short SGA SGA catch-up P-value
Birth: 635 439 196
Sex (boys/girls) 302/333 223/216 79/117 0.01
GA (weeks) 36.7 (3.6) 36.6 (3.8) 37.1 (3.0) 0.10
Length (SDS) -3.00 (1.48) a -3.14 (1.49) a -2.70 (1.41) a 0.001
Weight (SDS) -2.34 (1.01) a -2.28 (1.09) a -2.47 (0.81) a 0.03
At measurement:
Age (years) 12.7 (7.2) 8.9 (5.1) 21.1 (2.6) <0.001
Height (SDS) -2.24 (1.27) a -2.95 (0.63) a -0.64 (0.84) a <0.001
Height (SDS) – birth length (SDS) 0.81 (1.81) a 0.20 (1.60) c 2.04 (1.57) <0.001
BMI (SDS) -0.73 (1.34) a -1.13 (1.16) a 0.15 (1.31) <0.001
HC (SDS) -1.01 (1.00) a -1.19 (0.95) a -0.64 (0.99) a <0.001
HC (SDS) – height (SDS) 1.18 (1.38) a 1.75 (1.06) a 0.01 (1.22) a <0.001
IGF-I level (SDS) -0.93 (1.32) a -0.99 (1.33) a -0.45 (1.10) b 0.005
Values are means (standard deviation) unless indicated otherwise. When compared with 0.00 SDS: a P-value <0.001, b P-value <0.01, 
c P-value <0.05. Th e overall P-value is presented between the short SGA and the SGA catch-up group by ANOVA for continuous and 
by chi-square test for categorical variables. GA= gestational age, SDS= standard deviation score, HC= head circumference.
Short SGA subjects were born with a lower birth length SDS and tended to have a shorter 
gestational age than SGA catch-up subjects (Table 1). Short SGA subjects were younger at 
examination and by defi nition, shorter and had less catch-up growth in height from birth 
onwards compared to SGA catch-up subjects. Short SGA subjects also had a lower BMI, smaller 
head size and lower IGF-I levels than SGA catch-up subjects. Whereas there was no brain 
sparing within SGA catch-up subjects (0.01 SDS), short SGA subjects had a 1.75 SDS larger 
head than height SDS. Although SGA catch-up subjects had caught up to a normal height and 
head circumference, these measurements and their IGF-I level remained below the population 
mean of 0 SDS (P-value: < 0.001, < 0.001 and 0.005, respectively). 
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Factors associated with head circumference SDS
Th e –1245 A-allele was associated with a 0.3 SDS smaller head circumference in the total SGA 
population, although explaining a minor proportion of the variation in head size (P < 0.006, 
1.3%, Table 2). Birth weight was positively associated with postnatal head circumference, 
each SDS in birth weight resulting in a 0.2 SDS increase in postnatal head circumference. Th e 
–G1245A SNP remained a signifi cant explanatory factor, even aft er inserting birth weight and 
postnatal height into the model (P < 0.001, R2 13.1%). 
Table 2. Factors associated with head circumference SDS in the total SGA group.
Explanatory factors: Model 1 Model 2 Model 3
B P-value B P-value B P-value
-G1245A SNP* -0.26 0.006 -0.23 0.01 -0.20 0.03
Birth weight (SDS) - - 0.17 <0.001 0.20 <0.001
Height (SDS) - - - - 0.24 <0.001
R2 1.3% 3.9% 13.1%
P-value 0.006 <0.001 <0.001
*coded as: 0= [GG] and 1= [GA+AA].
–G1245A polymorphism 
Th e total SGA population consisted of 71.7 % [GG], 24.6% [GA] and 2.2% [AA] carriers. Th e 
short SGA and SGA catch-up group had comparable genotype frequencies (P = 0.40). Genotypes 
were in Hardy-Weinberg equilibrium (P = 0.88). 
 Th e association between head size and the –G1245A SNP was examined in each birth 
weight quartile in the total SGA population. Subjects who were most severe SGA at birth, being 
in the lowest birth weight quartile, had a signifi cantly 0.4 SDS smaller head size when carrying 
the -1245 A-allele (Table 3, Figure 1). SGA subjects with the -1245 A-allele also had 0.6 SDS less 
brain sparing than [GG] carriers (Figure 1). Short SGA and SGA catch-up groups showed the 
same diff erence, although it did not reach statistical signifi cance. No associations were found 
with birth length, birth weight and height SDS.
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Figure 1. Scatterplot of the correlation in the total SGA population between: birth weight SDS and head 
circumference SDS (left ), and birth weight SDS and brain sparing (HC-height SDS, right). 
Discussion
Th e aim of our study was to investigate whether the –G1245A SNP was associated with head 
circumference and brain sparing in a large cohort of 439 short SGA and 196 SGA catch-up 
subjects. Th e -1245 A-allele of the IGF1 promoter SNP was associated with a small head size 
and less brain sparing in SGA born subjects and particularly those with the lowest birth weight. 
Birth weight, birth length and postnatal height SDS were not associated with the –G1245A 
SNP. 
 Th is study demonstrated that the relation between the –G1245A SNP, head size and 
brain sparing was present in SGA born subjects and especially in those with the smallest size 
at birth. Th e head sparing adaptation of these severely SGA born neonates was reduced when 
carrying the –G1245 A-allele. As the –1245 A-allele is known to be in close linkage with the 
non192bp-allele in the IGF1 gene promoter, our study has shown another feature of carriers of 
this allele. Our study also showed that the association between the –G1245A SNP, head size and 
brain sparing, was present in the total SGA population which is suggestive for a general feature 
of SGA born children.
 Several studies have shown the important role of the IGF1 gene in brain growth [29,30]. 
Lee et al [29] demonstrated that transgenic mice overexpressing IGF1 could ameliorate brain 
growth retardation caused by undernutrition, which resulted in a comparable brain growth as 
the well-fed control mice. Th ey also demonstrated that IGF1 overexpression resulted in postnatal 
brain growth, which was localized in cerebral cortex, hippocampus and diencephalon. Also 
Simmons et al [30] suggested a tissue-specifi c eff ect of IGF1, showing that glucose transport in 
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the brain was preserved and unaff ected by treatment with IGF-I or insulin. Cheng showed that 
brains of IGF1 knock-out mice are highly dependent on locally produced IGF-I in promoting 
growth of the developing brain [31]. A reduced IGF1 gene expression has also been associated 
with a reduced brain size in mice whereas IGF1 overexpression gave rise to increased brain 
growth, although the IGF-I level in brain tissue was among the lowest one measured in all 
body tissues [32,33]. Th is might also be applicable to short SGA subjects having the -1245 
A-allele which might result in less local IGF-I expression in the brain and a smaller head size. 
All together these observations indicate that short SGA subjects might experience a diff erential 
IGF1 gene expression which infl uenced their head size. 
 Several studies have demonstrated that short stature and a small head size are important 
predictors for subnormal intellectual performance [4,34,35]. Our study showed that a small 
birth size in combination with the -1245 A-allele, was associated with the smallest head 
circumference in SGA subjects, and especially in short SGA subjects (A-allele carriers: -1.70 
SDS). Unfortunately, we do not have data on intellectual performance in these subjects, but it 
would be interesting to study the infl uence of the A-allele on intellectual performance in future 
studies.
 Th is study did not show associations between the –G1245A SNP and birth size, postnatal 
height and IGF-I level in the short SGA and SGA catch-up group. Although animal studies and 
case-reports of subjects with IGF1 gene mutations have shown that the IGF1 gene is important 
in pre- and postnatal growth, the short SGA subjects only had an association with head size. 
Th e absence of associations with pre- and postnatal growth in these SGA populations confi rm 
previous genome wide and large association studies in which IGF1 was not one of the genes that 
could explain variations in height [36-41]. 
 Additionally, animal models in which hepatic IGF-I levels were eliminated, have 
shown that mice kept growing with 75% reduced serum circulating IGF-I levels [42]. Th ese 
observations underline that the processes determining height are multifactorial in nature and 
that the IGF1 gene is not a main contributor in determining adult height. 
 Due to the ascertainment, short SGA subjects were investigated at 9 years of age and 
SGA catch-up subjects were investigated in early adulthood at 21 years of age. Several studies 
have demonstrated that SGA subjects do not show any catch-up growth in height aft er the age 
of fi ve years [1,43]. We therefore consider the diff erence in age unlikely to explain the observed 
associations.
 We observed that the most severely SGA born subjects had a 0.4 SDS smaller head size 
and 0.6 SDS less brain sparing when carrying the -1245 A-allele in contrast to G-allele carriers, 
which might be of clinical relevance. Our study has shown for the fi rst time that the –G1245A 
SNP is related to postnatal head size in SGA subjects regardless of their postnatal growth. 
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In conclusion, we found in a large group of SGA subjects that the -1245 A-allele of the IGF1 
promoter SNP was associated with a small head size and less brain sparing in SGA born subjects 
and particularly those with the lowest birth weight. 
Web resources
URLs for the presented data are:
HapMap genomic database: http://www.hapmap.org/
NCBI SNP browser: http://www.ncbi.nlm.nih.gov/entrez/
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Abstract
Context: Th e insulin-like growth factor 1 receptor (IGF1R) gene is an important factor in pre- 
and postnatal growth. Th e IGF1R gene promoter has multiple transcription factor binding sites 
aff ecting IGF1R protein expression.
Objective: To determine whether haplotypes of single nucleotide polymorphisms (SNPs) in 
the IGF1R gene promoter, rs4965425 and rs1319868, associate with postnatal growth in a large 
cohort of SGA subjects.
Patients: Cohort of 635 SGA subjects (439 short SGA, 196 catch-up SGA). 
Results: Th e rs4965425 C-allele was associated with a 0.3 standard deviation score (SDS) lower 
weight, BMI and catch-down in weight in short SGA subjects in contrast to the T-allele. Th ere 
were no associations with the rs1319868 SNP. Both SNPs were in complete linkage disequilibrium 
(D’ = 1.00, R2 = 0.14). Th e minor allel frequency of the rs1319868 SNP was signifi cantly higher 
in the total SGA population compared to controls. Haplotype analysis showed that Haplotype 1, 
consisting of the rs4965425 C-allele and the rs1319868 G-allele, was associated with a 0.4 SDS 
lower weight, BMI and catch-down in weight in short SGA subjects. Th is was most pronounced 
in short SGA subjects who had a birth length and -weight <-2.00 SDS as they had a 0.8 SDS 
lower postnatal weight and BMI, and the largest postnatal catch-down in weight compared to 
non-carriers (P = 0.002, P = 0.002 and P = 0.02, respectively). Th e rs4965425 C-allele drove 
these associations. Growth of SGA catch-up subjects was not associated with any SNP.
Conclusions: Short SGA subjects with the rs4965425 C-allele have a lower weight and BMI SDS 
due to a postnatal catch-down in weight compared to non-carriers. Th is was most pronounced 
in short SGA subjects born with both a birth length and -weight <-2.00 SDS. Our fi ndings 
suggest that genetic variation in the IGF1R gene promoter contributes to postnatal weight 
development of short SGA subjects.
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Introduction
Around 2% of all life-born neonates are born SGA and 10% of them remain short [1,2]. 
SGA subjects with a persistent short stature have a reduced lean body mass, fat mass, skin 
fold measurement and body mass index [3-5]. Th ey also have a decreased caloric, fat and 
carbohydrate intake [6]. SGA subjects with an accelerated postnatal growth are known for an 
increased risk for cardiovascular disease [7-9]. In addition to classical risk factors, modifi er 
genes may be of importance to postnatal growth of SGA subjects. 
Th e insulin-like growth factor 1 receptor gene (IGF1R: OMIM*147370, NM_000875, gene map 
locus: 15q25-q26) is an important candidate gene for subjects born SGA, being a major pre- and 
postnatal growth factor [10,11]. IGF1R knockout mice have a 55% reduction in birth weight and 
do not survive postnatally. Th e IGF1R promoter region is rich in GC nucleotides and contains 
numerous potential SP1 binding sites aff ecting IGF1R gene expression [12-14]. 
Several case-reports have described subjects born SGA with persistent short stature, who had 
mutations in the IGF1R gene [15-18]. Although these case-reports are limited, they illustrate 
that the IGF1R gene is involved in pre- and postnatal growth. 
IGF1R gene polymorphisms have rarely been investigated in SGA subjects. Several studies 
have investigated IGF1R polymorphisms but only one polymorphism has been investigated in 
relation with SGA-related outcomes. Namely, Rasmussen et al [19] observed no associations 
between the synonymous E1013E polymorphism (Rs2229765) and birth size or oral glucose 
tolerance.
It is unknown whether IGF1R gene polymorphisms in the promoter are associated with 
postnatal growth of SGA subjects. It might well be that promoter polymorphisms play a role in 
the degree of postnatal catch-up growth in weight and height of SGA subjects as the IGF1R gene 
promoter contains several transcription regulating area’s which infl uence protein expression. 
In this study we investigated whether the rs4965425 and rs1319868 polymorphisms in the 
IGF1R gene promoter were associated with postnatal growth in a large population of 635 SGA 
subjects. 
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Methods 
Study participants
We included 635 SGA subjects, and according to their ability to attain a postnatal height in 
the normal range, we divided the cohort into 439 short and 196 catch-up subjects. SGA was 
defi ned as a birth length and/or weight ≤ -2 SDS for gestational age [20]. Th e SGA subjects who 
remained short (height ≤ -2.00 SDS: short SGA, [21]) were drawn from a prospective cohort 
at start of GH treatment [4,22,23]. SGA subjects who had catch-up growth to a normal height 
(height ≥ age 3: > -2.00 SDS: SGA catch-up [21]) were randomly selected from hospitals in the 
Netherlands, where they had been registered because of being small at birth.
 Th e total SGA group was subdivided in SGAL and SGAL+W subjects. SGAL was defi ned 
as a birth length ≤ -2.00 SDS and a birth weight >-2.00 SDS, whereas SGAL+W was defi ned as a 
birth length and a birth weight ≤ -2.00 SDS [24]. Within the total SGA group, 553 subjects had 
birth length and -weight available, 104 were SGAL and 203 SGAL+W.
 All subjects were of Caucasian ethnicity and had an uncomplicated postnatal 
period. Subjects with severe chronic illness or endocrine disorders, chromosomal or genetic 
abnormalities, positive endomysial or transglutaminase antibodies, skeletal abnormalities and 
psychosocial dwarfi sm were excluded from the study. Th e study protocol was approved of by 
the Medical Ethics Committee and written informed consent was obtained from the parents/
guardians and subjects of age 12 years and older. A healthy control population of 100 subjects 
was acquired from a local bloodbank.
Anthropometrical measurements
Birth data and postnatal measurements of the SGA subjects were retrieved from records of 
hospitals, community health services, general practitioners and from baseline data of the GH 
trials. Height and weight were available from all subjects. All anthropometric measurements in 
the subjects were performed twice and the mean value was used for analysis. Body mass index 
was calculated (weight in kg/ height in meters2) and adjusted for age and sex, expressed as 
standard deviation score (SDS) [21]. 
Selection of SNPs and Linkage Disequilibrium
Two SNPs within the IGF1R gene promoter region were identifi ed by using the SNP selection 
tool, tagger in the HapMap database (Web resources). Th e rs4965425 [C/T] and rs1319868 
[G/T] SNPs were identifi ed as tagging SNPs for the linkage disequilibrium block in the promoter 
of the IGF1R gene. 
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Linkage Disequilibrium 
Th e pairwise linkage disequilibrium (LD) coeffi  cients (D’ and R2) were calculated with the 
use of Haploview soft ware (Web resources). Gene polymorphisms which were in high LD (D’ 
> 0.90) were used for haplotype construction. We inferred haplotypes of the rs4965425 and 
rs1319868 SNPs using PHASE 2.1 [25,26]. 
Genotyping
Genomic DNA was extracted from samples of peripheral venous blood according to salting out 
procedure [27]. Genotypes were determined using the Taqman allelic discrimination assay. Th e 
Assay-by-Design service (www.appliedbio-systems.com) was used to set up a Taqman allelic 
discrimination assay for the rs4965425 and rs1319868 SNPs. 
 Primer sequences for the rs4965425 and rs1319868 SNPs were: forward: GTGAA-
TGTTTCCAATCTCGCTTTTCT and GAAGCCTCCAGTTTCCATTTTGG, reverse: CACC-
AAGTCCAGGACACAGT and GGCCTGGGCCAAGAGT. Probe sequences for the rs4965425 
and rs1319868 SNPs were, Forward: CTTATGTTACGTGATTCC and CTCCAGGGTGCCTAT, 
reverse: CTTATGTTATGTGATTCC and TCTCCAGGTTGCCTAT. Th e PCR reaction mixture 
included 5ng of genomic DNA, 0.125 μl TaqMan assay (40*, ABI), 2.5 μl Master mix (ABI) 
and 2.375 μl water. PCR was performed in 384 wells PCR plates in an ABI 9700 PCR system 
(Applied Biosystems Inc., Foster City, CA, USA) and consisted of initial denaturation for 10 
minutes at 95° C, and 40 cycles with denaturation of 15 seconds at 92° C and annealing and 
extension for 60 seconds at 60° C. Results were analyzed by the ABI Taqman 7900HT using the 
sequence detection system 2.22 soft ware (Applied Biosystems Inc., Foster City, CA, USA). 
Statistical analysis
Continuous variables were compared between the short SGA and SGA catch-up subjects using 
univariate analysis of variance (ANOVA), corrected for age and gender by SDS. Th e Chi-square 
test was used to analyze categorical variables. 
 Th e Hardy-Weinberg equilibrium (HWE) was calculated by computing the chi-square 
test for deviations in HWE. Diff erences in allele frequencies were tested by a chi-square test. 
Subjects were grouped according to their genotypes. Haplotype 3 was grouped as carriers vs. 
non-carriers of haplotype 3, due to low frequency. Th e genotypic and haplotype groups were 
compared for all anthropometric parameters by univariate analysis of variance (ANOVA). 
P-values ≤ 0.05 were considered signifi cant. All statistical tests were performed using SPSS 15.0 
(SPSS Inc., Chicago, IL, USA).
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Results
Clinical data
SGA subjects had a mean birth length of -3.00 SDS and birth weight of -2.34 SDS (Total SGA 
group, Table 1). Both length and weight at birth and at examination were signifi cantly below the 
population mean of 0 SDS (all P-values < 0.001, Table 1). Short SGA subjects were born with a 
shorter birth length SDS and were younger at examination. Th ey were also shorter, lighter and 
had less catch-up growth in height and weight compared to SGA catch-up subjects. 
Table 1. Clinical data of the total SGA group and the short SGA and SGA catch-up subgroups.
Total SGA group SGA subgroups
Short SGA SGA catch-up P-value*
Sex (boys/girls) 302/333 223/216 79/117 0.01
Birth:
Gestational age (wks) 36.7 (3.1) 36.6 (3.8) 37.1 (3.0) 0.10
Length (SDS) -3.00 (1.48) a -3.14 (1.49) -2.70 (1.41) <0.001
Weight (SDS) -2.34 (1.01) a -2.28 (1.09) -2.47 (0.81) 0.03
At examination:
Age (yrs) 12.7 (7.2) 8.9 (5.1) 21.1 (2.6) <0.001
Height (SDS) -2.24 (1.27) a -2.95 (0.63) -0.64 (0.84) <0.001
Change in height (SDS) 0.81 (1.81) a 0.20 (1.60) 2.04 (1.57) <0.001
Weight (SDS) -2.01 (1.67) a -2.79 (1.16) -0.25 (1.24) <0.001
Change in weight (SDS) 0.33 (1.88) a -0.51 (0.37) 2.22 (1.46) <0.001
BMI (SDS) -1.29 (1.01) a -1.13 (1.16) 0.15 (1.31) <0.001
Values are means (standard deviation) unless indicated otherwise. *= Th e overall P-value is presented by ANOVA for continuous 
variables and by chi-square test for categorical variables. Th e total SGA group SDS is compared to 0 SDS by T-test: a P-value <0.001. 
SDS= standard deviation score. 
Linkage disequilibrium and haplotypes 
Th ere was high LD between the rs4965425 and rs1319868 SNPs (D’ = 1.00, R2 =  0.14, Figure 1), 
both located in the promoter region. We inferred haplotypes of the rs4965425 and rs1319868 
SNPs using PHASE 2.1 (Figure 1, Table 3) [25,26]. Haplotypes 1-3 occurred in > 10% of the 
population. 
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Figure 1. IGF1R gene structure. A. Th e IGF1R gene structure is presented with the currently investigated 
rs4965425 (C/T) and rs1319868 (G/T) IGF1R SNPs and their allele frequencies in the currently investigated 
SGA population. Also previously performed association studies are shown with the location of the 
investigated polymorphisms. B. Haplotypes of the rs4965425 (C/T) and rs1319868 (G/T) IGF1R SNPs are 
presented and their frequencies in the currently investigated SGA population of 635 subjects is shown. C. 
Linkage disequilibrium (D’ and R2) between the rs4965425 (C/T) and rs1319868 (G/T) IGF1R SNPs is 
shown.
IGF1R SNPs: allele frequencies
Th e SGA subjects had a higher rs4965425 and rs1319868 minor allele frequency than 
healthy controls, the latter being signifi cantly diff erent (rs4965425: 47.0% vs. 39.9%, P = 0.08 
and rs1319868: 11.1% vs. 6.1%, P = 0.02). Th e minor allele frequency of the rs4965425 and 
rs1319868 SNPs were not signifi cantly diff erent between the short SGA and SGA catch-up 
population (rs4965425: 48.6% and 43.4%, P = 0.09; rs1319868: 11.8% and 9.7%, P = 0.27). Th e 
total SGA population was in Hardy-Weinberg equilibrium for the rs4965425 and rs1319868 
SNPs (P = 0.71 and P = 0.14, respectively). 
IGF1R SNPs: associations with postnatal growth
Th e rs4965425 C-allele was not associated with postnatal growth in the total SGA and SGA 
catch-up population. However, in short SGA subjects, this SNP was associated with a 0.3 SDS 
lower postnatal weight, 0.3 SDS lower BMI and 0.4 SDS catch-down in weight from birth 
onwards compared to the T-allele (Table 2). Th ere was no association between the rs4965425 
SNP and birth length, birth weight, postnatal height and the change in height in short SGA 
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subjects. In addition, we exploratively analyzed in a small subpopulation of short SGA subjects 
of 18 years of age and older (n = 42), whether their rs4965425 genotype was related to their 
systolic blood pressure SDS. Although not statistically signifi cant, [CC] carriers tended to have 
a lower systolic blood pressure SDS than the other genotypes (mean (SD): 0.73 (1.00) vs. 1.27 
(1.09), respectively, P = 0.14). 
 Th e rs1319868 SNP was not associated with postnatal growth in the total SGA 
population, and with the short SGA and SGA catch-up subjects (data not shown). 
IGF1R haplotypes: associations with postnatal growth 
Short SGA subjects with Haplotype 1 (-C-G-, Figure 1B) had a 0.4 SDS lower postnatal weight, 
0.4 SDS lower BMI and 0.4 SDS catch-down in weight (Table 3) compared to non-carriers 
of Haplotype 1. Haplotype 2 carriers (-T-G-) also displayed comparable associations with 
weight, BMI and change in weight, however in an opposite direction. Th e change in weight 
was borderline signifi cant (P = 0.08). SGA catch-up subjects did not show any association 
between postnatal growth and the investigated haplotypes (data not shown). Haplotype 3 was 
not associated with the postnatal growth of both the short SGA and SGA catch-up group. 
 As Haplotype 1 contained the rs4965425 SNP C-allele, which was the only allele that 
was not present in Haplotype 2 and 3, it might be concluded that the C-allele of the rs4965425 
SNP was driving the association with postnatal weight, BMI and catch-up growth in weight of 
short SGA subjects. 
IGF1R haplotypes: associations in short SGAL and SGAL+W subpopulations
To further delineate the association between Haplotype 1 and the change in weight gain in the 
short SGA group, we exploratively investigated the association in the short SGAL and short 
SGAL+W subgroups. Whereas, short SGAL subjects did not show any association with Haplotype 
1, short SGAL+W subjects with Haplotype 1 had a 0.8 SDS lower postnatal weight, 0.8 SDS lower 
BMI and 0.7 SDS catch-down in weight from birth onwards (Table 4). When the SGA catch-up 
group was stratifi ed according to SGAL and SGAL+W subgroups, no associations were found.
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Discussion
Our study shows that short SGA subjects with the rs4965425 C-allele have a lower weight 
and BMI due to postnatal catch-down in weight compared to non-carriers. Th is was most 
pronounced in those who were born with both a birth weight and birth length <-2.00 SDS. Our 
fi ndings suggest that genetic variations in the IGF1R gene promoter play a role in postnatal 
catch-down in weight development of short SGA subjects. Th e minor allel frequency of the 
rs1319868 SNP was signifi cantly higher in the total SGA population compared to controls. 
Th e minor allele frequency of the rs4965425 SNP showed the same tendency, although not 
signifi cantly diff erent. 
 Th is study has shown for the fi rst time that the IGF1R rs4965425 promoter SNP might 
have a role in modifying postnatal weight, thereby infl uencing the risk for cardiovascular 
disease. It might well be that short SGA subjects carrying the rs4965425 C-allele and having 
both a low birth weight and –length, experience a long-term advantage by having a catch-down 
in weight. Although the majority of short SGA subjects experience varying degrees of postnatal 
catch-up growth, this study shows that a genetic variation in the IGF1R promoter contributes 
to postnatal catch-down in weight by which short SGA subjects remain lean. Leanness of short 
SGA subjects is oft en interpreted as a result of minimal appetite. Th is study has shown that 
genetic factors, like the investigated IGF1R promoter polymorphism, play a role in weight 
development of short SGA children. By our knowledge, it is unknown whether IGF1R promoter 
polymorphisms and appetite are related, although relationships have been reported between 
the IGF1R and food intake in animal models [28,29]. 
 Th e association between the rs4965425 C-allele and postnatal catch-down in weight 
of short SGA subjects was most pronounced in the most severe SGA subjects, having a birth 
length and weight ≤ -2.00 SDS instead of the subjects having only a birth length ≤ -2.00 SDS. 
It might well be that rs4965425 polymorphism has also contributed to the severity of the SGA 
condition due to reduced prenatal IGF1R expression which reduces prenatal growth. Th is was 
also found in IGF1R knockout mice [10,11].
 Th e IGF1R promoter contains a large linkage disequilibrium block ranging from 
rs4965425 until 2 kb before start of exon 1 (Web resources: Hapmap). It might well be that the 
tagging promoter SNPs which we investigated in this study, are markers for variations in IGF1R 
expression due to changes in the transcription factor binding sites in this region. Th e IGF1R 
promoter has been extensively studied with regard to the regulation of IGF1R gene expression 
[30]. Several studies have shown that transcription factors in the IGF1R promoter induce an 
increased IGF1R expression which would result in increased IGF1R protein levels [31,32-37].
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Th e signifi cantly higher minor allele frequency of the rs1319868 SNP in the SGA population 
might indicate a relation between the allelic status of the SNP and the SGA phenotype. However, 
further studies are needed to clarify an eff ect of the SNP on protein expression. 
 We were not able to perform functional studies of the rs4965425 SNP on IGF1R expression 
levels. However, preliminary searches in a transcription factor database (Web Resources: TESS) 
revealed an induction of a glucocorticoid receptor (GR) binding place in case of an rs4965425 
T-allele. In case of the rs4965425 C-allele, the binding site for GR was not present the IGF1R 
promoter sequence. Glucocorticoid receptors are well-known transcription regulators [38,39] 
which dose-dependently infl uence target genes. Th us, it might well be that that the GR acts as 
a growth enhancer in case of an rs4965425 T-allele. Our fi ndings merit further investigations, 
including functional studies. 
 A limitation of this study is the absence of a control group born appropriate for 
gestational age (AGA) with a detailed growth parameters. However, we do not expect that these 
IGF1R polymorphisms associate with postnatal growth in the normal population, due to the 
specifi c relation of the IGF1R gene, as shown by knock-out mice, with a reduced prenatal growth 
[10]. To determine the universality of this fi nding, it is necessary to replicate this study in an 
independent short SGA cohort with detailed birth and postnatal anthropometric measurements 
available. 
 In conclusion, short SGA subjects with the rs4965425 C-allele have a lower weight 
and BMI due to postnatal catch-down in weight compared to non-carriers. Th is was most 
pronounced in those who were born with both a birth weight and birth length <-2.00 SDS. 
Our fi ndings suggest that genetic variations in the IGF1R gene promoter contribute to weight 
development of short SGA subjects. Studies are warranted to identify the risk for cardiovascular 
disease in short SGA rs4965425 T-allele carriers.
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Abstract
Context: Th e INS gene region is an important region with regard to fetal growth, coronary 
heart disease and hypertension. It is unknown whether polymorphisms in the INS gene are 
related to blood pressure in subjects born SGA.
Objective: To determine whether haplotypes of three polymorphisms in the insulin gene region, 
rs7924316, rs3842748 and the INS VNTR, associate with blood pressure in a large cohort of 
SGA subjects.
Patients: 635 SGA subjects (439 short SGA and 196 SGA catch-up subjects). 
Results: We analyzed SNPs and haplotypes in short SGA and SGA catch-up subjects. Th e tagging 
SNP was investigated in the total SGA population aft er correction for potential confounders and 
according to weight gain stratifi cation. All polymorphisms were in high linkage disequilibrium 
(D’ = 96-100, R2 = 32-68). SGA catch-up subjects had a signifi cantly higher rs7924316 T-allele 
(P = 0.007) and rs689 T-allele (P = 0.03) frequency than short SGA subjects. Th e association 
between the rs7924316 and the INS VNTR and systolic blood pressure was most pronounced 
in SGA catch-up subjects (P = 0.003 and P = 0.007). Th ese associations were not seen in short 
SGA subjects. SGA catch-up subjects with Haplotype 1, consisting of the rs7924316 G-allele, 
rs3842748 G-allele and the class I INS VNTR, had a 0.6 SDS higher systolic and 0.5 SDS higher 
diastolic blood pressure. Th e rs7924316 G-allele drove these associations. Rs7924316 and the 
INS VNTR were associated with systolic blood pressure in the total SGA population (P = 0.05 
and P = 0.007) and remained signifi cant aft er correction for change in weight and age. Th e 
association of blood pressure with rs7924316 and the INS VNTR was most pronounced in 
subjects with postnatal weight gain (> 0.67 SDS: P = 0.006 and P = 0.01).
Conclusions: Subjects born SGA have a higher blood pressure when carrying the INS rs7924316 
G-allele and class I INS VNTR. Our fi ndings suggest that genetic variation in the INS gene may 
identify a higher risk for development of hypertension especially aft er postnatal weight gain.
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Introduction 
Around 2% of all life-born neonates are born small for gestational age (SGA) and 90% of them 
will attain a height in the normal range in early postnatal life (SGA catch-up) [1,2]. SGA catch-
up subjects have an increased prevalence of cardiovascular disease compared to SGA subjects 
who do not show an accelerated postnatal growth [3-5].
 Th e insulin (INS) gene (Figure 1) is considered to be a major candidate gene for the SGA 
phenotype as insulin is involved in fetal and early postnatal growth [6-9]. 
Figure 1. Genetic variation in the insulin gene region (11p15.5). A. INS gene structure with SNPs: 
rs7924316, rs3842748 and rs689, which were studied in the total SGA group. Th e allele frequencies are 
presented below the SNP rs number. B. Haplotypes were constructed of the rs7924316, rs3842748 and 
rs689 SNPs and their frequency is presented in the total SGA group. C. Linkage disequilibrium (D’) is 
shown for SNPs rs7924316, rs3842748 and rs689.
Th e most widely studied polymorphism in the INS gene, is a variable number of tandem repeats 
(VNTR, OMIM *147510) which is located 600bp upstream of the INS transcription start site 
and comprises 14-25bp tandemly repeated sequence units. In Caucasian populations there are 
two main classes; short so-called “class I alleles” (26-63 repeat units) and long, so-called “class 
III” alleles (141-209 repeat units) [10,11]. 
 Th e INS gene region has been recognized as an important region in relation to disease 
in later life. Th e insulin minisatellite (INS VNTR, rs689) class III, has been associated with 
variations in birth size [7,12,13], obesity [8,14-17], type I and type II diabetes mellitus [6] and 
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polycystic ovary syndrome [9]. However, other studies could not demonstrate that the INS 
VNTR was associated with accelerated weight gain, reduced beta cell function or adiposity [18-
21]. 
 Th e objective of this study was to determine whether genetic variation across the insulin 
gene region was associated with blood pressure in a large group of short SGA and SGA catch-
up subjects. To determine the universality of the genetic associations we analyzed SNPs and 
haplotypes in short SGA and SGA catch-up subjects. Th e tagging SNP was investigated in the 
total SGA population aft er correction for potential confounders and according to weight gain 
stratifi cation as reported in previous studies [13,22]. In this study, three polymorphisms in the 
insulin gene region were studied, rs7924316, rs3842748 and the insulin VNTR (rs689). 
Methods 
Subjects
We included 635 SGA subjects and divided these in two groups of 439 short SGA and 196 SGA 
catch-up subjects according to their ability to attain a postnatal height in the normal range. SGA 
was defi ned as a birth length and/or weight ≤ -2 standard deviation score (SDS) for gestational 
age [23]. Th e SGA subjects who remained short aft er age 3 (height ≤ -2.00 SDS: short SGA, [24]) 
participated in prospective Dutch cohort trials evaluating the eff ect of growth hormone (GH) 
treatment [25-27]. SGA subjects who had catch-up growth to a normal height (height > -2.00 
SDS: SGA catch-up [24]) were randomly selected from hospitals in the Netherlands, were they 
had been registered because of being born SGA.
 All subjects were of Caucasian ethnicity and had an uncomplicated postnatal 
period. Subjects with severe chronic illness or endocrine disorders, chromosomal or genetic 
abnormalities, positive endomysial or transglutaminase antibodies, skeletal abnormalities and 
psychosocial dwarfi sm were excluded from the study. Th e study protocol was approved by 
the Medical Ethics Committee and written informed consent was obtained from the parents/
guardians and subjects aged 12 years and older. A healthy control population of 100 subjects 
was acquired from a local bloodbank.
 
Clinical and biochemical measurements
Birth data of the SGA subjects were retrieved from records of hospitals, community health 
services and general practitioners. Postnatal measurements of the short SGA subjects were 
retrieved from the baseline visit of the GH trials. Postnatal height, weight and blood pressure of 
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the SGA catch-up group were obtained at the outpatient clinic. All anthropometric measurements 
were performed twice and the mean value was used for analysis. Blood pressure was measured 
three times at the same visit by an automatic blood pressure monitor (Omron Healthcare, Inc.) 
and the mean was used for analysis. Body mass index was calculated (weight in kg/ height in 
meters2) and expressed as standard deviation score (SDS), adjusting for age and sex, [24]. Blood 
pressure of the SGA subjects was expressed as SDS by adjusting for sex and height [28]. 
Selection of SNPs and Linkage Disequilibrium
 Th ree SNPs across the INS gene region capturing most of the common genetic variation, 
were identifi ed by using the SNP selection tool “tagger” in the HapMap database (Web resources) 
[29]. Th e rs7924316 (G to T), rs3842748 (G to C) and rs689 (A to T) SNPs were identifi ed as 
tagging SNPs for the linkage disequilibrium block surrounding the INS gene. Th e rs689 SNP 
was previously identifi ed as a marker for the INS VNTR polymorphism, as the A-allele tagged 
the class I VNTR alleles and the T-allele tagged the class III VNTR alleles [19].
 Th e pairwise linkage disequilibrium (LD) coeffi  cients (D’ and R2) were calculated with 
the use of Haploview soft ware (Web resources). Gene polymorphisms which were in high LD 
(D’ > 0.90) were used for haplotype construction. We inferred haplotypes of the rs7924316, 
rs3842748 and rs689 SNPs using PHASE 2.1 [30,31]. 
Genotyping
Genomic DNA was extracted from samples of peripheral venous blood according to salting out 
procedure [32]. Genotypes were determined using the Taqman allelic discrimination assay. Th e 
Assay-by-Design service (www.appliedbio-systems.com) was used to set up a Taqman allelic 
discrimination assay for the rs7924316, rs3842748 and rs689 SNPs, the latter tagging the INS 
VNTR. Th e rs689 A-allele tagging the class I VNTR allele and the rs689 T-allele tagging the 
class III VNTR allele [19]. 
 Primer sequences were for the rs7924316 SNP: forward GCACCGCCAGTAAA-
TCCATATTG and reverse CCTCTTCTCTAATTCCCAAGGTTT. 
 Primer sequences were for the rs3842748 SNP: forward GGAAGGAGGTGGGACATGTG 
and reverse GGCTGGACCCAGGTTAGAG. Probe sequences for the rs7924316 SNP were: 
forward CATGACCGGAGCTAC and reverse CCATGACCGTAGCTAC. Probe sequences for 
the rs3842748 SNP were: forward CCCACAGTGGGTGTG and reverse CCCACACTGGG-
TGTG. 
 Th e probe sequence of the rs689 SNP was: CATGGCAGAAGGACAGTGATCTGGG 
[A/T] GACAGGCAGGGCTGAGGCAGGCTGA. Th e PCR reaction mixture included 5ng of 
genomic DNA, 0.125 μl TaqMan assay (40*, ABI), 2.5 μl Master mix (ABI) and 2.375 μl water. 
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PCR was performed in 384 wells PCR plates in an ABI 9700 PCR system (Applied Biosystems 
Inc., Foster City, CA, USA) and consisted of initial denaturation for 10 minutes at 95° C, and 40 
cycles with denaturation of 15 seconds at 92° C and annealing and extension for 60 seconds at 
60° C. Results were analyzed by the ABI Taqman 7900HT using the sequence detection system 
2.22 soft ware (Applied Biosystems Inc., Foster City, CA, USA). 
Statistical analysis
Continuous variables were compared between the short SGA and SGA catch-up subjects by 
univariate analysis of variance (ANOVA). Th e Chi-square test was used to analyze categorical 
variables. 
 Th e rs7924316, rs3842748 and rs689 SNPs were determined in the total SGA group 
of 635 SGA subjects. Th e Hardy-Weinberg equilibrium (HWE) was calculated by computing 
the chi-square test for deviations in HWE. Allele frequencies were calculated and tested by 
chi-square. All genotypes for individual SNPs and genotypes for haplotypes were grouped 
according to a co-dominant model. Th e genotypic and haplotype groups were compared for 
all anthropometric parameters by univariate analysis of variance (ANOVA). Post-hoc pairwise 
tests employed a Bonferroni correction for multiple comparisons. Change in weight SDS was 
stratifi ed in three groups: (1) a decrease in weight SDS by > 0.67 SDS indicated “catch-down” in 
weight, (2) a clinically unchanged weight SDS ranging from -0.67 SDS until 0.67 SDS, (3) a gain 
in weight of > 0.67 SDS indicating clinically signifi cant “catch-up” in weight [7].
 Multiple linear regression analysis was used to investigate the contribution of the 
genotype on blood pressure (SDS) and to investigate potential confounders. P-values ≤ 0.05 
were considered signifi cant. All statistical tests were performed using SPSS 11.0 (SPSS Inc., 
Chicago, IL, USA).
Results
Clinical data
SGA subjects had a mean birth length of -3.00 SDS and birth weight of -2.34 SDS (Total SGA 
group, Table 1). Th ey had a signifi cantly higher systolic and diastolic blood pressure than the 
average population (P < 0.001). 
 SGA catch-up subjects were born with a higher birth length SDS (Table 1). SGA catch-
up subjects were older at examination and they were, by defi nition, taller and had more catch-
up growth in height from birth onwards (height SDS – birth length SDS). Whereas systolic 
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blood pressure tended to be higher in short SGA subjects, SGA catch-up subjects had a higher 
diastolic blood pressure SDS. 
Table 1. Clinical data of the total SGA group and the short SGA and SGA catch-up subgroups. 
Total SGA group SGA subgroups
Short SGA SGA catch-up P-valueb
635 439 196
At birth:
Sex (boys/girls) 302/333 223/216 79/117 0.01
Gestational age (weeks) 36.7 (3.1) 36.6 (3.8) 37.1 (3.0) 0.10
Length (SDS) -3.00 (1.48)a -3.14 (1.49) -2.70 (1.41) <0.001
Weight (SDS) -2.34 (1.01)a -2.28 (1.09) -2.47 (0.81) 0.03
At follow-up:
Age (years) 12.7 (7.2) 8.9 (5.1) 21.1 (2.6) <0.001
Height (SDS) -2.24 (1.27)a -2.95 (0.63) -0.64 (0.84) <0.001
Height (SDS) – birth length (SDS) 0.81 (1.81) 0.20 (1.60) 2.04 (1.57) <0.001
BMI (SDS) -1.29 (1.01)a -1.13 (1.16) 0.15 (1.31) <0.001
Weight (SDS) – birth weight (SDS) 0.33 (1.88) -0.51 (0.37) 2.22 (1.46) <0.001
Systolic BP (SDS) 0.92 (1.05)a 0.98 (1.08) 0.80 (0.97) 0.06
Diastolic BP (SDS) 0.66 (0.98)a 0.44 (0.99) 1.15 (0.77) <0.001
Values are means (standard deviation) unless indicated otherwise. a P-value < 0.001when the SDS of the total SGA group was 
compared with 0 SDS. b Th e overall P-value for the diff erence between short SGA and SGA catch-up subjects is presented by ANOVA 
for continuous and by chi-square test for categorical variables. SDS= standard deviation score, BP= blood pressure. 
Linkage disequilibrium and haplotypes 
Th ere was high LD between the rs7924316, rs3842748 and rs689 SNPs (D = 96-100, R2 = 32-
68, Figure 1), both located in the promoter region. We inferred haplotypes of the rs7924316, 
rs3842748 and rs689 SNPs (Figure 1, Table 3). Haplotypes 1-3 occurred in >10% of the 
population. 
Allele frequencies
Th e total SGA group was in Hardy-Weinberg equilibrium for the rs7924316, rs3842748 and 
rs689 SNPs (P = 0.74, P = 0.34, P = 0.65). Th e total SGA group had an rs7924316 T-allele, 
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rs3842748 C-allele and rs689 T-allele frequency of 46.7%, 22.7% and 30.5%, respectively (Figure 
1). Controls showed an rs7924316 T-allele, rs3842748 C-allele and rs689 T-allele frequency of 
31.3 %, 32.4 % and 32.2%, respectively. Short SGA subjects had an rs7924316 T-allele, rs3842748 
C-allele and rs689 T-allele frequency of 45.0%, 21.5% and 28.4%, respectively. SGA catch-up 
subjects had an rs7924316 T-allele, rs3842748 C-allele and rs689 T-allele frequency of 50.5%, 
25.7% and 34.6%, respectively. 
 Th e allelefrequencies of the rs7924316, rs3842748 and rs689 SNPs, were not statistical 
diff erent between the total SGA population and the controls. When the allelefrequencies of the 
three SNPs were compared between short SGA vs. SGA catch-up subjects, the SGA catch-up 
subjects had a signifi cantly higher rs7924316 T-allele (P = 0.007) and rs689 T-allele (P = 0.03) 
frequency than short SGA subjects. 
Short SGA vs. SGA catch-up: polymorphisms and blood pressure 
When short SGA and SGA catch-up subjects were compared, SGA catch-up subjects with the 
rs7924316 [GG] genotype had a 0.6 SDS higher systolic and 0.3 SDS higher diastolic blood 
pressure than the [TG] genotype (P = 0.003, P = 0.04, Table 2). However, no associations were 
seen in short SGA subjects. Similarly, SGA catch-up subjects with the rs689 [AA] genotype 
had a 0.5 SDS higher systolic and 0.3 SDS higher diastolic blood pressure (P = 0.007, P = 0.01), 
whilst no relation was found in short SGA subjects. Short SGA and SGA catch-up subjects did 
not show associations between these SNPs and weight or BMI SDS at follow-up. 
Short SGA vs. SGA catch-up: haplotypes and blood pressure
We inferred haplotypes of the rs7924316, rs3842748 and rs689 SNPs using PHASE 2.1 (Table 
3) [30,31]. Seven haplotypes were identifi ed of which three haplotypes occurred in >10% of 
the population (Figure 1). SGA catch-up subjects who were homozygous Haplotype 1 carriers 
had a 0.6 SDS higher systolic and a 0.5 SDS higher diastolic blood pressure (P = 0.003 and 
P = 0.008, respectively) compared to heterozygous carriers of Haplotype 1. No associations 
were found between Haplotype 2 and 3 and blood pressure in SGA catch-up subjects. Short 
SGA subjects did not show any associations. Th us, Haplotype 1 was signifi cantly associated 
with blood pressure SDS in SGA catch-up subjects, in contrast to Haplotype 2 and 3. As the 
G-allele of the rs7924316 SNP was the only allele that was not present in Haplotype 2 and 3, it 
can be concluded that the G-allele of the rs7924316 SNP was driving the association with blood 
pressure in SGA catch-up subjects.
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Total SGA population: polymorphisms and potential confounders 
Both rs7924316 G-allele and rs689 A-allele carriers had a higher systolic blood pressure SDS 
in the total SGA population ([GG] vs. [TG+TT], 1.06 (1.08) vs. 0.87 (1.05), P=0.05; [AA] vs. 
[AT+TT], 1.05 (1.06) vs. 0.82 (1.04), P= 0.007, representing mean (SD)). Th e rs3842748 SNP 
was not associated with systolic blood pressure in the total SGA population. Also diastolic 
blood pressure was not associated with any of the three SNPs in the total SGA population. 
Th e rs7924316 SNP remained signifi cantly associated with systolic blood pressure SDS aft er 
adjustment for change in weight SDS and age (Table 4). 
 In addition, we investigated whether the association between the rs7924316 SNP and 
the SGA catch-up group was infl uenced by height gain or weight gain since birth. Weight gain 
was signifi cantly related to the rs7924316 SNP but the gain in height was not associated with the 
rs7924316 SNP (P = 0.01 vs. P = 0.60, respectively).
Table 4. Systolic blood pressure and the rs7924316 INS SNP in the total SGA population. 
Systolic BP SDS 
Total SGA population
Model 1 Model 2 Model 3
B P-value B P-value B P-value
rs7924316 a -0.19 0.05 -0.20 0.04 -0.19 0.04
Change in weight (SDS) b - - 0.06 0.01 0.08 0.008
Age at measurement (years) - - - - -0.009 0.26
Overall P-value 0.05 0.006 0.01
R2 corrected 0.5% 1.3% 1.4%
BP= blood pressure, SDS= standard deviation score. a Genotype coding is: 0= [GG], 1= [TG+TT]. b Change is calculated by 
measurement SDS at follow-up minus birth SDS. 
Total SGA population: weight gain stratifi cation 
In a next step, the total SGA population was stratifi ed by their catch-up in weight from birth 
onwards (Table 5). SGA subjects with the highest gain in weight (> 0.67 SDS), had a 0.5 SDS 
and 0.4 SDS higher systolic blood pressure when the [GG] genotype of the rs7924316 SNP and 
the [AA] genotype of the rs689 SNP, were compared to their heterozygous genotypes (P = 0.006 
and P = 0.008).
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Discussion
Our study has shown that SGA subjects have a higher blood pressure when carrying the class I 
INS VNTR and the rs7924316 G-allele. Although rapid postnatal growth is a well-known factor 
associated with a higher blood pressure in later life [3,5], our study shows for the fi rst time that 
there is a polymorphism in the INS gene region which independently infl uences blood pressure 
in SGA subjects.
 In our study we fi rstly analyzed the rs7924316, rs3842748 and the INS VNTR in a group 
of short SGA and SGA catch-up subjects. SGA catch-up subjects had a signifi cantly higher 
rs7924316 T-allele (P = 0.007) and rs689 T-allele (P = 0.03) frequency than short SGA subjects. 
We showed that SGA catch-up subjects carrying the rs7924316 G-allele and the class I INS 
VNTR allele had a signifi cantly higher systolic and diastolic blood pressure. No associations 
were found in short SGA subjects. Th e rs3842748 SNP was not associated with blood pressure 
in any group. 
 Secondly, we performed haplotype analysis of the three SNPs to identify the driving 
genetic variant of the association between SGA catch-up subjects and an increased systolic 
and diastolic blood pressure. Our data showed that the rs7924316 G-allele was driving these 
associations indicating that the rs7924316 SNP in the INS gene region is either functional itself 
or strongly linked with other functional polymorphisms in the LD-block. 
 Because the diff erence between short SGA and SGA catch-up is an arbitrary cut-off  of 
-2.00 SDS in height, we also investigated the rs7924316 SNP and the INS VNTR in the total SGA 
population. In this analysis, we corrected the association between the rs7924316 G-allele and 
systolic blood pressure for possible confounders, as age at examination and postnatal weight 
gain, within the total SGA population. Regression analysis showed that the rs7924316 remained 
signifi cantly associated with systolic blood pressure of SGA subjects aft er correction for these 
confounders, indicating that the rs7924316 SNP is an independent genetic factor enhancing 
blood pressure in SGA subjects. 
 In addition, we analyzed whether the extent of weight gain was infl uencing the 
association between systolic blood pressure and the rs7924316 G-allele in SGA catch-up subjects 
by weight gain stratifi cation. We used cut-off s of 0.67 SDS which were based on “centile bands” 
on standard growth charts, indicating signifi cant “catch-up” or “catch-down” growth from birth 
onwards [7]. Th is analysis showed that marked postnatal weight gain was an enhancing factor 
for the association between systolic blood pressure and the rs7924316 G-allele in SGA catch-up 
subjects. As both, growth in height and weight accumulation concern diff erent physiological 
mechanisms in SGA subjects, we added both stratifi cations to the analysis. 
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Our results are in line with previous studies showing that children with a postnatal catch-up in 
weight (> 0.67 SDS), also had a higher BMI at age 7 when having the INS class I-allele vs. the class 
III/III genotype [13]. In addition, it was previously shown that the INS VNTR was associated 
with head and birth size implying a perinatal survival genotype [7]. However, also contrasting 
results have been reported on associations between the INS VNTR and early postnatal growth 
and the metabolic syndrome [18,19,22,33,34].
 Our haplotype study showed that class I of the INS VNTR and especially the rs7924316 
G-allele was the determining SNP in the haplotype association with blood pressure in SGA 
catch-up subjects. Other studies have also demonstrated that haplotypes capturing the INS gene 
region were associated with insulin production, and would predispose to an elevated blood 
pressure, fat mass or triglyceride level [16]. 
 Our study demonstrated that the heterozygote class I/III INS and especially rs7924316 
[TG] carriers had the lowest systolic and diastolic blood pressure in SGA catch-up subjects. 
Th ese results indicate that the combination of a T- and G-allele in case of the rs7924316 SNP, 
gives rise to the most protective eff ect on blood pressure. Th e phenomenon that the heterozygous 
state is associated with a certain phenotype which is diff erent from the two homozygous states, 
has been previously reported [35-37]. Heterozygous advantage or disadvantage of SNPs in 
regulatory regions, as the INS gene region [38], may be the result of allele-dependent regulation 
of gene expression. Th e central process in allele-dependent regulation of gene expression is trans-
regulation, which means that an enhancer from one allele acts in trans to activate transcription 
from the regulatory region of the second allele [39,40]. Transcription factors can bind two 
DNA molecules simultaneously, functioning as a protein bridge and mediating communication 
between two homologues [41]. Trans regulation might explain advantages or disadvantages of 
heterozygosity as found in several studies [42,43] and in the rs7924316 and the rs689 SNPs in 
our study. 
 Functional studies have shown that shorter class I alleles of the INS gene are associated 
with higher INS gene expression in the pancreas and higher IGF2 gene expression in the 
placenta [38,44-48]. Our results might be in line with these observations as an increased insulin 
production will be particularly associated with accelerated postnatal growth and particularly 
weight gain, giving a predisposition to cardiovascular disease. However, these functional studies 
did not investigate the infl uence of the rs7924316 G-allele in SGA catch-up subjects. Th us, our 
data merit further studies to investigate how the rs7924316 G-allele infl uences the INS VNTR 
and thereby INS and IGF2 gene expression in SGA subjects.
 In conclusion, our study has shown that the rs7924316 SNP is a contributing factor in 
blood pressure regulation of subjects born SGA, particularly in those with postnatal weight 
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gain. Th is study shows for the fi rst time that there is a polymorphism in the INS gene region 
which independently infl uences blood pressure in SGA subjects. 
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Abstract
Context: Small for gestational age (SGA) born children comprise a heterogeneous group in 
which only few genetic causes have been identifi ed.
Objective: To determine copy number variations in 18 growth-related genes in 100 SGA 
children with persistent short stature. 
Methods: Copy number variations in 18 growth-related genes (SHOX, GH1, GHR, IGF1, 
IGF1R, IGF2, IGFBP1-6, NSD1, GRB10, STAT5B, ALS, SOCS2, and SOCS3) were determined 
by an “in house” multiplex ligation-dependent probe amplifi cation (MLPA) kit. Th e deletions 
were further characterized by SNP array analysis.
Results: We found two short SGA children with a de novo IGF1R deletion. No deletions or 
insertions were found in the remaining genes. Patient A had a heterozygous deletion of the 
complete IGF1R gene (15q26.3, exon 1-21) including distally fl anking sequences. Surprisingly, 
she also had a low IGF-I level (-2.78 SDS), probably because of a co-existing growth hormone 
(GH) defi ciency. In the DNA of patient B, heterozygosity for a deletion comprising exon 3-21 of 
the IGF1R gene was detected which extended further into the telomeric region. Both children 
increased their height during GH treatment, with a GH dose of 1 mg/m2/day (Patient A: aft er 
4 yrs GH: delta height +1.65 SD; Patient B: aft er 4 yrs GH: delta height +1.69 SD) and continue 
to receive GH until their adult height will be attained. 
Conclusions: We demonstrate that IGF1R haploinsuffi  ciency was present in 2 out of 100 short 
SGA children. GH therapy gave moderate catch-up growth in our patients. A review of the 
literature shows that small birth size, short stature, small head size, relatively high IGF-I levels, 
developmental delay and micrognathia are the main predictors for an IGF1R deletion. 
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Introduction
Children born with a low birth weight and/or birth length corrected for gestational age (small 
for gestational age, SGA) comprise a heterogeneous group with a broad spectrum of clinical 
characteristics. Reduced size at birth may result from fetal, maternal, placental and/or genetic 
factors. While many children born SGA achieve suffi  cient growth to normalize their stature by 
2 years of age, approximately 15% maintain a height below -2 standard deviation scores (SDS) 
and continue to be short throughout adolescence and adulthood [1]. Short SGA children have 
a reduced lean body mass, fat mass, skinfolds and body mass index [2-4], as well as a lower 
caloric, fat and carbohydrate intake [5]. SGA children with a persistent short stature and/or 
a small head size have a higher risk of subnormal intellectual and psychological performance 
[6-9]. 
 Genetic causes have only been found in a small proportion of short SGA children, 
including point-mutations and deletions in the IGF1 [10-12] and IGF1R genes [13-26]. Th e 
availability of the complete sequence of the human genome and the introduction of high 
throughput DNA scanning techniques provides us with novel tools to investigate the genetic 
basis of short stature. In this study we used MLPA to rapidly investigate whether copy number 
variations in growth-related genes (SHOX, GH1, GHR, IGF1, IGF1R, IGF2, IGFBP1-6, NSD1, 
GRB10, STAT5B, ALS, SOCS2, SOCS3) were present in a group of 100 children born SGA with 
persistent short stature. Th e extent of the two deletions that were found was determined with 
SNP array analysis.
Methods
Study population
Th e fi rst hundred short SGA children participating in four prospective cohort trials evaluating 
the eff ect of GH treatment [3,27] were included in the study. Small for gestational age was 
defi ned as a birth length and/or weight ≤ -2 standard deviation score (SDS) for their gestational 
age [28] and only children were included who remained short in postnatal life (at age 3: height 
≤ -2.00 SDS: short SGA [29]). All children were Caucasian and had an uncomplicated postnatal 
period. Severe chronic illness or endocrine disorders, chromosomal or genetic abnormalities, 
positive endomysial or transglutaminase antibodies, skeletal abnormalities and psychosocial 
dwarfi sm were reasons to exclude children from the study. Th e study protocol was approved by 
the Medical Ethics Committee of the ErasmusMC (Rotterdam) and written informed consent 
was obtained. 
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Clinical and biochemical measurements
Birth and growth data before start of GH treatment were retrieved from records of hospitals, 
community health services and general practitioners. Children were systematically measured at 
the start and during the GH trials [3,27]. Height and head circumference were expressed as SDS 
[29]. Body mass index was calculated (weight in kg/ height in meters2) and adjusted for age and 
sex, expressed as SDS [30]. Body proportion was assessed by the sitting height/height ratio and 
expressed in SDS [31]. GH production was assessed by arginine and clonidine GH provocation 
tests and GH was measured by AutoDelphia [Perkin Elmer) and standardized according to 
WHO 80/505 guidelines. Serum IGF-I and IGFBP-3 levels were measured in the SGA subjects 
as described previously [32,33] and values were transformed to SDS by adjusting for sex and 
age [33]. Bone age was determined according to Greulich and Pyle [34]. Dysmorphological 
examination was performed by an experienced clinical geneticist (LCPG).
Genetic analysis
Genomic DNA was extracted from peripheral blood samples [35]. DNA from control samples 
was isolated from leucocytes using Puregene™ nucleic acid purifi cation chemistries for the 
Autopure LS Instrument (Gentra Systems, Minneapolis, USA). 
 Th e “in house” probe kit was designed according to the criteria described in White et 
al [36]. Th e kit contained 34 probes (supplementary data) in 18 diff erent growth-related genes 
(SHOX, GH1, GHR, IGF1, IGF1R, IGF2, IGFBP1-6, NSD1, GRB10, STAT5B, ALS, SOCS2, 
SOCS3). Reactions were performed as described by Walenkamp et al [25]. MLPA of all 21 IGF1R 
exons was performed using the MRC Holland P217 MLPA kit according to the manufacturer’s 
instructions (MRC Holland, Amsterdam, Th e Netherlands). 
 All MLPA kits that were used were validated with DNA from patients that have been 
diagnosed with a deletion in that particular gene with other molecular techniques. As a 
positive control a patient that was previously published [25] was used and a number of normal 
individuals, including their parents, and a blank (no DNA) were used as negative controls. 
 Th e Aff ymetrix GeneChip Human Mapping 262K NspI array was used according to the 
instruction provided in the Aff ymetrix GeneChip Human Mapping 500K Manual (http://www.
aff ymetrix.com). SNP copy number was assessed using CNAG (Copy Number Analyser for 
GeneChip®) Version 2.0 [37].
 IGF1 gene sequencing of all four exons and fl anking intron-exon boundaries was 
performed according to standard procedures (primers and conditions available upon request).
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Results
All 100 short SGA children were investigated with the “in house” MLPA growth-kit and two 
patients were identifi ed with a deletion of the IGF1R gene. No copy number variants (CNV’s) in 
the other growth related genes were detected.
Patient A
Clinical description
Patient A was a girl who was born spontaneously aft er 40 weeks of gestation as the third 
child of non-consanguineous parents. As maternal age was 36 years, her mother chose for 
amniocentesis showing a 46 XX karyotype. Th e pregnancy was complicated by vaginal bleeding 
and limited fetal movements. Her birth weight was 2890 g (-1.28 SDS), and birth length 47 
cm (-2.21 SDS). Th e height of her father was 184.7 cm (0.40 SDS) and of her mother 176.6 cm 
(1.34 SDS) resulting in a (secular-trend corrected) target height of 178.8 cm (1.25 SDS). She 
had bilateral hip dysplasia and clubfeet for which she had hip casting from 4 to 12 months of 
age. Her bilateral hearing loss improved by tympanostomy tubes, which were implanted at 3 
years of age. Psychomotor development was delayed. At 2.3 years of age, her height was 78.9 
cm (-3.46 SDS), weight 10.3 kg (-2.13 SDS weight for height) and head circumference 47.2 cm 
(-0.82 SDS). Arginine and clonidine stimulation tests were performed at age 2 with a maximal 
GH response of 19.1 mU/L and 14.1 mU/L, respectively. She had a delayed dentition, starting 
at age 2. At age 3 her bone age was 2 years. Her IGF-I level was 46 ng/ml (-1.61 SDS) and 
IGFBP-3 level 1.17 mg/L (-1.63 SDS). Cardiovascular, respiratory and abdominal examinations 
were all normal. On magnetic resonance imaging of the hypothalamic and pituitary region no 
abnormalities were seen. 
 From age 4 onwards, GH treatment was initiated at a dose of 1 mg/m2/day (Figure 1). At 
start of GH treatment, her height was 90.6 cm (-3.42 SDS), BMI 14.3 kg/m2 (-1.02 SDS), sitting 
height/height ratio 0.60 (0.00 SDS) and head circumference 48.6 cm (-0.95 SDS). Her serum 
total IGF-I level was 34 ng/ml (-2.78 SDS) , IGFBP-3 level 1.35 mg/l (-1.33 SDS) and her bone 
age was 1 year behind. Aft er 1 year of GH treatment, height had increased by 1.02 SD and head 
circumference by 0.58 SD. Her serum total IGF-I level was 197 ng/ml (1.51 SDS) and IGFBP-3 
level was 2.62 mg/l (0.92 SDS). Aft er 4 years of GH treatment, she had an increase in height of 
+1.65 SD and an increase in IGF-I level of +5.75 SD. Currently, at age 8.3, her height is 123.3 cm 
(-1.68 SDS). Cardiac ultrasound showed an undulating shape of the left  ventricular wall which 
could not be further specifi ed.
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Figure 1. Growth charts of the two children with a IGF1R deletion. 
Figure 2. Physical characteristics of Patient A, at age 9, and of Patient B at 18 years of age. 
Dysmorphological examination showed hypertelorism, hypocanthal folds, medial fl aring of the 
eyebrows, broad nasal bridge and thick hair (Figure 2). She had a triangular face, large mouth, 
short and pigmented upper lip, low placed, posterior rotated ears. Her abdomen was protruded. 
She had bilateral clinodactyly, short fi ngers and proximally placed, broad thumbs. She had a 
bilateral sandal gap and broad forefeet with pes planus. Th ere was hyperlaxity of the joints, 
especially of the elbows and knees (Beighton score 7/9). Dimples were present at the right fl ank 
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and in the lumbar region. Th ese dysmorphic features were absent in her parents. She goes to a 
regular primary school. Testing of her verbal and performance intelligence quotient showed an 
average intellectual level, with a score of 93 and 121 points, respectively. Th ese scores indicate a 
disharmonic intellectual profi le although being in the normal range. 
 Her two brothers were born aft er 40 weeks gestation, had a normal birth size and grew 
normally (data not shown). 
Genetic analysis
Patient A had a deletion of all three probes in the IGF1R gene on the MLPA growth kit. 
Confi rmation of this result with the MRC Holland P217 MLPA kit showed a heterozygous 
deletion of all probes in the IGF1R gene (exon 1-21) including the two telomeric control probes 
which were located at 2.0 and 2.8 Mb downstream of the IGF1R gene. Her parents and both 
brothers did not carry this deletion. SNP array-analysis showed a terminal deletion from 
location rs12912857, the fi rst detected SNP probe located at 95.883.282 bp until rs7169385, 
the last detected SNP probe located at 100.192.115 bp (Ensembl release 49), comprising a 4.5 
Mb region on chromosome 15 (Figure 3). No other pathogenic CNV’s were observed with SNP 
array analysis. Additional sequence analysis of the coding region of the IGF1 gene, to exclude a 
mutation as a cause of the low IGF-I level revealed no mutation. 
Figure 3. Array analysis of chromosome 15 of Patient A showed a heterozygous deletion of 15q26.2 to 
15qter, from rs12912857 to rs7169385 comprising the whole IGF1R gene. Patient B showed a heterozygous 
deletion of 15q26.3 to 15qter from rs11857366 to rs7169385. Th is deletion starts within intron 2 of the 
IGF1R gene.
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Patient B
Clinical description
Patient B was a boy born spontaneously aft er 40 weeks of gestation as the fi rst child of non-
consanguineous parents. A decrease in fetal growth was observed during the last trimester by 
ultrasound. His birth weight was 2600 g (-1.91 SDS) and birth length 47 cm (-2.21 SDS). Th e 
height of his father and mother was 187.6 cm (0.84 SDS) and 165.2 cm (-0.50 SDS), respectively. 
His secular-trend corrected target height was 187.4 cm (0.49 SDS). Bone age was 2 years 
delayed at the chronological age of 4 years. At age 2 a rotation deformity of both tibial bones 
was observed and tympanostomy tubes were implanted because of recurrent ear infections. At 
3.0 years of age, his height was 84.0 cm (-3.84 SDS), and his weight was 11.2 kg (-2.65 SDS). A 
clonidine stimulation test was performed at age 5 with a maximal GH response of 69.7 mU/L. 
Cardiovascular, respiratory and abdominal examinations were all normal.
 From age 7 onwards, he started GH treatment in a dose of 1 mg/m2/day (Figure 1). At 
start of GH treatment, his height was 109.4 cm (-3.57 SDS), BMI 16.5 kg/m2 (0.49 SDS), sitting 
height/ height ratio of 0.55 (-1.86 SDS) and head circumference 51.3 cm (-0.53 SDS). IGF-I was 
208 ng/ml (1.25 SDS) and IGFBP-3 level 2.99 mg/l (1.24 SDS). Aft er 1 year of GH treatment, 
his height had increased by 0.83 SD, and head circumference by 0.29 SD. His serum total IGF-I 
level was 356 ng/ml (2.28 SDS) and IGFBP-3 level was 1.99 mg/l (-0.40 SDS). Aft er 4 years of 
GH treatment, he had an increase in height of +1.69 SD and an increase in IGF-I of +0.39 SD. 
Currently, at age 17, his height is 168.9 cm (-1.89 SDS).
 From age 11 onwards, he used methylfenidate (10/5/5 mg) because of attention-defi cit 
hyperactivity disorder. Aft er primary school, he started a secondary school for children with 
hearing and speech diffi  culties. Currently, he receives training for becoming a baker. Cardiac 
evaluation showed no abnormalities.
 Dysmorphological examination showed hypertelorism, upward slant, thin upper lip, 
bilateral extra nipple, proximal implanted thumbs and broad feet (Figure 2). Th ese dysmorphic 
features were absent in his parents and brother. His brother has a height within the normal range.
Genetic analysis
MLPA analysis showed a deletion of two out of three IGF1R probes (exon 8 and 18). Th e 
MRC-Holland P217 MLPA kit showed a heterozygous deletion of exon 3-21 of the IGF1R gene 
comprising also both telomeric control probes located at 2.0 and 2.8Mb downstream of the 
IGF1R gene. His parents and brother did not carry the deletion. SNP array analysis showed a 
terminal deletion of 3.1 Mb on chromosome 15 ranging from rs11857366, fi rst detected SNP 
probe at 97081324 bp until rs7169385, last detected SNP probe at 100192115 bp, containing 282 
SNP probes (Figure 3). No other pathogenic CNV’s were observed in the SNP array analysis.
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Discussion
Th is study shows that IGF1R haploinsuffi  ciency was detected in 2 out of 100 short SGA children 
and that no other copy number variants were found in 18 other growth-associated genes. 
 As dominant de novo deletions are a well-recognized sign of pathogenicity, it is very 
likely that the observed deletions explain the short stature of both patients. Th is is supported 
by previous clinical studies reporting subjects with IGF1R point-mutations and deletions [13-
15, 17-24, 26], including functional analysis of a patient with a missense mutation and one 
with a complete deletion of the IGF1R gene [16,25]. In addition, according to the database of 
genomic variants (http://projects.tcag.ca/variation/) no deletion of the IGF1R gene region has 
been reported yet in the general population. 
 Both children responded to GH treatment, increasing their height by 1.02 SD and 0.83 
SD respectively, aft er 1 year of GH treatment, and a further increase to -1.68 and -1.89 SD in 
the following years. Th is growth response was comparable to the mean 1 year growth response 
in short SGA children (approximately 0.8 SD in prepubertal short SGA children on the same 
GH dosage) [38]. Th is may be a combination of the direct eff ect of GH on the epiphyseal 
chondrocytes which is independent of the biological actions of serum IGF [39], and elevated 
serum IGF-I levels which may partially overcome the diminished sensitivity. 
 When previous case reports of children with an IGF1R deletion or mutation were 
reviewed, only six other children had received GH treatment (Table 1). Th e children who 
received a GH dose of 1mg/m2/day, increased their height with ~1.0 SD per year of GH 
treatment. Th eir serum IGF-I level increased with ~1.0 SD except for Patient A (discussed in the 
next paragraph). Th e other children received a higher GH dose but showed a similar variable 
response: a similar response in two of them, and no apparent response in two other patients 
[13,16]. Th us, six out of eight children showed a benefi cial eff ect of GH treatment.
 An unexpected fi nding in Patient A was the low serum IGF-I level, in contrast to a 
high or normal serum IGF-I level usually observed in patients with an IGF1R mutation or 
deletion. Since no abnormalities in the IGF1 gene were found, we hypothesize that this may 
be explained by a partial GH defi ciency. Th e marginal response of GH in the provocation test 
and the observation that IGF-I and IGFBP-3 strongly rose by +4.3 SD and +2.2 SD aft er 1 
year of GH treatment supports our hypothesis. Low IGF-I serum levels (1.3 SDS, Dr. H.J. van 
der Kamp, personal communication) were also observed in the child with an IGF1R missense 
mutation [26]. However aft er realimentation by a gastrostoma her IGF-I levels increased up to 
+2.9 SDS. 
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Th e children we identifi ed had a relatively mild phenotype compared to the other patients with 
a terminal IGF1R deletion who had lung hypoplasia, atrial and/or ventricular septum defects, 
hypoplastic left  atrial or ventricular heart, dextrocardia and diaphragmatic hernia (Table 2) 
[19-25]. We believe that these clinical signs are primarily linked to other genes in the area, as in 
children with an IGF1R mutation a much smaller number of additional characteristics has been 
observed. Poot et al indicated IGF1R fl anking genes which might be responsible for several 
characteristics of the variation in the phenotypes of children with an IGF1R deletion [20]. 
 Both patients described here had hearing problems, showed mild developmental delay 
and had proximal implanted thumbs. Hearing problems and developmental delay have been 
described in previous case-reports of mutations in the IGF1 and IGF1R gene and might also be 
due to their tissue-specifi c expression in the auditory and central nervous system [40,41]. 
 To our knowledge, there are no diagnostic criteria for children with an IGF1R mutation 
or deletion. In Table 3 we have summarized clinical features of children with an IGF1R 
mutation or deletion according to their organ system. We identifi ed major criteria which are 
predominantly related to growth restriction and minor criteria which are based on dysmorphic 
features and signs of joint hypermobility. Based on the information summarized in Table 2, 
we propose the combinations of major and minor criteria which indicate a high likelihood 
of an IGF1R mutation or deletion. Interestingly, joint hypermobility is related to the fi brillin 
(FBN1) gene which is located upstream of the IGF1R gene on 15q21. FBN1 gene mutations are 
responsible for Marfan syndrome which however, instead of short stature, is associated with 
tall stature. Both phenotypes however display joint hypermobility. Further research is needed 
to identify whether the IGF1R and FBN1 gene together might explain variations in height and 
hypermobility in short SGA patients. 
 Th e remaining 98 short SGA children had no CNV’s in the 18 growth-associated genes 
we selected, but we did not exclude mutations in these genes. Future studies are needed to 
investigate whether deletions or mutations in other genes, or combinations of several gene 
defects, are associated with the short SGA phenotype. 
 In summary, this study has shown that IGF1R haploinsuffi  ciency was present in 2 out of 
100 short SGA children. Th is study illustrates that the combination of a small birth size, short 
stature, small head size, relatively high IGF-I level, developmental delay and micrognathia is 
suggestive for children with an IGF1R deletion. Since GH therapy leads to a moderate catch-
up growth of ~1.0 SD in the fi rst year, we recommend that the SGA children with a persistent 
short stature are tested for an IGF1R deletion, particularly if some of the major or minor criteria 
are present. Th e multiplex ligation-dependent probe amplifi cation (MLPA) has shown to be a 
valuable tool in rapidly identifying these relatively large deletions in short SGA children. 
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Table 3. Suggested clinical indicators for a heterozygous IGF1R mutation or terminal 
chromosome 15q deletion based on published cases.
Major Minor
1. Skeletal Height ≤ -2.00 SDS Triangular face/ micrognathia
Birth length ≤ -2.00 SDS Proximal placed thumb
Birth weight ≤ -2.00 SDS
Head circumference ≤ -2.00 SDS
IGF-I level SDS > 1.00 SDS
2. Nervous system Developmental delay Tethered spinal cord
Mental retardation Seizures
3. Cardiac Right sided aorta, Bicuspid aortic valve, aortic coarctation
VSD
Aberrant left  ventricular wall
4. Gastro-intestinal Diaphragmatic hernia
Gastroesophagal refl ux
5. Connective tissue Club feet
Hip dysplasia
Cubitus valgus
Genu recurvatum
Subluxation radial heads
Severe myopia
6. Skin Oculocutaneous albinism
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  D GCAGGAAACAAGAACTACAGGATGTAGGAAGA   
GH1 4 U CAACAGCCTGGTGTACGGCGCCTCTGACAGCAACGTCTATGA 116 FAM
  D CCTCCTAAAGGACCTAGAGGAAGGCATCCAAA   
GHR 4 U GCCACTGGACAGATGAGGTTCATCATGGTACAAAGAACC 112 FAM
  D TAGGACCCATACAGCTGTTCTATACCAGAAG   
 10 U GGTACTTTGGTGGCCACATAAGCCATTATTCACTAGTATGA 110 HEX
  D CTAGTTGTGTCTGGCAGTTTATATTTAACTCTC   
SHOX 3 U GGATTTATGAATGCAAAGAGAAGCGCGAGGACG 106 HEX
  D TGAAGTCGGAGGACGAGGACGGGCAGACCAAGCTGAA   
 8 U CCCTGAGTTTCTCTGGTGACGCCCTCATTCTCCTAA 108 HEX
  D CGTTCAATAATCTCAATGTTGAGTTGCAGCAACAGA   
IGFBP1 1 U CAAACTTATTTTGAACACTCAGCTCCTAGCGTGCG 102 HEX
  D GCGCTGCCAATCATTAACCTCCTGGTGCAAG   
 4 U GTGAGACATCCATGGATGGAGAGGCGGGACTCTGCT 104 HEX
  D GGTGCGTCTACCCTTGGAATGGGAAGAGGATC   
165
Chapter
8
G
en
e n
am
e
ex
on
U
ps
tr
ea
m
 (U
)/ 
D
ow
n 
st
re
am
 (D
)*
Se
qu
en
ce
To
ta
l f
ra
gm
en
t 
le
ng
th
 (b
p)
la
be
l
IGFBP2 2 U CACTCAGAAGGAGGCCTGGTGGAGAACCACGT 100 FAM
  D GGACAGCACCATGAACATGTTGGGCG   
 4 U CAAGATGTCTCTGAACGGGCAGCGTGGGGAGTGCT 108 FAM
  D GGTGTGTGAACCCCAACACCGGGAAGCTGAT   
IGFBP3 2 U GCTAAAGACAGCCAGCGCTACAAAGTTGACTACG 100 HEX
  D AGTCTCAGAGCACAGATACCCAGAACTTCT   
 5 U CTGGAGCTCACAGCCTTCTGTGGTGTCATT 96 HEX
  D TCTGAAACAAGGGCGTGGATCCCTCAACCA   
IGFBP4 3 U GACCTCTACATCATCCCCATCCC 84 HEX
  D CAACTGCGACCGCAACGGCAACTTC   
 4 U CAGAGTCAGAGGAGAAGAGACATGTACCTTGACCATCGTCC 114 HEX
  D TTCCTCTCAAGCTAGCCAGAGGGTGGGAGCCTAAGGA   
IGFBP5 2 U GATCTTCCGGCCCAAACACACCCGCATCTCCGAGCTGAAGGCT-
GAAG
120 HEX
  D CAGTGAAGAAGGACCGCAGAAAGAAGCTGACCCAGTC   
 3 U GTGCTGTGTACCTGCCCAATTGT 86 HEX
  D GACCGCAAAGGATTCTACAAGAGAAAG   
IGFBP6 2 U CCACAGGATGTGAACCGCAGAGA 92 FAM
  D CCAACAGAGGAATCCAGGCACCTCTAC   
 3 U CAAACACTCTACGTGCCCAATTGTG 90 FAM
  D ACCATCGAGGCTTCTACCGGAAG   
ALS 2 U GAACCTCTCTGGGAACTGTCTCCGG 88 FAM
  D AACCTTCCGGAGCAGGTGTTC   
Stat5b 2 U GATACAAGCTCAGCAGCTCCAAGGAGAAGCCCT 102 FAM
  D TCATCAGATGCAAGCGTTATATGGCCA   
 14 U GAGAATTTACCAGGACGGAATTACACTTTCTG 104 FAM
  D GCAATGGTTTGACGGTGTGATGGAAGTGTT   
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Socs3 2 U CTTCAGCATCTCTGTCGGAAGACCGTCAACG 98 FAM
  D GCCACCTGGACTCCTATGAGAAAGT   
GRB10 3 U GATGTGGACCTGGAAGCCCTGGTGAACGAT 96 FAM
  D ATGAATGCATCCCTGGAGAGCCTG   
 10 U CAGAGGACGAGCAAACCAGGACGTGCT 94 FAM
  D GGATGACAGCGTTCAGACTCCTCAA   
NSD1 3 U GAGATCTCATCTGGGCAAAATTCAAGAGACGCCCATGGTGGCCCT 116 HEX
  D GCAGGATTTGTTCTGATCCGTTGATTAACACACAT   
 13 U CACTGTTATGCAGAACAAGGGCTTCCGGTGCTCCCTCCACATCT-
GTA
118 HEX
 D TAACCTGTCATGCTGCTAATCCAGCCAATGTTTCT   
 20 U CTCGGTTCATGAATCATTGCTGCCAGCCCAACTGTGAAACACA-
GAAG
120 FAM
  D TGGTCTGTGAATGGAGATACCCGTGTAGGCC   
IGF2 2 U GAATCCCAATGGGGAAGTCGAT 86 FAM
(11p15)  D GCTGGTGCTTCTCACCTTCTTG   
 4 U CATCCTGCAGCCTCCTCCTGACCACGGACGTTTCCATCAGGTT 114 FAM
  D CCATCCCGAAAATCTCTCGGTTCCACGTC   
SOCS2 1 U GCCGCGGCCTCAACTAAAAGTGGCCATTGACCTTTCAA 110 FAM
  D GCTTTCGAGCAGTGATGCAATAGAATAGAA   
*Th e Upstream hybridising sequence (U) was extended with a labelled primer 5’-GGGTTCCCTAAGGGTTGGA-3’; the downstream 
hybridizing sequence was extended with an unlabelled primer 5’-GTGCCAGCAAGATCCAATCTAGA-3’.
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Abstract
Background: Th e network of studies into genes in growth (NESTEGG) is a growth genomics 
project in which subjects born small for gestational age (SGA), subjects with idiopathic short 
stature (ISS) and controls are studied.
Objectives: To determine postnatal and GH-induced growth and their relation with maternal 
hypertension, smoking and alcohol during gestation. 
Methods: 464 short SGA, 336 SGA catch-up, 464 ISS and 724 control subjects were investigated. 
GH treatment data were available of 262 short SGA and 109 ISS prepubertal subjects. Growth data 
were collected from medical records and gestational data were retrieved from questionnaires. 
Results: Birth length and postnatal height were signifi cantly diff erent between short SGA, SGA 
catch-up, ISS and control subjects (short SGA: -2.88 vs. -2.82 SDS, SGA catch-up: -2.50 vs. -0.49 
SDS, ISS: -0.59 vs. -2.49 SDS and controls: -0.01 vs. 0.05 SDS, respectively). Short SGA subjects 
increased 0.2 SDS more in height than ISS subjects during 1 year of GH treatment (P < 0.001). 
Mothers of SGA catch-up subjects had more gestational hypertension than mothers of short 
SGA, ISS and control subjects (27.9% vs. 16.4%, 6.0% and 12.3%, P<0.001). Mothers of short 
SGA subjects smoked more during gestation than mothers of ISS and control subjects (35.1% 
vs. 20.3% and 23.5%, P<0.001). During spontaneous postnatal growth, short SGA subjects 
increased more in height when their mothers had gestational hypertension compared to short 
SGA subjects without (0.64 SDS vs. -0.06 SDS, P<0.001). 
Conclusions: Prenatal growth restriction of SGA subjects was related to gestational 
hypertension and smoking. Spontaneous postnatal catch-up growth of short SGA subjects was 
most pronounced when their mothers had gestational hypertension. Gestational factors were 
not related to the ISS phenotype. 
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Introduction
In 2001 the network of studies into genes in growth (NESTEGG) was initiated by paediatric 
endocrinologists and molecular geneticists to investigate etiological factors of children 
with pre- and/or postnatal growth failure [1]. Th is cross-sectional study was performed in 
Th e Netherlands, France, Germany and the United Kingdom. Clinical data on growth and 
cardiovascular outcomes were collected in subjects born small for gestational age (SGA) with 
and without catch-up growth, subjects with idiopathic short stature (ISS) and controls. In 
addition, clinical data during GH treatment were attained from a subgroup of short SGA and 
ISS subjects. 
 Th e aim of the Network of Studies into Genes in Growth (NESTEGG), is to describe the 
phenotype of short SGA, SGA catch-up and ISS subjects and to identify genes that contribute 
to foetal or postnatal growth. Th ese genetic factors may allow for a more specifi c diagnosis 
and may be the base of more targeted treatment possibilities. In addition, novel genetic factors 
aff ecting growth might give rise to new treatment modalities. 
 Th e aim of the current study is to describe pre- and postnatal growth in SGA and ISS 
children compared with controls and to identify whether gestational factors are related to 
postnatal growth and growth during GH treatment. Previous studies have shown that gestational 
hypertension, maternal smoking and gestational alcohol infl uence pre- and postnatal growth 
[2-4). However, it is unknown to what extent these gestational factors infl uence spontaneous 
postnatal and GH-induced growth in short SGA, SGA catch-up, ISS and control subjects. 
 Th is is a unique insight into the relationship of gestational hypertension, gestational 
smoking and alcohol use with spontaneous postnatal and GH-induced growth in short SGA, 
SGA catch-up, ISS and control subjects in a large international cohort.
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Methods
Study population
Th e NESTEGG study comprises short SGA, SGA catch-up, ISS subjects, their parents and 
controls. All subjects were recruited by paediatric endocrinologists of the Sophia Children’s 
Hospital, Erasmus medical Centre, Rotterdam; University Children’s Hospital, Toulouse, 
University Children’s Hospital, Tübingen and Bart’s and the Royal London Hospitals, London. 
Short SGA and ISS subjects were recruited from the growth clinics, where GH treatment was 
in some cases prescribed. SGA catch-up and ISS subjects who did not use GH treatment were 
additionally recruited from young adult studies or on identifi cation through birth cohorts. 
Controls were acquired from blood banks, hospital staff  and student populations.
 SGA was defi ned as a birth weight and/or birth length ≤ -1.88 standard deviation score 
(SDS) according to the national growth charts (Th e Netherlands and Germany [5]; France [6]; 
United Kingdom [7]). Height at or aft er 3 years of age determined whether a child had caught 
up (> -1.88 SDS: SGA catch-up) or remained short (< -1.88 SDS: short SGA) (Th e Netherlands 
[8]; France [9]; United Kingdom [7]; Germany [10]). ISS was defi ned as a birth weight and/
or birth length > -1.88 to +2.00 SDS and a prepubertal height aft er 3 years of age ≤ –1.88 SDS 
(Th e Netherlands [8]; France [9]; United Kingdom [7]; Germany [10]). Inclusion criteria were: 
gestation ≥ 30 weeks with uncomplicated postnatal period (ventilation < 72 hours not including 
CPAP). Subjects were included only when they were of Caucasian origin and all grandparents 
and parents must have been born and living in Western Europe. Exclusion criteria were: a known 
syndrome or dysmorphic features (except Russell Silver syndrome), known chromosomal or 
genetic abnormality, known severe chronic illness or endocrine disease, or positive gliadin, 
endomysial or reticulin antibodies, growth hormone defi ciency, severe disproportionate short 
stature, psychosocial dwarfi sm, any psychiatric, neurodegenerative, or chronic illness in parents, 
which may aff ect their ability to give fully informed consent or donate blood and if the child 
was adopted. All centres obtained approval of their Medical Ethics Committee. Children and/
or their parents signed informed consent before participation in the study. 
Clinical parameters
Birth measurements and gestational age were obtained from birth records. Birth weight as 
qualifying parameter was available for all subjects. Anthropometric data during postnatal life 
were cross-sectionally collected at the out-patient clinic or retrospectively when GH therapy 
was started earlier. Anthropometric measurements were performed by standardized methods. 
Pubertal status was determined by the physician according to Tanner stage [11]. Gestational 
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data were retrieved as categorical variables by questionnaires answered by the mothers of all 
subjects. Gestational hypertension was coded as treated and untreated hypertension vs. no 
hypertension. Gestational smoking was coded as maternal smoking, paternal and maternal 
smoking vs. no smoking. Maternal alcohol use was coded as 1-4 units/week, 5-9 units/week 
and 10 or more units per week vs. no alcohol use.
 Of all 1988 study participants, 519 received GH treatment. For the aim of the present 
study, we selected prepubertal short SGA and ISS children. Prepuberty was defi ned as breast, 
genital and pubic hair stage ≤ 2, and/or testicular volumes ≤ 4 ml. Of the prepubertal children 
we excluded the older children by selecting girls ≤ 12 years of age and boys ≤ 14 years of age. 
In total 371 children were eligible for the analysis of growth during GH treatment. During 
GH treatment, biosynthetic GH was injected subcutaneously. GH doses of all centers were 
recalculated into mg/m2 body surface area/day. IGF-I levels were standardized according to 
national references (Th e Netherlands [12]; France: by Diagnostic System Laboratories, Inc; 
United Kingdom [13]; there were no IGF-I data from Germany). Th e growth response during 
GH treatment was corrected for midparental height SDS. Midparental height SDS was calculated 
by ((maternal height SDS + paternal height SDS)/2), according to the national growth chart 
[7-10,14]. 
Statistical analyses
All continuous anthropometric variables were tested for overall diff erences between the short 
SGA, SGA catch-up, ISS and control group by univariate analysis of variance. Post-hoc pair 
wise tests employed a Bonferroni correction for multiple comparisons. Categorical variables 
were tested for overall diff erences between the short SGA, SGA catch-up, ISS and control group 
by chi-square test and diff erences between the groups were tested by pair wise chi-square test. 
Measurements during GH treatment were corrected for GH dose and target height SDS by 
adding these covariates in the univariate analyses. Accumulation of gestational factors was 
investigated in 1270 subjects who had a complete dataset for all three gestational factors. 
P-values ≤ 0.05 were considered signifi cant. Statistical tests were performed using SPSS 15.0 
package (SPSS Inc., Chicago, IL, USA).
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Results
Birth size
Th e study population consisted of 1988 subjects, 464 short SGA, 336 SGA catch-up, 464 ISS 
and 724 control subjects (Table 1). All groups had a signifi cantly diff erent birth length SDS 
(P < 0.001). Short SGA subjects had a shorter birth length than SGA catch-up subjects (-2.88 
SDS vs. -2.50 SDS, P< 0.001), whereas they had a comparable weight at birth (-2.20 SDS vs. -2.26 
SDS). Both ISS subjects and controls had a birth size in the normal range. However, ISS subjects 
had a birth length and weight SDS signifi cantly below the average of 0 SDS (length: -0.59 SDS, 
weight: -0.49 SDS, both P < 0.001). Controls had a weight SDS which was signifi cantly below 0 
SDS (-0.20 SDS, P < 0.001) in contrast to their length SDS (-0.01 SDS, P = 0.79).  
Postnatal spontaneous growth
All groups had a signifi cantly diff erent height SDS (Table 1, P<0.001). Short SGA subjects were 
the shortest and leanest of all groups (height: -2.82 SDS, weight: -2.14 SDS). ISS subjects also 
had a height below the -2 SDS but their weight SDS was in the low-normal range (height: -2.49 
SDS, weight: -1.89 SDS). Although SGA catch-up subjects had a height and weight within the 
normal range, both were signifi cantly below 0 SDS (height and weight: P<0.001). Controls were 
relatively large, with a weight above the average (weight: 0.70 SDS, P<0.001). 
Growth during GH treatment
262 short SGA and 109 ISS children were prepubertal at start and aft er 1 year of GH treatment 
(Table 2). Short SGA children were, compared to ISS children, signifi cantly younger (6.7 vs. 
8.7 years, P<0.001), received a higher GH dose (1.20 vs. 1.05 mg/m2/day, P < 0.001) and were 
shorter (-2.96 vs. -2.49 SDS, P<0.001) at start of GH treatment. Short SGA children had a 0.3 
SDS higher IGF-I level at start of GH treatment compared to ISS children, however, aft er 1 year 
of treatment the IGF-I SDS levels were comparable. Weight SDS at start of GH treatment was 
comparable between the short SGA and ISS subjects.
 During one year GH treatment, short SGA subjects had a 0.2 SDS greater increase in 
height than ISS subjects (P < 0.001). Th e change in weight and IGF-I SDS was comparable 
between short SGA and ISS subjects.
Gestational factors: short SGA, SGA catch-up, ISS and controls
Mothers of short SGA subjects smoked more frequently during gestation than mothers of 
ISS and control subjects (35.1% vs. 20.3% and 23.5%, P < 0.001). Th e frequency of maternal 
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smoking during gestation between short SGA and SGA catch-up subjects was comparable 
(35.1% vs. 31.7%). Mothers of SGA catch-up subjects had a signifi cantly higher frequency of 
gestational hypertension than mothers of short SGA, ISS and control subjects (27.9% vs. 16.4%, 
6.0% and 12.3%, respectively, P < 0.001, Table 1). Mothers of the short SGA, SGA catch-up 
and ISS subjects reported a comparable frequency of alcohol use (13.2%, 11.7% and 11.4%, 
respectively). Maternal alcohol use during gestation was most frequently reported among 
mothers of controls (25.4%). 
Table 1. Birth size, spontaneous postnatal growth and gestational factors in short SGA, SGA catch-up, ISS 
and control subjects.
Short SGA SGA CU ISS Controls P-value
Number 464 336 464 724
Sex (%boys) 53.9% 39.6% 59.5% 45.9% <0.001
Birth
Length (SDS) -2.88 (1.23) -2.50 (1.26) -0.59 (0.83) -0.01 (1.07) <0.001a
Weight (SDS) -2.20 (0.98) -2.26 (0.86) -0.49 (0.88) -0.20 (1.01) <0.001b
Postnatal
Age (years) 8.3 (5.8) 15.6 (9.2) 9.7 (6.2) 27.9 (14.2) <0.001c
Height (SDS) -2.82 (0.69) -0.49 (1.37) -2.49 (0.53) 0.05 (1.09) <0.001a
Weight (SDS) -2.14 (1.14) -0.29 (1.39) -1.89 (1.02) 0.70 (1.34) <0.001d
Delta height (SDS)* 0.05 (1.30) 2.01 (1.91) -1.88 (0.92) 0.11 (1.25) <0.001e
Delta weight (SDS)* -0.10 (1.28) 1.96 (1.57) -1.43 (1.29) 0.82 (1.54) <0.001a
Gestational factors
Hypertension %(n) 16.4 % (72) 27.9% (77) 6.0% (27) 12.3% (26) <0.001e
Maternal smoking %(n) 35.1% (143) 31.7% (83) 20.3% (88) 23.5% (44) <0.001d
Alcohol use %(n) 13.2% (57) 11.7% (32) 11.4% (49) 25.4% (53) <0.001f
SGA= small for gestational age, CU= catch-up, ISS= idiopathic short stature, SDS= standard deviation score. Continuous variables 
are presented as mean (SD) and their P-values represent the comparison of the four groups in ANOVA, where aft er the overall P-value 
is presented. Categorical variables are presented as percentage (number) and their P-values are determined by chi-square test. a 
All groups diff ered signifi cantly from each other; b except for the short SGA and SGA CU group, c except for the short SGA and ISS 
group, d except for the controls and SGA CU, controls and ISS, and the SGA CU and short SGA groups, e except for the short SGA 
and controls, f except for the SGA CU and ISS, SGA CU and short SGA, and the ISS and SGA short groups. * Delta SDS= postnatal 
SDS minus birth SDS.
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Table 2. GH-induced growth in short SGA and ISS subjects.
Short SGA ISS P-value
Number 262 109
Sex (% boys) 58.4% 56.9% 0.79
Age (years) 6.7 (2.4) 8.7 (2.7) <0.001
GH dose (mg/m2/day) 1.20 (0.37) 1.05 (0.23) <0.001
At start GH:
Height (SDS) -2.96 (0.70) -2.49 (0.54) <0.001
Weight (SDS) -1.61 (1.11) -1.50 (0.72) 0.34
IGF-I (SDS) -1.27 (1.25) -1.58 (0.69) 0.04
Aft er 1 year GH*:
Height (SDS) -2.18 (0.04) -1.86 (0.07) <0.001
Weight (SDS) -1.26 (0.06) -1.30 (0.10) 0.72
IGF-I (SDS) 0.54 (0.10) 0.42 (0.24) 0.65
Change*:
Delta height (SDS) 0.81 (0.02) 0.64 (0.04) <0.001
Delta weight (SDS) 0.37 (0.03) 0.32 (0.05) 0.39
Delta IGF-I (SDS) 1.77 (0.11) 2.06 (0.29) 0.35
Gestational factors:
Hypertension %(n) 17.7% (45) 6.5% (7) 0.005
Maternal smoking %(n) 36.8% (85) 26.4% (28) 0.06
Alcohol use %(n) 11.6% (29) 15.7% (17) 0.28
*= corrected for GH dose and midparental height SDS. Presented as mean (SE). All subjects were prepubertal at start and aft er 1 
year of GH treatment.
Gestational factors: postnatal growth and growth during GH treatment 
Short SGA subjects had a signifi cantly greater spontaneous catch-up in height when their 
mothers had gestational hypertension than short SGA subjects whose mothers did not have 
gestational hypertension (delta height SDS: 0.64 vs. -0.06, P < 0.001). Gestational hypertension 
was not related with spontaneous postnatal growth of SGA catch-up, ISS and control subjects. 
ISS subjects had less postnatal growth retardation when their mothers had smoked during 
gestation compared to ISS subjects whose mothers did not smoke during gestation (delta 
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height SDS: -1.65 vs. -1.91, P = 0.02). Maternal alcohol use during gestation did not infl uence 
spontaneous postnatal growth of any group.
 Gestational hypertension, smoking and alcohol use were not related with GH-induced 
growth of short SGA subjects. ISS subjects increased signifi cantly more in height during GH 
therapy when their mothers did smoke during gestation compared to ISS subjects whose 
mothers did not smoke during gestation (0.77 vs. 0.53 SDS, P = 0.001). 
 
Accumulation of gestational factors
Short SGA and SGA catch-up mothers most frequently reported to have a combination of 
gestational hypertension and smoking (5.4% vs. 6.5%, Figure 1). Mothers of ISS and control 
subjects most frequently reported a combination of gestational smoking and alcohol (3.3% vs. 
9.2%). A minority of all mothers had a combination of gestational hypertension, smoking and 
alcohol use (short SGA: 0%, SGA catch-up 1.2%, ISS 0.2% and controls 2.2%).
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Figure 1. Accumulation of gestational factors in short SGA, SGA catch-up, ISS and control subjects: (1) 
no gestational hypertension, smoking and alcohol, (2) isolated gestational hypertension, (3) gestational 
smoking, (4) gestational alcohol, (5) gestational hypertension and smoking, (6) gestational hypertension 
and alcohol, (7) gestational smoking and alcohol, (8) gestational hypertension, smoking and alcohol. 
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Table 3. Gestational factors and spontaneous postnatal growth in short SGA, SGA catch-up, ISS and 
control subjects.
Delta height SDS* Short SGA SGA CU ISS Controls
Hypertension 
Present 0.64 (1.74) 2.04 (1.35) -2.02 (1.01) 0.03 (1.36)
Absent -0.06 (1.18) 1.99 (2.04) -1.86 (0.89) 0.00 (1.37)
P-value <0.001 0.87 0.43 0.94
Maternal smoking 
Present 0.14 (1.36) 2.23 (2.53) -1.65 (0.95) 0.08 (1.40)
Absent 0.01 (1.26) 1.94 (1.47) -1.91 (0.89) -0.03 (1.41)
P-value 0.34 0.28 0.02 0.68
Alcohol use 
Present 0.04 (1.31) 1.70 (1.26) -1.71 (0.88) -0.21 (1.51)
Absent 0.05 (1.31) 2.06 (1.94) -1.88 (0.90) 0.07 (1.32)
P-value 0.96 0.35 0.26 0.25
*Delta height SDS is calculated by: postnatal height SDS minus birth length SDS. Th e P-value represents the ANOVA test result for 
the diff erence in height SDS for each gestational factor. 
Discussion
Th is is the fi rst study in which gestational hypertension, gestational smoking and alcohol use 
were investigated in relation with spontaneous postnatal and GH-induced growth in short 
SGA, SGA catch-up, ISS and control subjects in a large international cohort. Th is study has 
shown that prenatal growth restriction of SGA subjects is related to gestational hypertension 
and smoking. Postnatal catch-up growth in height was most pronounced when their mothers 
had gestational hypertension. Gestational hypertension, smoking and alcohol use were not 
related to the ISS phenotype although maternal smoking during gestation was associated with 
less postnatal growth decline and more growth during 1 year of GH treatment. 
 Although many factors are associated with being born SGA [15], these factors do not 
fully explain their phenotype. SGA is a clinical defi nition and not a diagnosis. Our study showed 
that gestational hypertension and maternal smoking were related to 56% of all SGA subjects on 
average (short SGA: 16.4% and 35.1%, and SGA catch-up: 27.9% and 31.7%, respectively). Th is 
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observation is in line with previous studies which have shown that gestational hypertension 
and maternal smoking both result in prenatal growth restriction [2,3]. Other support comes 
from studies which show that although gestational hypertension and maternal smoking have a 
diff erent mode of action, both would result in maternal endothelial dysfunction and abnormal 
placentation, which are common features in fetal growth restriction [3,16-18]. 
Table 4. Gestational factors and growth aft er 1 year of GH treatment in short SGA and ISS children.
Delta height SDS* Short SGA ISS
Hypertension 
Present 0.84 (0.05) 0.52 (0.13)
Absent 0.81 (0.02) 0.60 (0.03)
P-value 0.60 0.52
Maternal smoking 
Present 0.74 (0.04) 0.77 (0.06)
Absent 0.83 (0.03) 0.53 (0.04)
P-value 0.07 0.001
Alcohol use 
Present 0.73 (0.06) 0.52 (0.08)
Absent 0.82 (0.02) 0.61 (0.04)
P-value 0.18 0.28
*= Delta height SDS is calculated by: height SDS aft er one year of GH treatment minus height SDS at start of GH treatment. Delta 
height SDS is adjusted for the GH dose. Means (SE) are presented.
In this study there was no association between maternal use of alcohol during gestation and 
postnatal growth. It might well be that mothers of control subjects reported a high frequency of 
alcohol use during gestation because they had children with a normal growth and may therefore 
not be hesitant to report alcohol use. 
 It is unclear which factors determine whether SGA subjects catch-up to the normal range. 
Many previous studies have shown that 85-90% of all SGA subjects catch-up in height and that 
10-15% remain short [19,20]. Although our study showed that gestational hypertension is more 
frequent in SGA catch-up than in short SGA subjects (27.9% vs. 16.4%, P < 0.001), SGA catch-
up subjects had no increased spontaneous postnatal growth aft er gestational hypertension. 
Th us, it is unlikely that gestational hypertension determines whether postnatal catch-up growth 
takes place. 
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Short SGA children might be disadvantaged in their postnatal growth by a genetic predisposition 
which prevents catch-up growth. Since 10-15% of the SGA populations remain small, this group 
might have disadvantageous single nucleotide polymorphisms (SNP). Th ese fi ndings merit 
further study in NESTEGG. It might well be that newly discovered height genes, can explain 
parts of the postnatally experienced short stature in SGA and ISS subjects.
Recently, many genome wide association (GWA) studies have published SNPs which contribute 
to small variations in height of the general population. Several gene clusters seem to be 
involved: Hedgehog signaling genes containing IHH, HHIP, PTCH1, the extracellular matrix 
genes containing EFEMP1, ADAMTSL3, ACAN, chondrocyte-diff erentiation gene as GDF5-
UQCC, a methyl-DNA-binding transcriptional repressor gene as ZBTB38, cancer-related genes 
as HMGA2, CDK6, DLEU7 and several others like GPR126, HIST1H1D, TRIP11-ATXN3, 
LIN28B, DOT1L, CHCHD7-RDHE2, PNPT1, BMP6 and GNA12 [21-25]. 
 We would hypothesize, that the disadvantageous genotypes that result in persistent 
short stature of short SGA subjects are the opposite genotypes of that in SGA catch-up subjects. 
Genes which are involved in vasoregulatory processes [26,27] seem good candidates to be 
associated with catch-up growth as prenatal maternal endothelial dysfunction and abnormal 
placentation might be a key in the development of the SGA phenotype.
 In the interplay between mother, placenta and fetus it should be considered that not 
only maternal factors as gestational smoking aff ect the placenta and the fetus, but that the fetal 
genotype might also aff ect the maternal status [28,29]. Th e fetal genotype might induce a rise in 
maternal blood pressure and glucose levels to provide adequate nutrition of the fetus [29]. Th is 
concept might apply to the SGA fetus. However, studies are needed to confi rm this hypothesis.
 In this study it was observed that gestational smoking was associated with less 
spontaneous postnatal growth decline and more growth during 1 year of GH treatment in ISS 
subjects. We do not have an explanation for these fi ndings, although it might be that mothers 
of ISS subjects who smoked during pregnancy were confounded with another etiological factor 
leading to a moderate short stature of their child compared to mothers of ISS subjects who did 
not smoke during gestation having a child with more severe short stature. Further research is 
needed to confi rm and clarify this observation. 
 Our study has some limitations. Data on gestational hypertension, smoking and 
alcohol use were obtained by questionnaires, which are vulnerable for underreporting and/ or 
misclassifi cation. Th is might give rise to an underestimation of the ultimate eff ect of gestational 
factors in pre- and postnatal growth. Th e anthropometrical measurements were collected in 4 
countries and several research centers per country which is prone to systematic measurements 
errors, however by using standard operating procedures and expressing measurements into 
standard deviation scores, these errors were minimized. 
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In conclusion, our study has shown that prenatal growth restriction of SGA subjects is related 
to gestational hypertension and smoking. Postnatal catch-up growth of short SGA subjects was 
most pronounced when their mothers had gestational hypertension. Gestational hypertension, 
smoking and alcohol use were not related to the ISS phenotype although maternal smoking 
during gestation was associated with less postnatal growth decline and more growth during 1 
year of GH treatment. 
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General discussion
Th e present thesis describes genetic and environmental factors which are important in pre- and 
postnatal growth in children born small for gestational age (SGA), either with short or normal 
stature. Th e fi rst part presents a novel subclassifi cation of short SGA subjects. Th e second part 
focuses on genetic polymorphisms in the insulin-like growth factor 1 (IGF1), the insulin-like 
growth factor 1 receptor (IGF1R) and the insulin (INS) genes in relation with growth and blood 
pressure in short SGA and SGA catch-up subjects. Th e third part describes the fi ndings of 
a study to identify relatively large deletions and duplications in 18 growth-related genes in 
a group of short SGA children. Detailed phenotypic and genotypic data are reported of two 
short SGA children with an IGF1R deletion. Finally, the relation between gestational factors, 
postnatal growth and phenotypic characteristics is described for a large population consisting 
of short SGA, SGA catch-up, idiopathic short stature (ISS) and control subjects. 
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Part 1. Subclassifi cation of short SGA children
Subclassifi cation of SGA children with persistent short stature: Growth patterns and 
response to GH treatment
In a group of short SGA children, we studied SGAL, SGAL+W and SGAL+W+HC children, who 
were divided according to their birth length (L), birth weight (W) and head circumference 
(HC) at birth ≤ -2.00 standard deviation score (SDS) (1). SGAL+W+HC children were the 
smallest at birth and thus likely to have experienced the most severe growth restriction 
during pregnancy. Although this might be partly explained by the defi nition of their group 
(birth length, birth weight and HC at birth ≤ -2.00 SDS), they had a considerably shorter 
birth length, weight and head circumference than expected. SGAL+W children showed 
an intermediate pattern with regard to birth length and birth weight in comparison with 
SGAL and SGAL+W+HC children. Notably, SGAL+W+HC had the greatest catch-up in height 
and HC during early postnatal life, although at the age of 3 years, HC SDS and weight SDS 
were still signifi cantly lower than in those born SGAL. Th e SGA subclassifi cation could not 
predict a diff erence in growth response to GH treatment as a similar response to GH was 
found for all three groups. HC and weight of SGAL+W+HC and SGAL+W children, however, 
remained signifi cantly below those of SGAL children aft er one year of GH treatment. 
SGAL
Whereas SGAL children had no postnatal increase in height and showed a marked 
decrease in weight and a decline in HC SDS, short SGAL+W and SGAL+W+HC children 
had a signifi cant catch-up in height during early postnatal life. Th ese diff erences 
might result from diff erent genetic and environmental infl uences leading to SGAL as 
compared to the SGAL+W and SGAL+W+HC children. SGAL children were mostly born 
aft er a vaginal delivery, were less small at birth and showed predominantly a decrease 
in weight and head circumference SD-scores aft er birth. In fact, the growth pattern of 
SGAL children resembles that of children with idiopathic short stature (ISS). It might 
well be that subtle skeletal abnormalities play a role in some short SGAL children. For 
this group of SGA children it might be interesting to perform genetic research into 
genes involved in pre- and postnatal bone development. In 2006, Demple et al. reported 
linkage between ISS subjects and the vitamin D receptor (VDR) gene region [2]. 
Several other studies reported a sex-specifi c association between VDR polymorphisms 
and height in the normal population [3,4]. Although in these studies no gestational-
age corrected birth size data were reported, these fi ndings are interesting and a next 
step might be to investigate tagging SNPs of the VDR gene region in SGAL children. 
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SGAL+W
SGAL+W children were characterized by their intermediate birth size and spontaneous 
postnatal growth in comparison with the SGAL and SGAL+W+HC children. Th e mothers of 
these children had the highest frequency of gestational hypertension which might explain their 
shorter gestational age and their spared HC at birth. Th is observation suggests that gestational 
hypertension might have resulted into fetal growth restriction of SGAL+W children. Our data 
are in line with a previous report showing that the combination of a low weight and height 
at birth is most frequent aft er gestational hypertension [5]. We did however not observe that 
SGAL+W children were more prone to have cardiovascular risk factors such as a higher catch-up 
in postnatal weight or BMI in comparison with the other groups [6-8].
SGAL+W+HC
SGAL+W+HC children were the smallest at birth, with regard to length, weight and HC. We 
expected to fi nd a comparable or somewhat smaller birth length SDS than in the other children, 
as all groups had by defi nition a birth length SDS ≤ -2.00. We found, however, that SGAL+W+HC 
children had a considerably shorter birth length than SGAL and SGAL+W children, despite of 
having the highest target height SDS of the groups. Interestingly, SGAL+W+HC children had the 
greatest postnatal catch-up of all growth parameters (including HC), indicating that SGAL+W+HC 
children might have had the most severe fetal growth restraint which disappeared aft er birth. 
Of note was the fi nding that 68% of SGAL+W+HC children were delivered by caesarean section 
in contrast to SGAL children of whom 76% were born aft er vaginal delivery. It is likely that 
the SGAL+W+HC children experienced growth retardation which started early in pregnancy, 
also aff ecting head growth. Th e high frequency of elective caesarean section (CS) might be 
due to the severe growth retardation. Namely, when serious fetal growth restraint is observed, 
gynecologists have to consider the fetal and maternal consequences of an elective CS vs. acute 
CS vs. vaginal delivery. Whereas CS is known to be benefi cial for the outcome of the child, 
vaginal delivery is more favorable for the mother. Th us, oft en an elective CS will be performed 
when the condition of the fetus is deteriorating. On the other hand, a Cochrane review on 
the management of delivery of the small baby, could not draw conclusions about the optimal 
method of delivery in case of a “small baby”, as randomized trials are lacking [9].
Clinical implications and conclusions
We have shown that an SGA subclassifi cation may provide a useful framework to explore the 
mechanisms underlying diff erences in the extent of spontaneous postnatal growth in short 
SGA children. Subclassifi cation might also be useful for elucidating underlying genetic or 
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environmental causes of SGA and future risk profi les with regard to adult diseases. Whereas 
SGAL children appeared to experience the least fetal growth retardation and postnatal height 
increment, SGAL+W children were most aff ected by gestational hypertension which might 
suggest associations with cardiovascular risk profi les in later life. SGAL+W+HC children were 
born with the smallest HC but experienced a major increase in HC postnatally. Although 
all three groups of short SGA children similarly increased their head circumference during 
GH treatment, this intervention seems most indicated for SGAL+W+HC children, having the 
smallest head size at birth and during postnatal life. Our data merit further studies to evaluate 
whether interventions such as remedial teaching, to improve cognition during early infancy, or 
to start GH treatment at a very young age in SGAL+W+HC children are benefi cial for this SGA 
subgroup.
 Studies investigating new methods to subclassify the heterogeneous SGA population are 
very limited. As short SGA children are known for their broad spectrum of pre- and postnatal 
growth, also during GH treatment, further studies are warranted. 
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Part 2. Genetic polymorphisms of the IGF1, Insulin and IGF1R gene
First, literature was investigated on genetic polymorphisms in the IGF1 and IGF1R gene. In 
a next step, genetic polymorphisms in the IGF1, Insulin and IGF1R genes were investigated 
in Dutch SGA patients. By assessing linkage disequilibrium, haplotypes could be constructed 
to capture genetic variations in the genes. Genetic variations were associated with prenatal, 
postnatal and GH-induced growth. In addition, the association between the INS genetic 
variations and blood pressure was investigated. 
Polymorphisms in the IGF1 and IGF1R gene and children born small for gestational 
age: Findings of large population studies 
Although many IGF1 gene polymorphisms have been studied, the 192bp CA-repeat in the 
promoter is the most extensively investigated polymorphism in relation with SGA-related 
outcomes. Th e region ranging from the promoter until intron 2 is part of a linkage disequilibrium 
block which is important in SGA-related outcomes as all association studies in SGA populations 
report associations with polymorphisms in this area [10,11]. Confl icting results arose especially 
in general populations and with associations between birth size measures and polymorphisms 
in this gene region [12-15]. Th ere was only one study evaluating associations between IGF1R 
polymorphisms and SGA-related outcomes, which could not demonstrate any association [16]. 
Limited gene-gene interaction studies have been performed with SGA-related outcomes and no 
associations were found [17]. None of these genetic association studies are currently suitable as 
a diagnostic measure because no therapeutic outcome has been identifi ed yet. 
Clinical implications and conclusions
Although several studies reported associations between IGF1 gene polymorphisms and SGA-
related outcomes, results are confl icting [10-12,14,15,17-22]. It is unclear whether this is the 
result of small sample sizes, population stratifi cation or the diff erent defi nitions of SGA. In 
addition, few studies have reported IGF1R genetic polymorphisms and SGA-related outcomes. 
Studies are needed on a methodological, phenotypic and genotypic level. First, an increase in the 
SGA sample size should be obtained by collaboration within international research consortia. 
Secondly, further phenotyping of SGA children should be performed, e.g., based on etiological 
factors, as a starting point for studies into genetic polymorphisms. Th irdly, as the IGF1 192bp 
CA repeat region has shown to be closely linked to the SGA phenotype, studies into the eff ect of 
this polymorphism on protein level are needed. At last, these studies into the IGF1 and IGF1R 
gene have shown to explain limited aspects of the SGA phenotyope, so studies are needed to 
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identify other candidate genes, e.g. by a genome wide approach, to identify additional, important 
genes related to the SGA phenotype. 
IGF1 gene
Genetic polymorphisms in the IGF1 gene and head size of short SGA children 
Short SGA children were investigated for four IGF1 gene polymorphisms in the promoter 
(-G1245A, -841(CA)n), intron 2 (+3703(CT)n) and 3UTR (+A1830G). Th e well-known 
-841(CA)n/192bp polymorphism in the IGF1 gene promoter, has been previously associated 
with birth size, cardiovascular disease and IGF-I levels, and is in linkage disequilibrium with 
the -G1245A SNP (rs35767). Our study showed that the -1245 A-allele was a marker-allele for 
the well-known -841(CA)n/ non192bp-allele. Th e -1245 A-allele was not associated with head 
circumference at birth, but was associated with a postnatal 0.3 SDS smaller head circumference 
at 1 and 2 years of age. Th e -1245 A-allele was also associated with a 1 week shorter gestational 
age. No associations were found with gestational age-adjusted birth size, height and weight 
SDS during postnatal life and with growth during GH treatment. Th ese results are in line 
with previous studies showing an association between the IGF1 gene promoter and the SGA 
phenotype, and an association between an IGF1 gene polymorphism and postnatal head size (10, 
11). Other studies could not demonstrate an association between the -841(CA)n polymorphism 
and head size, however, these studies have predominantly been executed in normal and diabetic 
populations [12,15,23]. 
Figure 1. Associations between IGF1 gene variations and head size in our SGA populations.
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Th e –G1245A IGF1 polymorphism relates with small head size and less brain sparing 
in short SGA and SGA catch-up children
We investigated whether the –G1245A SNP (rs35767) was associated with head circumference 
and brain sparing in a large cohort of 439 short SGA and 196 SGA catch-up subjects. All SGA 
subjects had a postnatal head size below the population mean. Whereas SGA catch-up subjects 
had a head size which was in proportion with their height, short SGA subjects displayed 
extensive brain sparing. Th e most severely SGA born subjects had a smaller postnatal head size 
and less brain sparing when carrying the -1245 A-allele, in contrast to G-allele carriers. 
 Previous studies have shown that the IGF1 gene plays an important role in brain growth 
[24,25]. Lee et al ]24[ demonstrated that transgenic mice overexpressing IGF1 could ameliorate 
brain growth retardation caused by undernutrition, which resulted in a comparable brain 
growth as the well-fed control mice. A reduced IGF1 gene expression has also been associated 
with a reduced brain size in mice whereas IGF1 overexpression gave rise to increased brain 
growth, although the IGF-I level in brain tissue was among the lowest one measured in all body 
tissues [26, 27]. Th is might also be applicable to short SGA subjects having the -1245 A-allele 
which might result in less local IGF-I expression in the brain and a smaller head size. Altogether 
these observations suggest that some short SGA subjects may experience a diff erential, tissue-
dependent IGF1 gene expression which infl uence their head size. 
Clinical implications and conclusions
Previous studies demonstrated that short stature and a small head size are important predictors 
for subnormal intellectual performance [28-30]. We have shown that a small birth size in 
combination with the -1245 A-allele in the IGF1 gene promoter, was asso-ciated with the 
smallest head circumference and less brain sparing in SGA subjects, and especially in short 
SGA subjects. Th ese data implicate that the -G1245A SNP might be an additional factor 
determining subnormal intellectual performance in these short SGA children. Studies are 
needed to investigate the association between the -1245 A-allele and intellectual performance in 
SGA children. Our fi ndings warrant further research into this gene region. Th e -G1245A SNP is 
an easy to determine gene variant by Taqman assay compared to the -841(CA)n/192bp VNTR 
which is mainly determined by a more laborious technique to analyze VNTRs (Genescan).
IGF1R gene
Genetic polymorphisms in the IGF1R gene and postnatal weight 
Th e insulin-like growth factor 1 receptor (IGF1R) gene plays an important role in pre- and 
postnatal growth and its promoter has multiple transcription factor binding sites aff ecting IGF1R 
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protein expression. We investigated whether the rs4965425 and rs1319868 polymorphisms in 
the IGF1R gene promoter were associated with postnatal growth in a large population of 635 
SGA subjects. Short SGA subjects with the rs4965425 C-allele had a lower weight and BMI due 
to postnatal catch-down in weight compared to non-carriers. Th is was most pronounced in 
those who were born with both a birth weight and birth length < -2.00 SDS. Our data show that 
the IGF1R rs4965425 promoter SNP might have a role in modifying postnatal weight, thereby 
potentially infl uencing the risk for cardiovascular disease. Our study was the fi rst association 
study investigating IGF1R promoter polymorphisms in SGA subjects. 
Clinical implications and conclusions
Our fi ndings demonstrate that genetic variations in the IGF1R gene promoter associate with 
postnatal loss in weight of short SGA subjects. Th is was most pronounced in those who were 
born with both a birth weight and birth length < -2.00 SDS. Th ese data stimulate further research 
into the identifi cation of predictors of postnatal weight development in SGA children.
Figure 2. Associations between IGF1R gene variations and weight development in our SGA populations.
INS gene region
Genetic polymorphisms in the INS gene region and blood pressure
Th e INS gene region is an important region with regard to fetal growth, coronary heart disease 
and hypertension [31-39], although also confl icting results have been reported [40-43]. Th ree 
polymorphisms in the insulin gene region were studied, the rs7924316 SNP, the rs3842748 SNP 
and the insulin VNTR (rs689). Our data show that SGA subjects have a higher blood pressure 
when carrying the class I INS VNTR and especially, the rs7924316 G-allele which is the major 
allele. Although rapid postnatal growth is a well-known factor associated with a higher blood 
pressure in later life [44,45], our study showed that there is also a polymorphism in the INS 
gene region which has an independent infl uence on blood pressure in SGA subjects, next to 
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rapid postnatal growth. Our results are in line with previous studies showing that children with 
a postnatal catch-up in weight (> 0.67 SDS), had a higher BMI at age 7 when having the class 
I-allele vs. the class III/III genotype [37]. 
Clinical implications and conclusions
Our data showed that the rs7924316 SNP is an independent contributing factor in blood pressure 
regulation of subjects born SGA, particularly in those with postnatal weight gain. Th is study 
shows, for the fi rst time, that there is a polymorphism in the INS gene region which infl uences 
blood pressure in SGA subjects. Further studies are needed to investigate the infl uence of the 
rs7924316 G-allele on protein expression, before a fi nal conclusion can be drawn and clinical 
implications can be addressed.
Figure 3. Associations between INS gene region variations and blood pressure in our SGA populations.
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Part 3. Copy number variants of growth-related genes in short SGA 
subjects
Relatively large deletions and duplications in 18 growth-related genes
We investigated whether copy number variations in growth-related genes (SHOX, GH1, GHR, 
IGF1, IGF1R, IGF2, IGFBP1-6, NSD1, GRB10, STAT5B, ALS, SOCS2, SOCS3) were present in 
a group of 100 children born SGA with persistent short stature. Our data showed that IGF1R 
haploinsuffi  ciency was present in 2 out of 100 short SGA children and that no other copy number 
variants were found in the 17 other growth-associated genes in the rest of the population. 
Short SGA children with IGF1R haploinsuffi  ciency
One patient had a heterozygous deletion of the complete IGF1R gene (15q26.3, exon 1-21) 
including distally fl anking sequences. Th e other patient was heterozygous for a deletion 
comprising exon 3-21 of the IGF1R gene which extended into the telomeric region. Both 
children moderately increased their height during GH treatment. Th ey both had a relatively 
mild phenotype compared to other patients who were reported with a terminal IGF1R deletion. 
Th e latter patients had lung hypoplasia, atrial and/or ventricular septum defects, hypoplastic 
left  atrial or ventricular heart, dextrocardia and diaphragmatic hernia [46-52]. We believe that 
these clinical signs are primarily linked to other genes in the area, as in children with an IGF1R 
mutation a much smaller number of additional characteristics have been observed [53-56]. Poot 
et al indicated IGF1R fl anking genes which might be responsible for the phenotypic variation in 
children with an IGF1R deletion [47]. 
Clinical implications and conclusions
Our study showed that IGF1R haploinsuffi  ciency was present in 2 out of 100 short SGA children. 
Th e combination of a small birth size, short stature, small head size, a relatively high IGF-I level, 
developmental delay and micrognathia is suggestive for an IGF1R deletion in SGA children. We 
recommend that children with these characteristics are tested for an IGF1R deletion, especially 
because GH therapy has shown to have a benefi cial eff ect on their height. Multiplex ligation-
dependent probe amplifi cation (MLPA) has shown to be a valuable tool in identifying these deletions. 
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Part 4. Phenotypic characteristics of short SGA, SGA catch-up and ISS 
subjects 
Spontaneous and GH-induced growth of short SGA, SGA catch-up and ISS subjects: 
relation with gestational hypertension, smoking and alcohol. Th e Network of Studies 
into Genes in Growth (NESTEGG)
Th e network of studies into genes in growth (NESTEGG) is a growth genomics project in 
which subjects born small for gestational age (SGA) with and without a postnatal short stature, 
subjects with idiopathic short stature (ISS) and controls are investigated. Our study showed that 
birth length and postnatal height were signifi cantly diff erent between short SGA, SGA catch-
up, ISS and control subjects. Short SGA subjects increased 0.2 SDS more in height than ISS 
subjects during 1 year of GH treatment. Postnatal catch-up growth of short SGA subjects was 
most pronounced when their mothers had gestational hypertension. Gestational hypertension, 
smoking and alcohol use were not related to the ISS phenotype although maternal smoking 
during gestation was associated with less postnatal growth decline and more growth during 1 
year of GH treatment. Th ese observations are in line with previous studies which have shown 
that gestational hypertension and maternal smoking both result in prenatal growth restriction 
[57,58]. Other support comes from studies which show that although gestational hypertension 
and maternal smoking have a diff erent mode of action, both would result in maternal endothelial 
dysfunction and abnormal placentation, which are common features in fetal growth restriction 
[58-61].
Clinical implications and conclusions
Our study has shown that prenatal growth restriction of SGA subjects is related to gestational 
hypertension and smoking. Furthermore, we have described for the fi rst time the growth-
phenotype of short SGA, SGA catch-up and ISS subjects in a large, European study. Hereby, it 
is in a next step, possible to identify genes that contribute to foetal or postnatal growth. Th ese 
genetic factors may allow for a more specifi c diagnosis and may be the base of more targeted 
treatment possibilities. In addition, novel genetic factors aff ecting growth might give rise to new 
treatment modalities. 
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General conclusions
Th e studies described in this thesis were performed to obtain insight in genetic and environmental 
factors which are important in pre- and postnatal growth disorders and specifi cally in children 
born small for gestational age (SGA) with or without postnatal catch-up growth. We studied 
frequent genetic polymorphisms, and low frequent copy number variants. Our data show that 
these polymorphisms had limited relations with the SGA-related phenotype. Th e study into 
relatively large deletions and duplications in 18 growth-related genes, illustrated that only 
2 out of 100 short SGA children had such a copy number variant. Th eir phenotypes were 
not related to extreme fetal and postnatal growth. Our study concerning gestational factors 
showed that gestational hypertension and smoking were related to both short SGA and SGA 
catch-up children. Th e extent of postnatal catch-up growth was partially related to these 
gestational factors. In conclusion, the studies in this thesis have shown that diverse genetic 
and environmental factors play a role in SGA and postnatal catch-up growth, making them so-
called complex genetic phenomena.
 In the fi rst part of this thesis, we showed that subclassifi cation of SGA based on birth 
length, birth weight and head circumference at birth, may provide a useful framework to explore 
the mechanisms underlying diff erences in the extent of spontaneous postnatal growth that are 
observed in a population of short SGA children. Such a subclassifi cation of short SGA children 
might also be useful for elucidating underlying genetic or environmental causes of SGA and 
future risk profi les with regard to adult diseases. 
 Th e second part of this thesis demonstrated that a small birth size in combination with 
the -1245 A-allele of the IGF1 promoter polymorphism, was associated with the smallest head 
circumference and less brain sparing in the group of SGA subjects, and especially in short SGA 
subjects (Figure 1). In addition, the C-allele of the rs4965425 SNP in the IGF1R gene promoter, 
associated with postnatal catch-down in weight development of short SGA subjects. Th is was 
most pronounced in those who were born with both a birth weight and birth length < -2.00 
SDS (Figure 2). Th e INS rs7924316 SNP turned out to be a contributing factor in blood pressure 
regulation of subjects born SGA, particularly in those with postnatal catch-up in weight (Figure 
3).
 Th e third part of this thesis reports that IGF1R haploinsuffi  ciency was present in only 
2 out of 100 short SGA children. None had deletions or duplications in the other 17 genes. Th e 
combination of a small birth size, short stature, small head size, a relatively high IGF-I level, 
developmental delay and micrognathia was suggestive for an IGF1R deletion. Th is is especially 
relevant as our study showed that GH treatment had in contrast to our expectation, a benefi cial 
196 General discussion
eff ect on the linear growth of these children. Our study also showed that SGA children with a 
telomeric IGF1R deletion display a heterogeneous phenotype. 
 Finally, our study showed that prenatal growth restriction of SGA subjects is related to 
gestational hypertension and smoking. Postnatal catch-up growth of short SGA subjects was 
most pronounced when their mothers had gestational hypertension. Gestational hypertension, 
smoking and alcohol use were not related to the ISS phenotype. 
Considerations and directions for future research
Subgrouping of SGA children would increase our knowledge of the variability of the SGA 
phenotype, helping to thereby identify potential predictors which may fi nally lead to improved 
patient care. It is unknown whether SGA subgroups, either based on dysmorphic features, 
intelligence or response to GH treatment, indicate the etiology of the initial growth disorder.
 Genetic studies into polymorphisms in genes of SGA children can be performed by 
candidate-gene and genome-wide approaches. Currently, candidate-gene approaches have not 
been able to fi nd important genetic variations in the genes which may serve as predictors for 
postnatal growth and metabolism. Th is might be due to the very heterogeneous phenotype of 
subjects born SGA. It is likely that when genome-wide approaches are used, the same problem 
will occur. Th erefore we believe that a very detailed phenotypic description is mandatory to 
perform focused genetic research in SGA subjects. Both candidate-gene and genome-wide 
approaches might be tools to identify genes which are specifi c for subgroups of SGA children.
 Genetic studies into mutations and large copy number variants may follow a diff erent 
approach. Our study on copy number variants has shown that the unrestricted inclusion of 
short SGA children was benefi cial, as the children with an IGF1R deletion did not appear to 
have an aberrant growth pattern compared to other short SGA children.
  Pharmacogenetic studies might be interesting to perform in order to clarify the 
genetic background of the wide variation in growth response to GH therapy in these children. 
Both quantitative and qualitative genome-wide approaches can provide new insights in this 
phenomenon. A quantitative approach, like gene expression profi ling, requires however 
clarity on the choice which tissue type and which time moment in growth should be taken, to 
investigate the response to GH therapy. Th ese methodological issues should fi rst be clarifi ed 
before further steps can be taken. 
 Epigenetic studies have been previously performed in the H19-IGF2-INS gene region 
in children with Silver-Russell syndrome as well as in short SGA children [62,63]. It might well 
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be that detailed phenotypic studies regarding dysmorphic features in short SGA children will 
identify Silver-Russell-like phenotypes in the short SGA population. A second approach would 
be to identify diff erential methylation of the H19-IGF2-INS gene region, which may be related 
to the various Silver-Russell-like phenotypes in the short SGA population. 
 In conclusion, the studies described in this thesis aimed to investigate diff erences in 
phenotype, growth, genetic variations and deletions, in children born small for gestational age 
(SGA), either with or without short stature. Th ese and future studies can improve our knowledge 
regarding the etiology of SGA and might generate predictors of spontaneous and GH-induced 
growth. Th is will eventually lead to better counseling and treatment strategies.
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202 Summary
Chapter 1
Th is chapter gives an overview of the defi nitions, prevalence and etiology of SGA born 
children with and without postnatal catch-up growth. In addition, the IGF1, IGF1R and INS 
gene region are described. Several clinical and endocrinological aspects associated with SGA 
are pointed out, including the GH-IGF-IGFBP axis, fetal and postnatal growth, short stature 
and cardiovascular risk factors. It also presents the Dutch genetic study and the Network of 
European Studies in Genes in Growth (NESTEGG). Th an, the investigated genetic variations, 
strategy and techniques in the Dutch study are summarized. At the end of this chapter, the aims 
and outline of the thesis are presented. 
Chapter 2
Short SGA children appear to benefi t from growth hormone (GH) treatment in terms of height 
increment. However, even aft er accounting for diff erences in parental height, age and duration 
of treatment, there appears to be a wide variation in the response to GH treatment that has been 
diffi  cult to explain. We investigated whether subclassifi cation of short SGA children according 
to their birth anthropometrics could delineate diff erences in gestation, type of delivery, postnatal 
growth, response to GH treatment and parental height. 
 SGAL+W+HC children were born aft er the shortest gestational age and more oft en by 
caesarean section than SGAL children (36.3 vs. 38.1 weeks, 68.4 vs. 24.4%). SGAL+W children 
had an intermediate pattern and experienced most gestational hypertension (P = 0.01). At 
birth, SGAL+W+HC children were shorter than SGAL or SGAL+W (-4.12 vs. -2.67 and -3.72 
SDS, P ≤ 0.001). During the fi rst 3 years of life, SGAL+W+HC children exhibited a greater catch-
up in height (0.98 SDS) and HC (1.28 SDS) compared to SGAL (height, -0.06 SDS; HC, -0.30 
SDS) and SGAL+W (height, 0.62 SDS; HC, -0.31 SDS). However, HC SDS remained smaller 
for SGAL+W+HC than the other groups at age 3. Th e groups did not diff er in growth response 
during GH treatment. SGAL children tended to have shorter parents and target height than 
SGAL+W+HC children.
 Our study suggests that subclassifi cation of SGA children with persistent short stature 
according to their birth length, weight and HC, may provide a useful framework to explore 
the mechanisms underlying diff erences in the extent of spontaneous postnatal growth. Such a 
subclassifi cation of short SGA children might also be useful for elucidating underlying genetic 
or environmental causes of SGA and future risk profi les with regard to adult diseases. 
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Chapter 3
In this review, we performed a literature search into genetic association studies of the IGF1 and 
IGF1R gene and SGA-related outcomes. Also, linkage disequilibrium and haplotype studies in 
the IGF1 and IGF1R gene and gene-gene interaction studies were investigated. 
 Th is review showed that many IGF1 polymorphisms have been studied but that the 
192bp CA-repeat in the IGF1 promoter was most likely to associate with SGA-related outcomes. 
Th e region ranging from the promoter until intron 2 is part of a linkage disequilibrium block 
which is important in SGA-related outcomes as all association studies in SGA populations 
report associations with polymorphisms in this area. Confl icting results arise especially in 
“normal” cohorts and with associations between birth size measures and polymorphisms 
in this gene region. Th ere was only one study which evaluated associations between IGF1R 
polymorphisms and SGA-related outcomes such as birth size and insulin sensitivity. In this 
study, no associations could be demonstrated. Limited gene-gene interaction studies have been 
performed with SGA-related outcomes and no associations were found. None of these genetic 
association studies are currently suitable as a diagnostic measure because no therapeutic 
outcome has been identifi ed yet. 
Chapter 4
It was unknown whether the IGF1 gene 192bp polymorphism associated with gestational age, 
birth head circumference and postnatal growth in short SGA children. Also it was unknown 
whether the 192bp allele associated with the response to GH treatment and whether nearby 
genetic variants might function as a genetic marker for the 192bp allele. We evaluated whether 
anthropometric measurements at birth, during postnatal growth, and during GH treatment, 
were associated with IGF1 gene polymorphisms and haplotypes in a population of 201 short 
SGA children. Th e -1245 A-allele was identifi ed as a marker-allele for the well-known -841(CA)
n/ non192bp-allele, both part of Haplotype 2. Th e -1245 A-allele was not associated with head 
circumference at birth, but was associated with a postnatal 0.3 SDS smaller head circumference 
at age 1-3. Th e -1245 A-allele was also associated with a 1 week shorter gestational age which 
explained the association with a smaller absolute birth size. No associations were found with 
gestational age-adjusted birth size, height and weight SDS during postnatal life and with growth 
during GH treatment. In conclusion, the -1245 A-allele in the IGF1 promoter was the only 
polymorphism which associated with a smaller head circumference SDS during spontaneous 
postnatal growth and a shorter gestational age. No other associations were found with birth size 
and growth, neither spontaneously, nor during GH treatment. Th e –G1245A SNP appeared to 
be a marker for the well-known -841(CA)n/192bp polymorphism.
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Chapter 5
It was unknown whether the IGF1 192bp gene polymorphism was related to head size and 
brain sparing in short SGA versus SGA catch-up subjects. In addition, it was unknown whether 
SGA severity modifi es the relation between brain sparing and this genetic polymorphism. We 
investigated 635 SGA subjects of which 439 remained short and 196 had a postnatal height 
> -2.00 SDS for the association between the -G1245A SNP IGF1 gene polymorphism and 
head size. All SGA subjects had a postnatal head size below the population mean (-1.01 SDS, 
P<0.001). Whereas SGA catch-up subjects had a head size which was in proportion with their 
height, short SGA subjects displayed extensive brain sparing (HC SDS minus height SDS: SGA 
CU: 0.01 vs. short SGA: 1.75, P<0.001). Th e most severely SGA born subjects had a 0.4 SDS 
smaller postnatal head size and 0.6 SDS less brain sparing when carrying the -1245 A-allele in 
contrast to G-allele carriers (P = 0.03). Th e association between the -G1245A SNP and head 
size remained signifi cant aft er correction for birth weight SDS and postnatal height SDS (P 
= 0.03). Birth weight SDS, birth length SDS and postnatal height SDS were not related with 
the -G1245A SNP. In conclusion, we observed that the most severely SGA born subjects had a 
0.4 SDS smaller head size and 0.6 SDS less brain sparing when carrying the -1245 A-allele in 
contrast to G-allele carriers, which might be of clinical relevance. Our study has shown for the 
fi rst time that the -G1245A SNP is related to postnatal head size in SGA subjects regardless of 
their postnatal growth. 
Chapter 6
It was unknown whether IGF1R gene polymorphisms in the promoter were associated with 
postnatal growth of SGA subjects. We investigated whether haplotypes of two single nucleotide 
polymorphisms (SNPs) in the IGF1R gene promoter, rs4965425 and rs1319868, were associated 
with postnatal growth in 635 SGA subjects (439 short SGA, 196 catch-up SGA). Th e rs4965425 
and rs1319868 SNPs were in complete linkage disequilibrium (D’ = 1.00, R2 = 0.14). Th e minor 
allele frequency of the rs1319868 SNP was signifi cantly higher in the SGA population compared 
to controls. Haplotype 1, consisting of the rs4965425 C-allele and rs1319868 G-allele, was 
associated with a 0.4 SDS lower weight, BMI and catch-down in weight in short SGA subjects. 
Short SGA subjects carrying Haplotype 1 and with a birth length and -weight < -2.00 SDS, 
had a 0.8 SDS lower postnatal weight and BMI, and the largest postnatal catch-down in weight 
compared to non-carriers (P = 0.002, P = 0.002 and P = 0.02, respectively). Th e rs4965425 
C-allele drove these associations. Growth of SGA catch-up subjects was not associated with any 
SNP. In conclusion, short SGA subjects with the rs4965425 C-allele have a lower weight and BMI 
due to postnatal catch-down in weight compared to non-carriers. Th is was most pronounced 
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in those who were born with both a birth weight and birth length < -2.00 SDS. Our fi ndings 
suggest that genetic variations in the IGF1R gene promoter contribute to weight development 
of short SGA subjects. Studies are warranted to identify the risk for cardiovascular disease in 
short SGA rs4965425 T-allele carriers.
Chapter 7
Th e INS gene region has been recognized as an important region in relation to diseases in later 
life. Th e insulin minisatellite (INS VNTR, rs689) class III, has been associated with variations in 
birth size, obesity, type I and type II diabetes mellitus and polycystic ovary syndrome. However, 
other studies could not demonstrate that the INS VNTR was associated with accelerated weight 
gain, reduced beta cell function or adiposity. We determined whether haplotypes of three 
polymorphisms in the insulin gene region, rs7924316, rs3842748 and the INS VNTR, associate 
with blood pressure in 635 SGA subjects (439 short SGA and 196 SGA catch-up subjects). 
 All polymorphisms were in high linkage disequilibrium (D’ = 96-100, R2 = 32-68). SGA 
catch-up subjects had a signifi cantly higher rs7924316 T-allele (P = 0.007) and rs689 T-allele (P 
= 0.03) frequency than short SGA subjects. Th e association between the rs7924316 and the INS 
VNTR and systolic blood pressure was most pronounced in SGA catch-up subjects (P=0.003 
and P = 0.007). Th ese associations were not seen in short SGA subjects. SGA catch-up subjects 
with Haplotype 1, consisting of the rs7924316 G-allele, rs3842748 G-allele and the class I 
INS VNTR, had a 0.6 SDS higher systolic and 0.5 SDS higher diastolic blood pressure. Th e 
rs7924316 G-allele drove these associations. Th e rs7924316 and the INS VNTR were associated 
with systolic blood pressure in the total SGA population (P = 0.05 and P = 0.007) and these 
associations remained signifi cant aft er correction for change in weight and age. Th e association 
of the rs7924316 and the INS VNTR with blood pressure, was most pronounced in subjects 
with postnatal weight gain (> 0.67 SDS: P = 0.006 and P =0 .01). Our study has shown that the 
rs7924316 SNP is a contributing factor in blood pressure development of subjects born SGA, 
particularly in those with postnatal weight gain. Th is study shows for the fi rst time that there is 
a polymorphism in the INS gene region which independently infl uences blood pressure in SGA 
subjects. 
Chapter 8
Genetic causes have only been found in a very small proportion of short SGA children, including 
point-mutations and deletions in the IGF1 and IGF1R genes. Th e availability of the complete 
sequence of the human genome and the introduction of high throughput DNA scanning 
techniques provides us with novel tools to investigate the genetic basis of short stature. In this 
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study we used MLPA to rapidly investigate whether copy number variations in growth-related 
genes (SHOX, GH1, GHR, IGF1, IGF1R, IGF2, IGFBP1-6, NSD1, GRB10, STAT5B, ALS, SOCS2, 
SOCS3) were present in a group of 100 children born SGA with persistent short stature. We 
found two short SGA children with a de novo IGF1R deletion. No deletions or insertions were 
found in the other genes. Patient A had a heterozygous deletion of the complete IGF1R gene 
(15q26.3, exon 1-21) including distally fl anking sequences. Surprisingly, she also had a low 
IGF-I level (-2.78 SDS), probably because of a co-existing growth hormone (GH) defi ciency. 
In the DNA of patient B, heterozygosity for a deletion comprising exon 3-21 of the IGF1R gene 
was detected which extended further into the telomeric region. Both children increased their 
height during GH treatment, with a GH dose of 1 mg/m2/day (Patient A: aft er 4 yrs GH: delta 
height +1.65 SD; Patient B: aft er 4 yrs GH: delta height +1.69 SD) and continue to receive GH 
until their adult height will be attained. 
 We have shown that IGF1R haploinsuffi  ciency was present in 2 out of 100 short SGA 
children. Th is study also illustrated that the heterogeneity in phenotype in case of IGF1R 
haploinsuffi  ciency. Th e combination of a small birth size, short stature, small head size, 
relatively high IGF-I level, developmental delay and micrognathia is suggestive for an IGF1R 
deletion. Since GH therapy leads to a moderate catch-up growth of ~1.0 SD in the fi rst year, 
we recommend that an IGF1R deletion is ruled out in SGA children with a persistent short 
stature. Particularly, if small birth size, short stature, small head size, relatively high IGF-I level, 
developmental delay and micrognathia are present. Th e multiplex ligation-dependent probe 
amplifi cation (MLPA) has shown to be a valuable tool in rapidly identifying these relatively 
large deletions in short SGA children. 
Chapter 9
Previous studies have shown that gestational hypertension, maternal smoking and gestational 
alcohol infl uence pre- and postnatal growth. However, it is unknown to what extent these 
gestational factors infl uence spontaneous postnatal and GH-induced growth in short SGA, 
SGA catch-up, ISS and control subjects. To determine postnatal and GH-induced growth and 
their relation with maternal hypertension, smoking and alcohol during gestation, 464 short 
SGA, 336 SGA catch-up, 464 ISS and 724 control subjects were investigated. GH treatment data 
were available of 262 short SGA and 109 ISS prepubertal subjects. Birth length and postnatal 
height were signifi cantly diff erent between short SGA, SGA catch-up, ISS and control subjects 
(short SGA: -2.88 vs. -2.82 SDS, SGA catch-up: -2.50 vs. -0.49 SDS, ISS: -0.59 vs. -2.49 SDS 
and controls: -0.01 vs. 0.05 SDS, respectively). Short SGA subjects increased 0.2 SDS more in 
height than ISS subjects during 1 year of GH treatment (P < 0.001). Mothers of SGA catch-
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up subjects had more gestational hypertension than mothers of short SGA, ISS and control 
subjects (27.9% vs. 16.4%, 6.0% and 12.3%, P < 0.001). Mothers of short SGA subjects smoked 
more during gestation than mothers of ISS and control subjects (35.1% vs. 20.3% and 23.5%, 
P<0.001). Short SGA subjects increased more in height when their mothers had gestational 
hypertension compared to short SGA subjects without (spontaneous growth: 0.64 SDS vs. -0.06 
SDS, P < 0.001). 
 In conclusion, our study has shown that prenatal growth restriction and postnatal 
growth of SGA subjects are related to gestational hypertension and smoking. Postnatal catch-
up growth of short SGA subjects was most pronounced when their mothers had gestational 
hypertension. Gestational hypertension, smoking and alcohol use were not related to the ISS 
phenotype although maternal smoking during gestation was associated with less postnatal 
growth decline and more growth during 1 year of GH treatment. 
Chapter 10
In the general discussion, we discuss our fi ndings in relation to the current literature. We end 
this chapter with general conclusions and suggestions for future research.

Chapter 12
Summary in Dutch
Samenvatting
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Hoofdstuk 1
Dit hoofdstuk beschrijft  de prevalentie van kinderen die met een te kleine lengte en/of laag 
gewicht ten opzichte van de zwangerschapsduur werden geboren (SGA) en die daarna ofwel 
te klein zijn gebleven ofwel een lengte binnen het “normale” bereik kregen. Tevens worden 
de defi nities en mogelijke oorzaken van SGA geboorte beschreven. Vervolgens worden het 
insuline-achtige groeifactor1 gen (IGF1), het IGF1-receptor gen (IGF1R) en de insuline gen 
regio besproken, zo ook klinische en endocrinologische aspecten die met SGA samenhangen 
zoals, de GH-IGF-IGFBP as, foetale en postnatale groei, een te kleine lengte en risicofactoren 
voor hart- en vaatziekten. Ook de Nederlandse en de Europese studie (NESTEGG) naar genen 
en groei worden gepresenteerd. Tenslotte wordt een overzicht gegeven van de doelstellingen van 
dit proefschrift  en wordt de opzet van de Nederlandse genetische studie en de NESTEGG studie 
besproken, zo ook de belangrijkste genetische technieken die in de studies werden toegepast. 
Hoofdstuk 2
SGA geboren kinderen met een te kleine lengte (short SGA) werden geclassifi ceerd aan de hand 
van de geboortelengte, het geboortegewicht en de hoofdomtrek bij de geboorte. De samenhang 
tussen deze classifi catie en factoren als: de zwangerschapsduur, de bevalling, de postnatale 
groei, de groei tijdens groeihormoon (GH) behandeling en de lengte van de ouders, werden 
onderzocht. Kinderen met zowel een geboortelengte, geboortegewicht als hoofdomtrek bij de 
geboorte onder de -2,0 standaard deviatie score (SDS) (SGAL+W+HC), werden na een kortere 
zwangerschapsduur geboren en vaker na een keizersnede dan kinderen die alleen kort waren bij 
de geboorte (36,3 weken versus 38,1 weken en 68,4% versus 24,4%) (SGAL). Kinderen met zowel 
een korte geboortelengte als een laag geboortegewicht (SGAL+W) toonden een tussenliggend 
patroon en hun moeder had het meest frequent zwangerschapshypertensie (P=0,01). Bij de 
geboorte waren SGAL+W+HC kinderen korter dan de SGAL en SGAL+W kinderen (-4,12 versus 
-2,67 en -3,72 SDS, P ≤ 0,001). Tijdens de eerste drie levensjaren, hadden SGAL+W+HC kinderen 
een betere groei in lengte (0.98 SDS) en hoofdomtrek (1,28 SDS) in vergelijking met SGAL 
(lengte, -0,06 SDS; hoofdomtrek, -0,30 SDS) en SGAL+W (lengte, 0,62 SDS; hoofdomtrek, 
-0,31 SDS) kinderen. Desalniettemin bleef de hoofdomtrek van SGAL+W+HC kinderen kleiner 
dan die van de andere groepen op de leeft ijd van 3 jaar. De groepen verschilden niet in hun 
groeirespons tijdens GH-behandeling. SGAL kinderen hadden niet-signifi cant kleinere ouders 
en een kleinere streefl engte dan SGAL+W+HC kinderen. 
 Een onderverdeling van kleine SGA kinderen op basis van de geboortelengte, het 
geboortegewicht en de hoofdomtrek bij de geboorte, is een methode om mechanismen die 
verschillen in spontane groei veroorzaken, te onderzoeken. Deze onderverdeling van kleine 
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SGA kinderen maakt het mogelijk om onderliggende erfelijke- en omgevingsfactoren, die een 
rol spelen bij het SGA geboren worden, te bestuderen. Dit betreft  ook eventuele risico’s die deze 
kinderen hebben op het ontstaan van ziekten in het volwassen leven.
Hoofdstuk 3
In dit hoofdstuk wordt een literatuuronderzoek beschreven naar genetische associatie studies 
van het IGF1 en IGF1R gen en SGA-gerelateerde uitkomsten. Dit betrof ook resultaten van 
“linkage disequilibrium” (LD) en haplotypes van deze genen, alsmede gen-gen interacties. 
Het literatuuronderzoek laat zien dat de zogenaamde “192bp CA-repeat” in de IGF1 promoter 
frequent is geassocieerd met SGA-gerelateerde uitkomsten. De promoter regio tot aan 
intron 2 is onderdeel van een LD-blok waarmee frequent associaties met groei-gerelateerde 
uitkomsten worden beschreven. Tegenstrijdige resultaten worden met name bij “normale” 
onderzoekspopulaties gezien en bij associaties met het absolute gewicht bij de geboorte. 
Associaties tussen genetische polymorfi smen in het IGF1R gen en SGA-gerelateerde uitkomsten 
werden slechts eenmaal onderzocht, deze konden toen niet worden aangetoond. 
Hoofdstuk 4
Het was onbekend of het zogenaamde “192bp CA-repeat” polymorfi sme in de IGF1 promoter, 
geassocieerd is met de zwangerschapsduur, geboorte hoofdomtrek en postnatale groei 
van kleine SGA kinderen. Het was ook onbekend of het zogenaamde “192bp CA-repeat” 
polymorfi sme, geassocieerd was met de groeirespons tijdens GH-behandeling, en of genetische 
polymorfi smen die nabij gelegen zijn, als een marker voor dit polymorfi sme kunnen dienen. 
Wij onderzochten of de lengte, het gewicht en de hoofdomtrek bij de geboorte, de spontane 
postnatale groei en de groei tijdens GH-behandeling geassocieerd waren met IGF1 gen 
polymorpfi smen en haplotypes in 201 te kleine SGA kinderen. Het A-allel van de –G1245A 
SNP bleek een marker-allel te zijn voor het “192bp CA-repeat” polymorfi sme, en beiden waren 
onderdeel van Haplotype 2. Het -1245 A-allel was niet geassocieerd met de hoofdomtrek bij de 
geboorte maar wel met een 0,3 SDS kleinere hoofdomtrek op de leeft ijd van 1-3 jaar. Het -1245 
A-allel was ook geassocieerd met absolute geboortemetingen, hetgeen verklaard kon worden 
door een associatie tussen het -1245 A-allel en een één week kortere zwangerschapsduur. Er 
werden geen associaties gevonden met de geboorte metingen die waren gecorrigeerd voor de 
zwangerschapsduur, met de lengte en gewicht SDS tijdens het postnatale leven en met de groei 
tijdens GH-behandeling. Concluderend was het -1245 A-allel in de IGF1 gen promoter het 
enige polymorfi sme dat geassocieerd was met een kleinere hoofdomtrek tijdens de spontane 
postnatale groei en met een kortere zwangerschapsduur. Er werden geen andere associaties 
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gevonden met metingen bij de geboorte, de spontane postnatale groei en de groei tijdens GH-
behandeling. De –G1245 SNP bleek een marker te zijn voor het bekende “192bp CA-repeat” 
polymorfi sme. 
Hoofdstuk 5
Het was onbekend of het zogenaamde “192bp CA-repeat” polymorfi sme in de IGF1 promoter, 
gerelateerd was aan de hoofdomtrek en de mate waarin het hoofd gespaard blijft  van SGA 
geboren kinderen met een te kleine lengte (short SGA) of zonder een te kleine lengte (SGA 
catch-up). Een gespaard hoofd houdt in dat ondanks de verminderde (prenatale) groei van het 
lichaam, het hoofd een normale groei heeft  weten te behouden waardoor het ook relatief groter 
is dan de rest van het lichaam is. Ook was het onbekend of de ernst van het SGA geboren zijn, 
een relatie had met de associatie tussen het genetische polymorfi sme en de mate waarin het 
hoofd gespaard blijft . Wij onderzochten 635 SGA kinderen waarvan 439 een te kleine lengte 
hadden en 196 een inhaalgroei hadden tot een lengte boven de -2,0 SDS. Alle SGA kinderen 
hadden een postnatale hoofdomtrek onder het gemiddelde (-1,01 SDS, P<0,001). Terwijl SGA 
catch-up kinderen met een normale lengte na de geboorte een hoofdomtrek hadden die in 
proportie was met hun lengte, hadden SGA kinderen met een te kleine lengte een gespaard 
hoofd (hoofdomtrek-lengte: SGA catch-up: 0,01 versus short SGA: 1,75 SDS, P<0,001). De 
meest ernstig SGA geboren kinderen hadden een 0,4 SDS kleinere postnatale hoofdomtrek en 
een 0,6 SDS minder gespaard hoofd als ze het -1245 A-allel in plaats van het G-allel hadden 
(P=0,03). De associatie tussen het –G1245A polymorfi sme en de hoofdomtrek bleef statistisch 
signifi cant na correctie voor het geboortegewicht en de postnatale lengte SDS (P<0,001). De 
lengte en het gewicht bij de geboorte, en de postnatale lengte SDS bleken niet gerelateerd aan 
de –G1245A SNP. 
Concluderend, de meest ernstig geboren SGA kinderen bleken een 0,4 SDS kleinere hoofdomtrek 
en 0,6 SDS minder gespaard hoofd te hebben als ze het -1245 A-allel hadden in tegenstelling 
tot -1245 G-allel dragers hetgeen klinische relevant is. Deze studie laat ook voor de eerste keer 
zien dat het –G1245A polymorfi sme gerelateerd is aan de postnatale hoofdomtrek vam de totale 
groep SGA kinderen, onafh ankelijk van de mate van postnatale lengtegroei. 
Hoofdstuk 6
Het was onbekend of polymorfi smen in de promoter van het IGF1R gen geassocieerd waren met 
de postnatale groei van SGA kinderen. We onderzochten of haplotypes van twee polymorfi smen, 
de rs4965425 en rs1319868, in de IGF1R gen promoter geassocieerd waren met de postnatale 
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groei van 635 SGA kinderen waarvan 439 een te kleine lengte hadden en 196 een inhaalgroei 
hadden tot een lengte boven de -2,0 SDS. De rs4965425 en rs1319868 polymorfi smen waren 
in compleet “linkage disequilibrium” (D’=1,00, R2= 0,14). De frequentie van het minst 
voorkomende allel van rs1319868, was signifi cant hoger in de totale SGA populatie dan in 
controles. Het rs4965425 C-allel was geassocieerd met een 0,3 SDS lager gewicht en “body mass 
index” (BMI) en lagere postnatale gewichtstoename in te kleine SGA kinderen, vergeleken met 
de kinderen die het T-allel hadden. Er waren geen associaties met rs1319868. De combinatie 
van het rs4965425 C-allel en het rs1319868 G-allel (Haplotype 1), was geassocieerd met een 0,4 
SDS lager gewicht, BMI en een lagere postnatale gewichtstoename in te kleine SGA kinderen. 
Te kleine SGA kinderen met een geboortelengte en geboortegewicht ≤ -2,0 SDS, hadden een 0,8 
SDS lager postnataal gewicht, BMI en lagere postnatale gewichtstoename, in vergelijking met 
niet-dragers (P= 0,002, P=0,002 en P=0,02, respectievelijk). Het rs4965425 C-allel dreef deze 
associaties. De groei van SGA kinderen met een normale lengte was niet geassocieerd met dit 
polymorfi sme. Concluderend, te kleine SGA kinderen die drager zijn van het rs4965425 C-allel, 
hebben een lager gewicht en BMI door een lagere postnatale gewichtstoename vergeleken met 
niet-dragers. Dit was het meest uitgesproken in de kinderen die zowel een geboortelengte als 
een geboortegewicht onder de -2,0 SDS hadden. Onze bevindingen suggereren dat genetische 
variaties in de IGF1R gen promoter een rol hebben bij de ontwikkeling van het lichaamsgewicht 
van te kleine SGA kinderen. Onze studie laat zien dat onderzoek naar het risico op hart- en 
vaatziekten bij te kleine SGA kinderen met het rs4965425 T-allel, geïndiceerd is.
Hoofdstuk 7
De insuline gen regio is een belangrijke regio met betrekking tot genetische variaties en 
associaties met ziekten in het volwassen leven. De insuline minisatelliet (INS VNTR, rs689) 
klasse III is geassocieerd met geboorte antropometrie, obesitas, type I and type II diabetes 
mellitus en polycysteus ovarium syndroom. Desalniettemin konden andere studies geen relatie 
aantonen tussen de INS VNTR en een versnelde gewichtstoename, verminderde beta-cel 
functie of adipositas. Wij onderzochten of haplotypes van de drie polymorfi smen in de insuline 
gen regio, rs7924316, rs3842748 and the INS VNTR, geassocieerd waren met de bloeddruk van 
635 SGA kinderen waarvan 439 een te kleine lengte hadden en 196 een inhaalgroei hadden tot 
boven de -2,0 SDS. Alle polymorfi smen waren in compleet “linkage disequilibrium” (D’= 96-
100, R2= 32-68). SGA kinderen met inhaalgroei tot boven de -2,0 SDS hadden een signifi cant 
hogere rs7924316 T-allel (P=0,007) en rs689 T-allel (P=0,03) frequentie dan SGA kinderen met 
een te kleine lengte. De associatie tussen de rs7924316, de INS VNTR en systolische bloeddruk, 
was het meest uitgesproken in SGA kinderen met inhaalgroei tot boven de -2,0 SDS (P=0,003 
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en P=0,007). Deze associaties waren niet aanwezig bij de SGA kinderen met een te kleine 
lengte. SGA kinderen met een inhaalgroei tot boven de -2,0 SDS en Haplotype 1, hadden een 
0,6 SDS hogere systolische en 0,5 SDS hogere diastolische bloeddruk. Het rs7924316 G-allel 
dreef deze associaties. Rs7924316 en de INS VNTR waren ook geassocieerd met de systolische 
bloeddruk in de totale SGA populatie (P= 0,05 en P= 0,007, respectievelijk), en deze associaties 
bleven signifi cant na correctie voor de gewichtsverandering en de leeft ijd. De associatie tussen 
de bloeddruk, rs7924316 en de INS VNTR, was het meest uitgesproken in kinderen met een 
postnatale gewichtstoename (>0,67 SDS: P=0,006 en P=0,01). Onze studie heeft  laten zien dat het 
rs7924316 polymorfi sme bijdraagt aan bloeddruk regulatie van kinderen die SGA zijn geboren 
en met name bij kinderen met een grotere postnatale gewichtstoename. Deze studie heeft  voor 
het eerst laten zien dat er een polymorfi sme in de insuline gen regio is dat de bloeddruk van 
SGA kinderen beïnvloedt. 
Hoofdstuk 8
Erfelijke oorzaken van SGA geboorte zijn in een beperkt deel van de kinderen met een te 
kleine lengte vastgesteld. Dit betreft  onder meer puntmutaties en deleties in het IGF1 en IGF1R 
gen. De beschikbaarheid van de complete menselijke DNA sequentie en de introductie van 
“high throughput” DNA technieken, hebben nieuwe middelen geleverd om de genetische 
oorzaken van een te kleine lengte te onderzoeken. In deze studie is de “multiplex-dependent 
probe amplifi cation” (MLPA) techniek gebruikt om snel te onderzoeken of er veranderingen 
in het aantal genkopieën aanwezig waren in een groep van 100 SGA geboren kinderen met 
een te kleine lengte. We onderzochten 18 groeigerelateerde genen: SHOX, GH1, GHR, IGF1, 
IGF1R, IGF2, IGFBP1-6, NSD1, GRB10, STAT5B, ALS, SOCS2, SOCS3. We vonden twee 
kinderen met een nieuw-ontstane deletie in het IGF1R gen. Er werden geen veranderingen 
in de andere groeigerelateerde genen gezien. Patiënt A had een heterozygote deletie van het 
complete IGF1R gen (15q26.3, exon 1-21) inclusief de distale sequentie. Tot onze verrassing 
bleek Patiënt A een laag IGF-I gehalte in het bloed te hebben (-2,78 SDS), waarschijnlijk door 
een gelijktijdige groeihormoon defi ciëntie. In het DNA van patiënt B werd een heterozygote 
deletie gezien van exon 3-21 van het IGF1R gen ook inclusief de distale sequentie. Beide 
kinderen hadden een versnelde lengtegroei tijdens GH-behandeling, bij een GH dosis van 1 
mg/m2/dag (Patiënt A: na 4 jaar GH: delta lengte +1,65 SDS; Patiënt B: na 4 jaar GH: delta 
lengte +1,69 SDS). Onze studie heeft  laten zien dat IGF1R haploinsuffi  ciëntie aanwezig was 
bij twee van de honderd SGA kinderen met een te kleine lengte. Deze studie liet zien dat de 
combinatie van SGA geboren zijn, een te kleine lengte, een te kleine hoofdomtrek, relatief 
hoge IGF-I niveaus, ontwikkelingsachterstand, een kleine onderkaak en laaggeïmplanteerde 
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duimen, suggestief is voor een deletie van het IGF1R gen. Aangezien GH-behandeling leidt 
tot een redelijke inhaalgroei van ~1,0 SDS in het eerste jaar van behandeling, adviseren wij om 
SGA kinderen met een te kleine lengte te testen op een IGF1R deletie, zeker als de genoemde 
kenmerken aanwezig zijn. De MLPA-techniek blijkt een waardevolle methode te zijn om snel 
veranderingen in het aantal kopieën van genen te onderzoeken in SGA kinderen met een te 
kleine lengte. 
Hoofdstuk 9
Eerdere studies hebben laten zien dat zwangerschapshypertensie alsmede roken en alcoholgebruik 
tijdens de zwangerschap, de pre- en postnatale groei beïnvloeden. Desalniettemin is onbekend 
in hoeverre deze invloeden tijdens de zwangerschap, de spontane postnatale groei en de GH-
geïnduceerde groei beïnvloeden van kinderen met en zonder een te kleine lengte (short SGA 
versus SGA catch-up), kinderen met een idiopathisch te kleine lengte (ISS) en controles. 
In dit hoofdstuk worden de eerste resultaten van het Netwerk van Europese Studies naar Genen 
in Groei (NESTEGG) beschreven. Deze studie vond plaats in Nederland, Frankrijk, Duitsland 
en het Verenigd Koninkrijk. Deze studie is opgezet om erfelijke- en omgevingsfactoren die de 
pre- en postnatale groei beïnvloeden van te kleine SGA, SGA catch-up, ISS en controle kinderen, 
te bestuderen. Om de postnatale en de GH-geïnduceerde groei te bepalen en de relatie met 
zwangerschapshypertensie en roken en alcoholgebruik tijdens de zwangerschap, werden 464 te 
kleine SGA, 336 SGA catch-up, 464 ISS en 724 controle kinderen onderzocht. Gegevens over 
GH-behandeling waren beschikbaar van 262 short SGA en 109 ISS kinderen. De geboortelengte 
en de postnatale lengte waren signifi cant verschillend tussen de vier groepen (short SGA: -2,88 
en -2,82 SDS, SGA catch-up: -2,50 en -0,49 SDS, ISS: -0,59 en -2,49 SDS en controles: -0,01 en 
0,05 SDS, respectievelijk). Short SGA kinderen hadden 0,2 SDS meer lengte-groei tijdens 1 jaar 
GH-behandeling dan ISS kinderen (P<0,001). Moeders van SGA catch-up kinderen hadden 
frequenter zwangerschapshypertensie dan moeders van short SGA, ISS of controle kinderen 
(27,9% versus 16,4%, 6,0% en 12,3%, P<0,001). Moeders van short SGA kinderen rookte 
frequenter tijdens de zwangerschap dan moeders van ISS en controle kinderen (35,1% versus 
20,3% en 23,5%, P<0,001). Short SGA kinderen hadden een betere postnatale lengte groei als 
hun moeders zwangerschapshypertensie hadden doorgemaakt, in vergelijking met short SGA 
kinderen waarvan de moeders geen zwangerschapshypertensie hadden doorgemaakt (spontane 
groei: 0,64 SDS versus -0,06 SDS, P<0,001). Concluderend, onze studie heeft  aangetoond dat 
SGA geboorte gerelateerd is aan zwangerschapshypertensie en roken tijdens de zwangerschap. 
Postnatale inhaalgroei van te kleine SGA kinderen is het meest uitgesproken als hun moeders 
zwangerschapshypertensie hebben doorgemaakt. Zwangerschapshypertensie, roken tijdens de 
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zwangerschap en alcoholgebruik tijdens de zwangerschap waren niet gerelateerd aan het ISS 
fenotype. 
 
Hoofdstuk 10
In de discussie worden onze bevindingen besproken in relatie met de huidige literatuur. 
Het hoofdstuk wordt afgesloten met algemene overwegingen en suggesties voor toekomstig 
onderzoek.
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